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1) HISTORICAL PERSPECTIVE OF NEONATOLOGY AND INFECTION CONTROL 
 
Neonatology has its origins in antiquity. Soranus from Ephesus (2nd century) mentioned in his manual for 
instruction of midwives that: “the infant has been born at the due of time, best at the end of nine months, 
but also after only seven months”.1 This manual was the standard of newborn care in Europe until the 
Renaissance. The care for the newborns had traditionally been regarded as the responsibility of the mother. 
During the 18th and 19th centuries, midwifery was transformed, and childbirth moved more decisively into 
the sphere of physician and surgeon, but far into the 19th century, obstetricians were more interested in the 
immediate welfare of the mother, and not in the babies they delivered; preterm neonates were expected to 
die, as were neonates with malformations.1
In the second half of the 19th century, the anxiety for depopulation in France, compared to rival Germany, 
generated a powerful infant mortality crusade. The first published report on an incubator for use in the care 
of preterm infants was by Jean-Louis-Paul Denucé in 1857; it consisted of a double-walled zinc tub in 
which the space between the walls was filled with warm water (Figure 1).2 Around 1880 the first closed 
incubator, which could house several infants, was developed by the French obstetrician Stéphane Tarnier, 
who was inspired by a visit to the chicken incubator display in the Paris Zoo.3 In the 1890’s, Alexandre 
Lion, a physician and son of an inventor, developed a more sophisticated incubator, an expensive 
apparatus with a thermostat and independent forced ventilator system.3 Technological enthusiasm at the 
turn of the century led to popular “incubator shows” where, for a small financial contribution, the public 
could watch a functional preterm infant nursery with complex incubators, situated at the forefront of a 
busy boulevard.  
In the 1920s, in Chicago, Julius Hess introduced the concept of a “quiet premature nursery” with a policy 
of gentleness with minimal intervention, where only preterm neonates were admitted.3,4 To prevent 
infection, staff wore gowns, caps and masks. Parents were not allowed to enter the ward. Furthermore, he 
designed a transport incubator, as many neonates died before they reached the first preterm infant stations 
in the United States. Over the years, more was discovered of the unique physiology of (preterm) neonates 
based on knowledge derived from a fetal sheep model.5,6
Alexander Schaffer proposed the name “neonatology” in 1960 for the specific care of neonates, which had 
its roots in obstetrics, paediatrics and physiology.7 Since that moment, major advances, particularly 
respiratory therapy for hyaline membrane disease and the possibility for complete intravenous 
alimentation, have improved life expectancy of the preterm neonate and led to the survival of smaller and 
smaller infants. As a consequence, the mean gestational age of the population in the neonatal intensive 
care unit (NICU) has decreased for many decades, with increased intensity of monitoring and therapeutic 
interventions. With the decrease of mortality the attention focuses on morbidity.8,9 Nowadays, more is 
learned about the long-term consequences of the intensive treatment of preterm neonates and quality of life 
of children and adolescents that have been admitted to the NICU in the past.10,11  
 
2) INFECTION CONTROL IN THE NEONATAL INTENSIVE CARE UNIT OF THE VU         
    UNIVERSITY MEDICAL CENTER 
 
Neonatal intensive care in the Netherlands is provided in ten neonatal centers, with a total capacity of 157 
incubators.12 The mean admission rate is about 4500 neonates per year, on a total national birth rate of 
approximately 200.000 births per year (2.25%). Education on infection control is an integral part of the 
basic training of nurses and the specific training for neonatal intensive care nurses. 
The NICU of the VU University Medical Center consists of 20 incubators with intensive care facilities. 
The department is divided in two units, which can be separated from each other. Because of the limited 
availability of qualified nursing personnel, the maximum capacity of the NICU is 14 neonates. 
Approximately 75% of neonates admitted to the NICU is preterm. The mean duration of admission is 10 
days, after which the majority of neonates is transferred to a high or medium care facility in a general 
hospital. 
In the NICU of the VU University Medical Center an infection control practitioner (ICP) routinely 
consults the nursing staff once a month. Major topics that are discussed are, amongst others, frequency of 
care for and change of instruments and respiratory equipment, disinfection procedures for reusable 
materials, hand hygiene, catheter care and enteral feeding. Based on these consultations, clinical lessons 
on specific infection control subjects are organized for nursing and medical staff. Whenever possible, 
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procedures which pertain a risk of nosocomial infection are formalized in protocols. Persons who enter the 
NICU are obliged to disinfect their hands with an alcohol rub. Before and after handling the neonate or the 
environment, disinfection of hands is repeated.  Aprons are not used as a standard.  
After the release of a new national guideline on infection control in the NICU by the Dutch Working party 
on Infection Prevention (WIP) in February 1998,13 all local guidelines in our NICU were evaluated and, if 
necessary, adjusted to the new guideline. Because NICUs often have specific infection control problems, 
which are different from those of other wards, in 1997 a national consultative body on Neonatology and 
Infection Control was established, in which ICPs of all hospitals that provide neonatal intensive care are 
represented. 
The NICU is an ideal place for nosocomial infections to occur. In fact, in several publications, the NICU 
has been reported as the number one ward with respect to the incidence of nosocomial infections, with 
blood stream infections and pneumonia as the main contributors in this patient category.14-32 Nosocomial 
infection causes an increase in length of stay and mortality.30,33-38 Therefore, the prevention of these 
infections deserves high priority. 
 
3) RISK FACTORS FOR NOSOCOMIAL INFECTION IN (PRETERM) NEONATES      
 
The neonate in the NICU has a high intrinsic risk for infection; within this population preterm neonates are 
the most infection-prone. There are various intrinsic and extrinsic factors that contribute to this increased 
susceptibility to infection. 
 
INTRINSIC FACTORS 
 
Colonization-resistance
The commensal microflora has a valuable defensive role. Colonization-resistance is defined as the 
inhibiting effect of a person’s own commensal flora on colonizing exogenous microorganisms. Such 
commensal microflora is not present in neonates at birth. The fetus grows in the uterus under sterile 
conditions. At birth, the neonate that is admitted to the NICU is exposed to and colonized by bacteria of 
the hospital staff and environment of the delivery room and the NICU, and not, like healthy babies, by 
bacteria acquired from the mother.39-42 These nosocomial bacteria tend to be more antibiotic resistant (i.e. 
coagulase negative staphylococci)43-46 or more pathogenic, (i.e. Klebsiella spp or Pseudomonas 
aeruginosa).47,48
Immunologic factors 
Passive immunity. The developing fetus receives maternal IgG antibodies via the placenta by an active 
process, so that antibody levels in the term neonate are even higher than the levels in the mother. Most of 
those maternally acquired antibodies disappear in the first half-year of life.49 In general, the preterm 
neonate has therefore suboptimal titers at birth and maternal antibodies disappear sooner compared to 
those in term neonates.50,51 Related to this, it has to be reminded that the preterm neonate has a small 
circulating volume, that is sometimes significantly reduced by frequent venapuncture for various 
diagnostic investigations.52
Active immunity. Various components of the immune system function sub optimally, such as the 
respiratory burst of neutrophil granulocytes, the opsonizing capacity of IgG, and the activity of serum 
complement.53-58
Skin 
As an additional risk factor, the skin of the preterm neonate is very thin and vulnerable in the first two 
weeks of life59 and often lacks antibacterial polypeptide-containing vernix.60,61  
 
EXTRINSIC FACTORS 
 
Immunosuppressive therapy. 
Neonates with bronchopulmonary disease (BPD) are treated with corticosteroids to facilitate weaning from 
mechanical ventilation.62,63 Although several small studies did not indicate that the use of corticosteroids 
increases the risk of infection,64 a recent study showed their use does significantly affect the immune 
defences of the (premature) neonate.65
Invasive procedures
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The neonate in the NICU is subject to various invasive procedures for diagnostic and therapeutic 
interventions. Intravascular catheters,66-72 parenteral feeding,73-79 and mechanical ventilation80,81 have all 
been recognized as risk factors for nosocomial infection.  
Intensive care 
In the NICU, the frequency of hands-on care is high, and consequently the chance of colonization with 
hospital bacteria is high.41,42,45,46,48,81,82 The NICU is known for a high degree of crowding, which means a 
high density of patients and staff on a relatively small surface area. Crowding is a known risk factor for 
nosocomial transmission of bacteria.83,84 Also the patient-nurse ratio is sometimes unfavourable, which 
leads to a reduction of adherence to infection control practices.84,85
Hospital stay 
With the increased survival of preterm infants of younger gestational age, these infants stay longer on the 
NICU and are therefore exposed to nosocomial pathogens for a longer period.  
 
4) HOSPITAL EPIDEMIOLOGY 
 
IN THE HOSPITAL IN GENERAL  
Epidemiology is derived from the Greek words ‘epi’ (on) and ‘demos’ (people, population) and is the 
science that studies phenomena that occur in a population. Since the 18th century, hospital epidemiology 
studies phenomena that occur in the hospital. Nosocomial infections are infections that develop during, or 
as a consequence of, stay in the hospital.86 They were the first topics that have been studied, by, amongst 
others, Semmelweis, Lister and Nightingale.87 Later, epidemiological methods have been used to study 
other phenomena in the hospital. For neonates, infections that occur after a clinical delivery are also 
considered nosocomial. Antenatal infections, such as for example infections caused by cytomegalovirus or 
Toxoplasma gondii, are not considered as nosocomial infections. 
Microorganisms that cause nosocomial infections can be from different sources. The distinction between 
sources has main implications for preventive measures that can be instituted. Endogenous infections are 
caused by the patient’s own flora (e.g. skin flora causing catheter-related sepsis); exogenous infections 
result from transmission of organisms from a source other than the patient, e.g. the hands of hospital 
workers or instruments.86 For patients who stay in the hospital for a longer period, the distinction between 
the two types of nosocomial infection is not so clear. These patients become colonized with 
microorganisms prevalent on the ward and these can cause infections later.  
 
IN THE NICU  
The most important nosocomial infections in the NICU are bloodstream infection, pneumonia and 
meningitis.19,20,88-91 Sepsis-associated mortality has improved over the last two decades.92 Nosocomial 
infections are commonly classified as early onset (<48 hours after birth) and late onset (> 48 hours after 
birth). This classification is correlated to causative agents of infection. Early onset infections are usually 
maternally acquired, whereas late onset infections are usually hospital-acquired, with some exceptions; i.e. 
infection with Ureaplasma urealyticum93-95 and Chlamydia trachomatis,96 which are maternally acquired, 
can become symptomatic after more than one week.  
Important causes of early onset infection are group-B streptococci, Listeria monocytogenes, and 
Escherichia coli.87 The frequency of the latter bacterium is increasing, because of increased use of 
antibiotic prophylaxis for group-B streptococci.97 Pathogens frequently involved in late onset blood stream 
infection are coagulase negative staphylococci (CoNS),98-100 and Candida species.101-110 While most of 
CoNS infections are considered catheter-associated,111 the gastro-intestinal tract may be another source of 
CoNS infection.112,113 Epidemiological studies show that strains of multi-resistant CoNS can be present in 
the NICU for many years.114-118 Late onset pneumonia is mainly caused by Gram-negative rods that 
colonize neonates during their stay on the NICU.47,119,120 The incidence of early- and late-onset Gram-
negative infections in the NICU is increasing.30,121-125 Also, strains of Gram-negative bacteria can be 
present on the ward for longer periods.126,127 Other causes of infection are maternally acquired organisms, 
such as Ureaplasma urealyticum,128 Mycoplasma hominis129 and Chlamydia trachomatis.130,131 
Ureaplasma colonization of the airways has been identified by some authors as a risk factor for 
bronchopulmonary disease (BPD).94,132-136 Furthermore, viruses are increasingly recognized as causative 
agents of nosocomial infection.137-148 Necrotizing enterocolitis (NEC) is a multifactorial disease entity, 
specific for premature neonates, in which infection is thought to play a crucial role.149-151
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Nosocomial infection rates in NICUs that have been reported in international literature are high.14-32 
Unfortunately the comparability of these studies is low, because of differences in patient population, and 
the use of different criteria for defining nosocomial infection.  
 
5) SURVEILLANCE OF NOSOCOMIAL INFECTION 
 
SURVEILLANCE 
 
Nosocomial infection can be detected in different ways.152 Surveillance is the systematic, active, ongoing 
collection, analysis, and dissemination of data on the occurrence of nosocomial infections for the purpose 
of reducing infection risks.153 The frequency of nosocomial infections is measured by estimation of the 
incidence rate, which is the number of newly infected patients within a specified population at risk during 
a specific time period, and the prevalence rate, which is the proportion of all current cases of infection 
within a specified population at risk. 
 
Prevalence rate: no. patients with infection / no. patients investigated  
no. infections / no. patients investigated 
Incidence rate: no. patients with new infection / no. patient-years at risk  
no. new infections / no. patient-years at risk during specific time period 
 
For the calculation of either rate several important issues have to be considered. 
 
NUMERATOR DATA 
 
If data from one hospital are to be compared to those of another hospital or with an aggregated database, 
the use of uniform definitions is critical.154 Definitions of nosocomial infections are composed of clinical 
evidence of infection (direct observation by physician or review of the patient’s chart) and laboratory 
evidence (results of cultures, antigen or antibody detection, or microscopic visualization). Supportive data 
are derived from radiological evidence, biopsy, or needle aspiration. The Centers of Disease Control and 
Prevention, Atlanta, USA (CDC), at present the leading institute in hospital epidemiology, has performed 
pioneering work in this field. In 1988, it published definitions for various nosocomial infections,155 which 
can be used for comparison of nosocomial infection rates from various hospitals.19,156  
 
Numerator data for neonates 
For the clinician, diagnosis of infection in premature neonates is often troublesome, which makes it 
difficult to gather good numerator-data in the NICU.  A “golden standard” is not available; the 
combination of several symptoms and laboratory investigations gives various results in accuracy of 
diagnosis.157 Although “sepsis-work-up” is one of the most frequent neonatal discharge diagnoses,158 
diagnosis of neonatal sepsis is difficult because the first signs may be minimal and are similar to those of 
various non-infectious processes (e.g. apnoea of infancy, variation in environmental temperature or acute 
exacerbation of chronic lung disease) and definitive blood culture results are not immediately available. 
Non-specific symptoms for sepsis that are frequently described are: temperature instability, irritability, 
feeding problems, abdominal distension, poor skin colour, diminished peripheral circulation, 
brady/tachycardia, cyanosis, apneoa, tachypnea, lethargy.15,159,160 Another problem in diagnostics is that 
the volume of blood that can be obtained for culture is small (0.5-1.0 ml per blood culture); this can 
compromise sensitivity.161-164 In acute situations it is sometimes not possible, and generally not accepted, 
to obtain multiple blood cultures. Therefore, frequently a diagnosis of culture-negative clinical sepsis is 
made, when all other possible causes of clinical deterioration are excluded and blood cultures remain 
negative. Furthermore, for the physician it is often very difficult to gain access to the vascular system, 
which increases the risk for contamination and compromises the specificity of blood cultures.165 Blood 
culture samples are often drawn through available intravascular catheters, which may be colonized with 
bacteria.111,166  
 
Theoretically there are three ways to accelerate/improve diagnosis of neonatal infection, which have all 
been used with varying success.  
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1) Microbiological tests 
Blood stream infection. Several investigators have attempted to speed up microbiologic methods for 
identifying microorganisms, before the usually needed 48 hours for blood cultures to become positive.167 
For example, direct Gram-stain of blood, or direct isolation of coagulase-negative staphylococci  (CoNS) 
have been described.168 For the near future, PCR-based molecular biologic testing of blood samples for the 
main pathogenic microorganisms seems promising.169-171 Quantification by real-time PCR might 
distinguish contamination from true bacteraemia. This is very important because CoNS are a true cause of 
sepsis in neonates, but also a frequent cause of contamination of blood cultures.160,172,173
Pneumonia. Diagnosis of ventilator-associated pneumonia is difficult.80,174 When bacteria are cultured 
from tracheal aspirates, it is often difficult to differentiate between colonization and infection. Quantitative 
culture may be helpful if an endotracheal tube is recently placed.175
2) Biochemical tests 
Various interleukins and other mediators of the immunologic response to infection, such as G-CSF, IL-1, 
IL-6, IL-8, TNFα, E-selectin and procalcitonin, have been described as reasonably sensitive and/or specific 
in diagnosis of infection in neonates, but they are not routinely used yet.176-195 C-Reactive Protein (CRP) is 
an acute phase protein produced by the liver in case of infection, with a fairly high sensitivity.181,185,191,196-
199 Estimation of CRP, which is generally available in the hospital and can be measured quickly, is 
nowadays used in the NICU as a diagnostic marker in sepsis work-up and in the follow-up of the effect of 
antibiotic therapy.200 The main disadvantages are that CRP is aspecifically elevated in neonates in the first 
days of life, it can be elevated in some other conditions and it is only fairly reactive in viral infection.201 Its 
specificity for late-onset bacterial infection is high enough.202 Others have investigated the combination of 
several haematological findings for predicting / ruling out of sepsis.203
3) Clinical tests: bedside scoring systems 
Several bedside scoring systems have been developed to predict the likelihood of infection. Mahieu et al. 
developed a computer-weighted NOSocomial SEPsis (NOSEP) score for neonates, consisting of clinical 
and  laboratory data, with good predictive values.204,205 Griffin et al. found that specific ECG aberrations 
were predictive for sepsis syndrome in neonates.206 However, none of these bedside scoring systems have 
been sufficiently validated for use in routine practice. 
 
The CDC has developed infection definitions specific for children < 1 year, because they have different 
symptoms than adults and older children. However, these definitions are not suitable for (preterm) 
neonates. The CDC still has not published definitions for nosocomial infection for the neonatal population, 
except for the definitions for neonatal pneumonia, which were released in 2002. In designing suitable 
specific definitions, there are problems in all three components (clinical, laboratory and radiological) of 
surveillance of infection, compared to definitions for older infants of 1 month – 1 year.  
1) Clinical evidence of infection   
As mentioned before, symptoms of infection in the (preterm) neonate are non-specific. Body temperature 
of neonates is not stable,207 and is artificially regulated by incubator temperature. The reaction to infection 
can be fever, but reveals itself more often as temperature instability. Furthermore, fever can be caused by 
non-infectious causes,208 and normal values for body temperature (as well as other clinical findings of 
infection, such as blood pressure and urine production) are depending on body weight.209 With respect to 
defining pneumonia, the problem is that most neonates are mechanically ventilated, which masks 
respiratory symptoms. 
2) Laboratory evidence of infection 
In case of sepsis caused by microorganisms belonging to normal skin flora CDC demands two separate 
positive blood cultures. As stated before, usually only one blood culture is obtained during sepsis work-up 
in neonates, because of their small circulating blood volume. This makes interpretation of positive blood 
cultures with CoNS difficult.210-212 Even when multiple blood cultures are positive with CoNS with the 
same antibiogram, this may reflect multiple contamination.213,214 Also cerebrospinal fluid is contamination 
prone.91
For pneumonia, bronchoalveolar lavage is the best diagnostic procedure. However, this procedure is not 
routinely used because of the great risk of collapse of the preterm lung.   
3) Radiological evidence of infection 
Broncho Pulmonary Disease (BPD) and Infant Respiratory Distress Syndrome (IRDS) in preterm neonates 
give rise to radiological changes of the chest X-ray, which are often indistinguishable to those of 
pneumonia.174,215  
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DENOMINATOR DATA 
 
For interhospital comparison of nosocomial infection rates, the choice of the denominator data is 
crucial.216,217 Since the beginning of the 1990s, there is growing awareness of several confounding factors, 
which can influence local nosocomial infection rates. Adjustment for confounding factors is necessary for 
correct inter-hospital comparison.218 Measurement of risk factors is a central feature of hospital 
epidemiology, which can be used to identify factors for preventive measures. A risk factor is a variable for 
which the probability of nosocomial infection is different according to whether or not the factor is 
present.219 Different patients have different risks for nosocomial infection; therefore, for good 
interpretation, surveillance data have to be stratified according to risk, to appreciate the true influence of 
certain risk factors. Stratification involves assigning patients to different levels or categories of risk, e.g. 
severity of illness or presence of an intravascular catheter.218,220  
The National Nosocomial Infection Surveillance System (NNIS) in the United States of America, has, 
since its inception in 1970, grown from 19 to 315 general acute care hospitals (2000), which perform 
continuous surveillance of nosocomial infection, using CDC-criteria.221,222 To date, about 140 high-risk 
nurseries in the U.S.A. are participating in the system. The NNIS provides hospitals with comparative 
data, based on data which are stratified for main confounding factors, that can be used within the hospital 
for both benchmarking and internal quality assessment with the capacity to measure improvements in 
nosocomial infection rates.23,216,223 Main outcome measures are number of central line-associated 
bloodstream infections per 1000 central line days, number of ventilator associated pneumonias per 1000 
mechanical ventilation days and number of catheter-associated urinary tract infections per 1000 urinary 
catheter days.  
Statistical modelling is another way of analysing a data set. Although modelling can be useful for 
detecting and summarizing data in a more efficient manner than simple stratified analyses, these 
advantages are obtained with a higher risk of bias.218,224-226
 
Denominator data for neonates 
Another reason for difficulties in formulation of standard definitions for neonates, is that the neonatal 
population is very diverse. There is “a world of difference” between a preterm neonate of 25 weeks 
gestation, weighing 500 g, which is admitted to the NICU because of respiratory insufficiency, and a term 
neonate of 42 weeks gestation, weighing 4500 g, which is admitted to the NICU because of meconium 
aspiration. Birth weight has been recognized as the main risk factor for neonatal death.227-229 This is also 
the case for infants born at term with a weight at or below the 3rd percentile for their gestational age.230 
Therefore, for comparison of results of different NICUs or results of a single NICU over time, 
stratification of surveillance results for birth weight is mandatory.218,220,224,231-234 Traditionally, neonates 
are divided in 4 birth weight cohorts: (1) < 1000 g; (2) 1001-1500 g; (3) 1501-2500 g; and (4) > 2500 g. 
However, many other hospital- and physician-related characteristics, e.g. born in a non-teaching 
hospital,235 utilization rate of central venous catheters and mechanical ventilation,236,237 overcrowding,85 
and intrinsic patient factors, e.g. severity of illness,227 and impaired immunity,55,57 can affect the risk for 
nosocomial infection. Within birth weight strata there is still considerable variability in mortality risk. 
Therefore in the 1990s several scoring-systems have been developed and validated, such as the 
Physiologic Stability Index,238 the Berlin score,239 the Clinical Risk Index for Babies (CRIB),240-246 and the 
Score for Neonatal Acute Physiology (SNAP),247-249 which in general perform better in predicting 
mortality than birth weight alone.250 There is no uniform agreement, however, among the different 
studies.251The predictive power of SNAP declines with day of life.252 Others have developed scoring 
systems that are indirectly based on illness severity, e.g. the Neonatal Therapeutic Intervention Scoring 
System.253 The Apgar-score is not usable in the prediction of mortality in preterm neonates.254 Some 
authors found a relation between illness severity and the risk for nosocomial infection in the NICU255,256 or 
paediatric ICU.257  
 
6) PREVENTION OF NOSOCOMIAL INFECTION IN NEONATES 
“The first requirement of a hospital is that it should do the sick no harm”.258 
 
Nosocomial infections have been, and still are, an important cause of morbidity and mortality in the 
hospital.29,35,259 It has been estimated that at least 20% of them are preventable.260 For effective prevention, 
the knowledge of the risk factors of nosocomial infection is necessary. Most nosocomial organisms reach 
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the patient via the hands of health care workers.261,262 Rings, artificial nails or skin damage increase this 
risk on transmission.263-265 The chance of transmission of nosocomial organisms is related to the number of 
hand contacts with the patient; the more intensively treated patient has a higher chance of becoming 
colonized with hospital bacteria.266 Other routes of transmission are contaminated medical equipment / 
hospital environment or aerosols.267-271 Normal defence mechanisms against infection are disrupted in the 
hospitalised patient. Firstly, normal anatomical barriers are undermined by invasive procedures, which 
facilitate the entrance of microorganisms, e.g. intravenous catheters, mechanical ventilation, or bladder 
catheters. Secondly, the host response to invading microorganisms is often impaired because of the 
underlying condition of the patient.  
In the Netherlands, the Infection Control Practitioner (ICP) together with the medical microbiologist, are 
the driving forces behind infection control in the hospital, although it is the responsibility of every 
individual health care worker. In general, the adherence to preventive measures in medical personnel is not 
optimal; especially hand hygiene has been subject to continuous efforts for optimalization.272 It is the task 
of the “infection control team” to motivate the health care workers and, where ever possible, to formalize 
critical procedures in protocols, based on the most recent scientific knowledge. The implementation of 
these protocols should be periodically monitored by the ICP. Therefore, infection control is moving into 
the quality improvement field.273-275
 
There are many circumstances that go beyond the field of classic infection control, which are suitable for 
direct and indirect preventive measures that can decrease the risk for (preterm) neonates of becoming 
infected. In public health, preventive measures are traditionally classified in primary, secondary and 
tertiary measures. A short overview of prevention of nosocomial colonization and infection in neonates is 
presented in the following. 
 
PRIMARY PREVENTION 
Primary prevention involves preventing a disease or other situation from arising. 
In general  
The most important risk factor for nosocomial infection in neonates is gestational age / birth weight.228-230 
Therefore prevention of preterm labour is one of the most important efforts in the prevention of 
nosocomial infection in neonates. In a few studies it was found that bacterial vaginosis and asymptomatic 
bacteriuria were risk factors for preterm labour and that antibiotic treatment of these conditions could 
reduce the incidence.276,277 Furthermore, maternal hypertension is related to neonatal neutropenia, which 
poses a risk for nosocomial infection.278 Induction of labour, in case of premature rupture of membranes at 
term, does not reduce the risk of neonatal infection.279 Understaffing, leading to an unfavourable nurse-
patient ratio, is associated with an increase in nosocomial infection.280 In some cases, hospital personnel 
can be carriers of pathogenic bacteria, causing infection in neonates.281-283 Also, parents can act as vectors 
for nosocomial bacteria.284
Prevention of colonization with hospital flora 
This is the classical field of infection control. Disinfection of hands by hospital workers remains the 
cornerstone of prevention of nosomial infection.285,286 Also parents have to be instructed in hand 
disinfection.284 Efforts to improve adherence to hand disinfection procedures are obligatory, although a 
compliance of 100% is never reached.287 Other measures are the use of disposable materials,267,288 
sterilization / disinfection of equipment and enteral feeding.289-292 Furthermore, dividing enteral feeding in 
small portions, prevents the growth of spore-forming bacteria, which are not killed by boiling, to clinically 
significant numbers.293
Barrier nursing of all neonates is an effective means of prevention of transmission of microorganisms.294 
Good disinfection of hands by all hospital workers would essentially be equivalent to barrier nursing of all 
neonates in the NICU. Gowning is not necessary, and gloving is not either.295  
Preterm rupture of membranes exposes the neonate to microorganisms of the genital tract.296 Surgical 
treatment of preterm ruptured membranes may have a preventive effect.297 Pre-partum ampicillin prevents 
colonization of the neonate with group-B beta-haemolytic streptococci,298 but increases the risk for early-
onset amoxicillin-resistant E. coli  infection.125 Also erythromycin has been found to be effective.299
Some investigators have studied the effect of colonizing newborns with apathogenic bacteria in order to 
build up colonization-resistance for the more pathogenic and antibiotic-resistant hospital bacteria, but this 
has never become general practice.300,301
The subject of antibiotic prophylaxis is at least controversial. Prophylactic use of oral fluconazole does 
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have a protective effective effect for Candida bloodstream infections in a NICU with a high endemicity of 
colonization.302 Selective gut decontamination has been tried with varying results.303-305
Prevention of infection 
Frequent manipulation of catheters is a risk factor for BSI,306 especially when intravenous lipid therapy is 
given.307  Lipids contribute to the survival and growth of CoNS on contaminated catheters.73,74,307 The care 
of intravascular catheters is critical, and the prevention of contamination is better guaranteed in the hands 
of more experienced persons. It has been shown that special teams or special programs for quality care of 
catheters can lead to a significant reduction of catheter-associated BSI.308,309 Furthermore, the risk of BSI 
is related to the insertion site and the duration of the period that catheters are in situ; the necessity of each 
catheter should be evaluated every day.310-312 Other methods that have been studied are (1) methods to 
protect the catheter from becoming colonized by the use of e.g. antimicrobial dressings313,314; (2) methods 
to prevent CoNS sepsis, e.g. the selective use of intravenous315-318 or oral vancomycin319; and (3) rules for 
frequency of changing intravenous tubing sets.78 Promising preventive measures that could be introduced 
in the future are antiseptic coated/impregnated catheters.320-325 In a recent meta-analysis they proved 
effective in adult patients with underlying immunodeficiency.326       
In case of a varicella zoster (VZV) infection on the NICU, anti-VZV immunoglobulin prophylaxis is 
administered to all exposed VZV-IgG seronegative neonates.327 Banning seronegative siblings from the 
NICU and vaccination of seronegative hospital workers are other measures to minimize the risk of 
transmission of varicella-zoster virus. 
Several investigators have studied immunoprophylaxis, e.g. intravenous gammaglobulin, recombinant 
human granulocyte-macrophage colony-stimulating factor (G-CSF), with various results.328-334
 
SECONDARY PREVENTION 
The detection of a disease or situation as early as possible once it has arisen, is called secondary 
prevention. 
Prevention of colonization with antibiotic-resistant hospital flora 
In NICUs antibiotics are frequently used; this poses a high selective pressure for the emergence of resistant 
bacteria. Therefore, in some institutions it is routine to perform surveillance cultures on a regular basis to 
detect antibiotic resistance as quickly as possible.42,335,336 As soon as the first bacterium is isolated which is 
resistant to the empiric antibiotic regimen, empiric antibiotics are changed (cycling), to prevent 
transmission to other neonates. Surveillance of individual neonates for colonization by (resistant) 
potentially pathogenic bacteria, however, is not proven to be useful, and the predictive value of 
surveillance culture results for infection is poor in most studies.42,337-342   
A different way for early detection of the emergence of outbreaks is the determination of the endemic rates 
and threshold testing for different bacteria.343 By prospective registration of clinical isolates, unexpected 
changes in endemic rates can be detected in an early phase, so that appropriate measures can be taken. In 
the last decennium, the detection of nosocomial transmission of a single strain has been improved by 
sophisticated molecular techniques for typing strains at DNA-level.344 This is especially useful for bacteria 
that belong to the normal flora of neonates, e.g. CoNS,117,345-348 but also for (resistant) Gram-negative 
rods270,349,350 and other microorganisms.127,261   
Prevention of infection 
As stated before, the early distinction between infection and other causes of clinical deterioration in 
neonates is very difficult, because symptoms are aspecific and cultures take at least 24-48 hours to become 
positive.  
 
TERTIARY PREVENTION  
Finally, to cure a disease and to minimize its consequences, as well as the chance of recurrence, is called 
tertiary prevention. Tertiary prevention relates to the individual, as well as to the hospital microbial flora 
and the total patient population 
Individual  
Adequate therapy has to be instituted as soon as possible, not only as a therapeutic measure, but also 
because it minimizes the period of communicability. Besides antibiotics, the effect of other immuno-
modulating therapies has been studied, for example: fresh frozen plasma,351 gamma-globulins,329,330,351,352 
G-CSF334,353,354 and exchange transfusions.351 For none of these adjuvant therapies there is enough 
evidence to make it routine practice in the treatment of sepsis. Ideally, in case of a catheter associated BSI, 
the source is removed. However, in clinical practice this is not always possible, because the patient’s 
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critical condition does not allow it.355-357
Hospital flora/ patient population 
Pathogenic or multi-resistant microorganisms can be transmitted in the NICU very easily. This has been 
experimentally shown by using DNA-markers.358 Outbreak management involves several measures to 
prevent further transmission of microorganisms. These measures are instituted in close cooperation 
between medical and nursing staff, infection control practitioner and the medical microbiologist. Firstly, 
hand hygiene and existing protocols for critical procedures have to be reinforced.359 Sometimes it is useful 
to sample the environment to identify environmental sources, but frequently patients are the only 
source.127,268,291,292,360-362
Colonized/infected neonates have to be identified by surveillance cultures, and these neonates have to be 
cohorted, which implies that they are spatially separated from the other neonates.363,364 Ideally, also 
nursing staff and medical staff are cohorted. Risk factors can sometimes be identified by epidemiological 
studies.292 If, despite these measures, new cases continue to occur, a change of empiric antibiotic regimen 
can be helpful; the goal of this is to take away selective pressure.359,365 Systemic antibiotics do not seem to 
eliminate intestinal carriership of Gram-negative rods.365 If the outbreak still is uncontrolled, the ward has 
to be closed for new admissions, until all colonized/infected patients have left the ward.366  
 
7) PREVENTION OF ANTIBIOTIC RESISTANCE 
 
Once bacterial strains that are resistant to the empiric antibiotic regimen have evolved or have been 
introduced on the ward, transmission has to be prevented by infection control measures. Evolvement of 
antibiotic resistant strains is prevented by a sound antibiotic policy on the ward. Inadequate or unnecessary 
use of antibiotics give a selective pressure from which resistant bacteria can emerge. There is clear, though 
circumstantial, evidence for the relation between the volume of use of antibiotics and the frequency of 
resistance.367 The NICU (and ICUs in general) is a place in the hospital where the selective pressure for 
the development of resistance and the transmission of resistant bacteria is a continuous threat.368-373  
As pointed out earlier, in case of significant worsening of the clinical condition of the neonate, potentially 
life-threatening sepsis can never be excluded from differential diagnosis, so empiric antibiotics have to be 
started immediately. In good clinical practice, the patient is regularly evaluated over the next 48 hours. If 
the clinical condition of the patient improves and cultures do not identify any significant pathogen within  
48 hours, it is generally considered safe to discontinue antibiotic therapy.374-376 A significant decline of 
CRP can help in the decision whether it is safe to stop antibiotic therapy,201 although exceptions occur.377 
Antibiotics have to be continued when the clinical situation is still poor and no other explanation than an 
infection can be found, or cultures are positive. This leads to an overuse of antibiotics, even when their use 
is strictly monitored.378 Inadequate use of antibiotics is one of the main reasons for antibiotic resistance to 
occur.379   
Important considerations when formulating an empiric antibiotic regimen are coverage of probable 
infecting microorganisms, good penetration in the central nervous system, and low selective pressure for 
development of drug resistance.124,335,380-383 Furthermore, the specific pharmacodynamic features of the 
neonatal body have to be taken into consideration.384 Therefore, the empiric antibiotic regimen is 
developed in cooperation by neonatologist and microbiologist.  
When micro-organisms evolve that are resistant to the empirically used antibiotics, a change of regimen 
can be used as an additive measure to control an outbreak.359 In some NICUs, regular surveillance cultures 
of neonates (usually rectal swabs) are performed to detect the emergence of resistance before resistant 
strains appear in clinical samples.341 Some have studied the effect of timely rotation of the empiric regimen 
to prevent the emergence of resistant Gram-negative rods, but although rotation is theoretically valid, 
effect has not been demonstrated convincingly yet.385 Infection control measures must prevent resistant 
bacteria from being transmitted to other patients.372  
During the last 5 years, the empiric antibiotic regimen on the NICU of the VU University Medical Center 
has been changed on a few occasions in response to outbreaks with resistant Gram-negative bacteria 
(Table 1). Vancomycin is never used empirically and  is only used when oxacillin-resistant coagulase 
negative staphylococci are isolated from a blood culture and the clinical condition has not improved 
sufficiently.386  
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Figure 2. The Amplified Fragment-Length Polymorphism principle 389
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Schematic representation of the AFLP analysis principle. 1, point mutations incorporated in the adapter 
sequences to prevent digestion after ligation are shaded. 2, one of the primers is labeled. In this representation both 
primers contain one selective nucleotide (shaded) in the unknown fragment. xxxxxxxxxxxxxxxxxxxxxxxx
 
Table 1. Chronological outline of empiric antibiotic policy in the neonatal intensive 
care unit of the VU University Medical Center 1996-2001  
 
Empiric antibiotic regimen awaiting 
culture results 
Time period 
First line 
 
Second line 
First choice antibiotic when clinical 
relevant CoNS is isolated from blood 
Jan 1996-Oct 1997 
 
penicillin-gentamicin meropenem vancomycin 
Sep 1997-Nov 1997 
 
Outbreak with Klebsiella pneumoniae resistant to gentamicin 
Nov 1997-Oct 1999  
 
penicillin-amikacin meropenem  vancomycin 
Nov 1999-Jan 2000 
 
penicillin-gentamicin cefotaxime vancomycin 
Dec 1999-Feb 2000 Outbreak with Enterobacter cloacae resistant to 3d-generation cephalosporins and 
intermediate resistant to gentamicin 
 
Feb 2000- Jan 2001 
 
penicillin-amikacin meropenem vancomycin 
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8) GENETIC FINGERPRINTING OF BACTERIAL ISOLATES 
 
Modern molecular biologic techniques give us the opportunity to type bacterial strains at the DNA level 
(fingerprinting),349-351 which can be helpful in epidemiological studies.387 These techniques have an 
improved discriminatory power, compared  to methods based on morphological or biochemical features of 
strains.387 When strains of the same species, isolated from different patients, have genotypes that             
are not related, nosomial transmission is excluded. When genotypes have a high degree of  homology, 
endemic or epidemic transmission is probable.117,388 To this purpose, in the VU University Medical Center 
we use Amplified-Fragment Length Polymorphism (AFLP). This typing method has a good reproducibility 
and specificity for microorganisms involved in nosocomial outbreaks (Figure 2).389 Typing of isolates is 
of value in the decision process about the type of measures to be implemented to prevent nosocomial 
transmission.390 An additional advantage of improved identification of cases is that case-control studies for 
risk factors have an increased likelihood for identifying relevant risk factors. 
 
9)  AIMS OF THE STUDY 
 
In 1996, there were concerns among neonatologists and microbiologists that the incidence of nosocomial 
infections on the NICU of the VU University Medical Center was high. Also, outbreaks had  occurred 
which had great impact. Unfortunately, at that time, little was known about the incidence and prevalence 
of nosocomial infections in neonatal intensive care units in general, and no data were available for Dutch 
NICUs. Also little was known about risk factors in neonates, hence it was difficult to devise  meaningful 
interventions. Therefore we proposed to start a prospective study on the incidence on nosocomial 
infections on the NICU, to provide baseline data on these infections and to define potential risk factors.  
The only definitions for nosocomial infections in the pediatric population available at that time were those 
for children < 1 year of the Centers for Disease Control and Prevention (CDC).155 The neonatologists did 
not agree with these definitions, which were thought to be unspecific  for the neonatal population. 
Therefore, we  first developed definitions for nosocomial infection in neonates in cooperation with the 
department of neonatology.  In chapter 2 the results of the surveillance study performed in the NICU of 
the VU University Hospital in 1998-2000 are presented. Furthermore, as a result of a case of ongoing 
sepsis with CoNS in a premature neonate, it was discovered that the causative Staphylococcus capitis 
strain was hetero-resistant to vancomycin and that it had been endemic on the ward for 3 years. This is 
described in chapter 3. Beside an endemic level of nosocomial infection, infections can also occur as 
epidemics. Bacillus cereus, a bacterium with a unique epidemiology because of the formation of resistant 
spores, which can survive for a long period in the environment, caused an outbreak in 1998. The 
description of this outbreak, the ensuing analysis and the control measures taken to halt it is presented in 
chapter 4. In 1997, a few months before the start of the surveillance, an outbreak of gentamicin-resistant 
Klebsiella pneumoniae occurred. This is described in chapter 5.Also viruses have the potential to become 
epidemic in the NICU. Most neonates are protected from varicella-zoster virus (VZV) infection by 
maternal antibodies (passive immunity). Introduction of VZV in the NICU is an alarming situation, 
because infection with this virus can be severe in the unprotected neonate. The relation between anti-VZV 
IgG titers of premature neonates in relation to maternal anti-VZV IgG titers was studied in a cohort of 
neonates (chapter 6). Finally, the role of  the genotype of the MBL-2 gene, which encodes for mannose 
binding lectin (MBL), in relation to susceptibility for nosocomial infection was investigated. MBL is an 
acute phase protein formed by hepatocytes and is involved in innate immunity. MBL-deficiency, caused 
by mutations in the MBL-gene, has been identified as a risk factor for infection in other patient categories. 
The results of this study are presented in chapter 7. In chapter 8, the general conclusions of our studies 
are summarized.  
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Summary 
 
The incidence of nosocomial infection in neonatal intensive care units (NICUs) is high compared to 
other wards. However, no definitions for hospital-acquired infection are available for NICUs. The aim 
of this study was to measure the incidence of such infections and to identify risk factors in the NICU 
of the VU University Medical Center, which serves as a level-III regional NICU. For this purpose, a 
prospective surveillance was performed in 1998-2000. We designed definitions by adjusting the 
current definitions of the Centers for Disease Control and Prevention (CDC) for children < 1 year of 
age. Birth weight was stratified into four categories and other base-line risk factors were dichotomized. 
Analysis of risk factors was performed by Cox regression with time-dependent variables. The 
relationship between the Clinical Risk Index for Babies (CRIB) and nosocomial infection was 
investigated. Furthermore, for a random sample of cases we determined whether bloodstream infection 
and pneumonia would also have been identified with the CDC-definitions. Seven hundred and forty-
two neonates were included in the study. One hundred and ninety-one neonates developed 264 
infections. Bloodstream infection (n = 138, 14.9/1000 patient-days) and pneumonia (n = 69, 7.5/1000 
patient-days) were the most common infections. Of bloodstream infections, 59% were caused by 
coagulase-negative staphylococci; in 21% of neonates, blood cultures remained negative. In 25% of 
pneumonias, Enterobacteriaceae were the causative micro-organisms; 26% of cultures remained 
negative. Compared with the Nosocomial Infections Surveillance System (NNIS) of the CDC, our 
device utilization ratios, and device-associated nosocomial infection rates were high. The main risk 
factors for bloodstream infection were birth weight [hazard ratio (HR); 1.79, 95% confidence interval 
(CI) 1.45-2.17] and parenteral feeding with hospital pharmacy-produced all-in-one mixture ‘Minimix’ 
(HR 3.69, 95% CI 2.03-6.69); administration of intravenous antibiotics (HR 0.39, 95% CI 0.26-0.56) 
was a  protective risk factor. The main risk factors for pneumonia were low birth weight (HR 1.37, 
95% CI 1.01-1.85) and mechanical ventilation (HR 9.69, 95% CI 4.60-20.4); intravenous antibiotics 
were protective (HR 0.37, 95% CI; 0.21-0.64). In a subcohort of 232 very-low-birthweight neonates, 
the CRIB was not predictive for infection. With the CDC-criteria, only 75% (21/28) of bloodstream 
infection and 87.5% of pneumonias (21/24) would have been identified. In conclusion, our local 
nosocomial infection rates are high compared to those of NICUs participating in the NNIS. This can be 
partially explained by: (1) the use of our definitions for nosocomial infection, which are more suitable 
for this patient category; and (2) the high device utilization ratios.xxxxxxxxxxxxxxxxxxxxxxxxxxxx 
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Introduction  
 
The incidence of nosocomial infections in neonatal intensive care units (NICUs) is high; it has been 
reported to occur in up to 30% of all neonates.1-19 Diagnosis of infection, especially in preterm 
neonates, is difficult because symptoms of infection are often non-specific and different from those in 
older infants.20-21  In addition, as diagnostic procedures are different in the NICU, the definitions of 
such infections for children < 1 year of the Centers of Disease Control and Prevention (CDC) are less 
suitable in this patient population.22 The lack of standardized definitions for nosocomial infection in 
the NICU and the huge diversity in patient mix in different NICUs makes comparison of studies on the 
incidence of infection in neonates difficult.23 Lacking better definitions, the National Nosocomial 
Infections Surveillance System (NNIS), consisting of approximately 140 American NICUs, uses the 
CDC definitions for children < 1 year as the best available for surveillance.24 
Diagnosis of bloodstream infection (BSI) in premature neonates is hampered by several factors, 
including the relatively small volume of blood that can be drawn for culture, which compromises 
sensitivity.25,26 Also, the diagnosis of ventilator-associated pneumonia is more difficult in neonates 
than in older children because of the low sensitivity of chest X-rays.27-29 
The NICU of our hospital is a level-III NICU. Indications for admission are: preterm birth (< 32 weeks 
of gestation), respiratory distress, infections, congenital malformations and birth asphyxia. The aims of 
this prospective surveillance study were: (1) to test the applicability of CDC definitions for children 
aged < 1 year adjusted for neonates for detection of nosocomial infection; (2) to determine the 
incidence of nosocomial infection in the NICU of the VU University Medical Center, Amsterdam, 
based on these  definitions; and (3) to identify risk factors for nosocomial infection in our NICU.  
 
 
Methods  
 
Definitions of nosocomial infections. Definitions for infection surveillance were developed by the 
Department of Medical Microbiology and Infection Control and the Department of Neonatology. CDC 
definitions for children aged < 1 year for BSI, pneumonia, meningitis, urinary tract infection (UTI), 
eye infection, infection of the umbilicus, and skin infection were adjusted with respect to specific 
neonatal symptomatology and diagnostic procedures. During the surveillance period, problems with 
definitions were discussed regularly. After 6 months of use and assessment, definitions were adjusted 
to their final form. Infections detected in those 6 months were then re-evaluated with the adjusted 
definitions. Figures 1 and 2 present the final version of this process for BSI and pneumonia.  
The NICU of the VU University Medical Center. Tracheal aspirates from mechanically ventilated 
neonates are routinely cultured weekly. At  least one blood sample for culture is obtained whenever 
BSI is suspected, before empirical antibiotic treatment (penicillin with amikacin) is started. If there is 
no clinical improvement after 48-72 h and no microorganisms are cultured, these antibiotics are 
replaced by meropenem. Vancomycin is only used when clinically relevant oxacillin-resistant 
coagulase-negative staphylococci are isolated from blood. The empirical antibiotic regimen for 
meningitis is meropenem. After the intensive care period, the majority of the neonates are transferred 
to regional general hospitals for further care.  
Surveillance. Surveillance was started after a two-month trial period, in which infection control 
practitioners were trained in gathering information efficiently and getting used to working with the 
infection definitions. ICPs visited the NICU twice a week. Relevant information was abstracted from 
the charts of all neonates that were present in the NICU for > 24 h on specially designed registration 
forms. Once a month, all neonates suspected of infection (based on culture results or antibiotic 
treatment) were discussed with the neonatologist. If neonates were transferred from another hospital to 
our NICU and infections occurred before or within 48 hours after admission to our NICU, these 
infections were not included as numerator data in our surveillance. Surveillance was continued until 
the neonate was transferred to another center or until death. The following denominator information 
was recorded (base-line variables): sex, place of birth (VU University Medical Center or elsewhere), 
single or multiple birth, type of delivery (Caesarian section or vaginal), premature rupture of 
membranes (> 24 hours before delivery), presence of meconium-stained amniotic fluid, gestational 
age, birthweight category (< 1000 g, 1000-1499 g, 1500-2499 g and >= 2500 g) and Apgar-score. 
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Furthermore, the following time-dependent factors were recorded daily: presence or absence of enteral 
feeding, parenteral feeding with hospital-pharmacy-produced, all-in-one mixture ‘Minimix’ or other 
formula, mechanical ventilation or other ventilatory support, mostly continuous positive airway 
pressure, intravenous antibiotic treatment (at least one intravenous antibiotic), and indwelling 
catheters.   
Comparison of  device-associated rates of BSI and pneumonia. Rates for umbilical and central line 
and ventilator utilization and device-associated infection rates were compared with results of the high-
risk nursery surveillance component of the semi-annual report of the NNIS of December 2000.30  
Multi-variate analysis of risk factors for late-onset infection. We performed separate analyses for 
risk factors for BSI and pneumonia, as these nosocomial infections were the most common and most 
serious. For neonates with multiple BSI or multiple pneumonia during their admission, only the first 
event was included in the analysis. A neonate with both BSI and pneumonia was included in both 
analyses. Early-onset infections, defined as infections occurring < 48 h after birth, are generally 
considered to be maternally-acquired, and these were not included in the analysis. 
For each analysis, base-line risk factors were tested first. Significant base-line factors were included in 
the analysis of time-dependent risk factors, for which we used Cox regression with time-dependent 
variables. This is a variant of multi-variate regression modelling in which we related the risk of an 
infection on day T to the presence of a risk factor on day T - 1. In this analysis, time-dependent factors 
can change over time. For analysis of results, Microsoft Excel 2000, SPSS version 11.0, and STATA 
version 8.0 were used. 
Clinical Risk Index for Babies (CRIB) in relation to nosocomial infection. In a subcohort of 232 
inborn neonates with a birthweight < 1500 g and/or gestational age < 31 weeks, the CRIB was 
calculated.31 The relationship between the CRIB, stratified into four strata (0, 1-4, 5-9 and > 9), and 
birth weight, also stratified into four strata, with mortality, pneumonia and BSI was evaluated with 
univariate and bivariate analysis.   
Comparison of local definitions with CDC definitions. For a random sample of 28 cases of BSI and 
24 cases of pneumonia, patient charts were evaluated retrospectively to determine whether these 
infections would also have been identified with CDC criteria.22 
 
 
Results    
 
Surveillance 
Surveillance was performed over two periods: February-November 1998, and June 1999-December 
2000. A total of 742 neonates was included. We recorded 264 infections in 191 neonates. General 
information on the study population, the incidence of infection and the causative agents is provided in 
Tables 1, 2 and 3, respectively. BSI and pneumonia were the most frequently occurring nosocomial 
infections. BSI was predominantly caused by coagulase-negative staphylococci and other Gram-
positive bacteria, whereas pneumonia was mainly caused by Gram-negative species. A significant 
percentage of BSIs and pneumonias were culture negative; 21% and 26%, respectively. The 
percentages of culture-negative BSI in period A and B were 27% and 11%, respectively. This 
difference was not significant (95%CI -0.53 – 32.8%). 
Comparison of device-associated rates of BSI and pneumonia with results of the NNIS 
Eighty-three of 129 (64%) episodes of BSI were related to central vascular catheters. Fifty of 69 (73%) 
pneumonias occurred in neonates who were mechanically ventilated. Results for device utilization and 
device-associated infections are shown in Table 4. In general, the ventilation utilization ratios were 
higher than those reported by most of the NICUs participating in the NNIS. 
Multivariate analysis of risk factors for infection 
Results are shown in Table 5 and 6.  
Baseline factors. Of the significant baseline factors, only birthweight category remained significant in 
the multi-variate analysis with other baseline factors. Therefore, birthweight category was the only 
baseline factor that was included in the models with time-dependent risk factors. Combined with time-
dependent risk factors, birthweight category remained a significant risk factor. Apgar score was not 
always available and was therefore not included in the analysis. 
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Table 1. General results 
 
Duration of surveillance (months) 
   
 29 
Total no. neonates included    742 
 
Gender 
 
Male 
Female 
 
430   ( 58%) 
312 
Type of birth 
    
Vaginal 
Caesarian section 
 
380   ( 51%) 
362 
Place of birth 
 
VU University Medical Center 
Elsewhere 
 
442   ( 60%) 
300 
Multiple birth Yes 
No 
 
173   ( 23%) 
569 
Neonates infected  191   ( 26%) 
Nosocomial infections  264  
Patient-days   9233 (100%) 
Central-line-days  3794 (  41%) 
Mechanical-ventilation-days 
 
 3967 (  43%) 
Use of antibiotics (days) Penicillin  2806 ( 30.3%) 
 Amikacin    2731 ( 29.6%) 
 Meropenem    722 (   7.9%) 
 Amphotericin B             3 (   0.0%) 
 Vancomycin    678 (   7.3%) 
 At least one antibiotic  4601 ( 49.8%) 
 
 
Table 2. Incidence of nosocomial infection  
 
Infections / 1000 patient-days 
 
  
 28.6 (25.2-32.0) 
Infected patients /1000 patient-days 
 
 20.7 (17.8-23.6) 
BSI / 1000 patient-days 
 
 14.9 (12.5-17.4) 
Patients with BSI / 1000 patient-days 
 
 13.9 (11.5-16.2) 
Pneumonia / 1000 patient-days 
 
   7.5 (  5.7-  9.2) 
Patients with pneumonia / 1000-patient days 
 
   6.3 (  4.7-  7.9) 
 
BSI, bloodstream infection 
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Table 3. Causative organisms of infection  
 
Early onset,  < 48 hours after birth; CoNS, coagulase-negative staphylococci 
 
 
Infection 
 
  N 
  
Causative organism 
 
 N   (%) 
 
Bloodstream infection 
 
Early onset: 5 (4%) 
 
138 
 
     
 
Culture-negative 
CoNS 
Staphylococcus aureus 
Bacillus cereus 
Other or mixed Gram-positive  
Enterobacteriaceae 
Other or mixed Gram-negative 
Mixed Gram-positive/negative 
 
29 (21%) 
81 (59%) 
  6 
  7 
  8 
  3 
  2 
  2 
 
Pneumonia 
 
Early onset: 4 (6%) 
 
  69  
 
 
 
Culture-negative / no pathogens 
Staphylococcus aureus 
Other Gram-positive  
Enterobacteriaceae 
Other/mixed Gram-negative 
Mixed Gram-positive / negative 
Ureaplasma urealyticum 
 
 
18 (26%) 
  9 
  5 
17 (25%) 
  7 
  5 
  8 
Meningitis     4 Culture negative 
CoNS,  
Enterococcus faecium 
 
  2 
  1 
  1 
Urinary tract infection   10 Enterobacteriaceae 10 
 
Eye infection 
   
  12 
 
Staphylococcus aureus  
Enterobacteriaceae 
Neisseria spp. 
 
  
  8 
  1 
  3 
Umbilical infection     5 Staphylococcus aureus 
Enterobacter cloacae 
  4 
  1 
 
Skin infection 
 
 
  26 
 
 
 
Candida spp. 
Other Gram-positive 
 
 
  
23 
  3 
 
Total 264   
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Time-dependent risk factors for pneumonia and BSI. Mechanical ventilation was a strong risk factor 
for pneumonia, and parenteral feeding with Minimix was a strong risk factor for BSI. Intravenous 
antibiotics were a protective factor for BSI as well as for pneumonia. 
CRIB score 
In a bivariate analysis with birthweight, no relation existed between the CRIB and BSI, and between 
the CRIB and pneumonia [hazard ratio (HR) 0.91, 95%CI 0.67-1.24; HR 1.39, 95%CI 0.90-2.15; 
respectively].   
Comparison of CDC definitions with adapted definitions (developed at the VU University 
Medical Center) 
BSI. Nine of the 28 (32%) cases detected with our definitions would not have been identified by CDC-
definitions because of the lack of  hyperthermia > 38 °C or hypothermia < 37 °C as a defining variable. 
Temperature instability is considered to be an important symptom of possible infection in 
neonatology.21 Re-evaluation of these 9 cases with the addition of neonatal hypo/hyperthermia (i.e. < 
36.5 °C and > 37.5 °C) resulted in only one of 28 cases that would not have been identified according 
to CDC criteria. We identified this case with our definitions because the neonate was apathic and had a 
grey skin colour.  
Pneumonia. Three of 24 cases (12.5%) were not detected by CDC-definitions. All were caused by 
Ureaplasma urealyticum, a bacterium acquired from the mother during delivery, and associated with 
bronchopulmonary dysplasia.32-34 This type of pneumonia is specific for preterm neonates. If such 
pneumonia is suspected in our NICU, sputum is cultured for U. urealyticum; if the culture is positive, 
the neonate is treated with erythromycin. 
 
 
Discussion  
 
CDC definitions for children aged < 1 year are not suitable in some aspects for (preterm) neonates. 
Symptomatology of infection is different in this patient category. Irritability, apathy and grey skin 
colour are considered symptoms of possible infection, but they are difficult to assess and somewhat 
subjective.21 A classic symptom of infection, which is used as a defining symptom in all studies on 
nosocomial infections, is body temperature above 38.0 °C. Body temperature, however, acts 
differently in infection in neonates. It will seldom exceed 38.0 °C, as it is artificially adjusted by 
lowering the incubator temperature, but hypothermia, hyperthermia, and temperature instability can 
occur.21 Recently, the CDC published new definitions for pneumonia, that are currently used in the 
NNIS, in which ‘temperature instability with no other recognized cause’ is included as a criterion in 
children < 1 year.35 CDC definitions for (premature) neonates are still lacking. Pneumonia in the NICU 
is very frequently ventilator-associated, therefore clinical signs of pneumonia are obfuscated. As chest 
X-rays are often difficult to assess for infiltrates in the presence of respiratory distress syndrome, the 
presence of infiltrates is not a good criterion of pneumonia in neonates. Here again, we developed 
specific definitions for neonates, also suitable for mechanically ventilated neonates, by adjustment of 
CDC-criteria for children < 1 year. In the new CDC definitions for infants < 1 year, worsening gas 
exchange is also incorporated as an obligatory sign, which makes the definitions more suitable for 
surveillance of ventilator-associated pneumonia.35   
Evidently, there is still a subjective part in surveillance which may influence surveillance results, 
especially in the diagnosis of  clinical BSI. This is the case for our own surveillance definitions as well 
as those from the CDC. This definition depends on the administration of relevant antimicrobial therapy 
by the physician for at least 7 days when a neonate experienced clinical deterioration, which could not 
be explained by other causes than BSI although blood cultures remained negative after three days. 
During the two surveillance periods, different neonatologists supervised the NICU, but this did not 
seem to influence the assessment of BSI, since the incidence of culture-negative BSI was similar in 
both periods. The probable explanation is that the neonates on the ward were treated by all of the 
medical staff (n = 8), independent of the surveillance study. For good surveillance, treatment policies 
on the ward should be standardized as much as possible.  
To our knowledge, Gastmeier et al. published the only study on nosocomial infection in a NICU, that 
compared results of local definitions with definitions of the CDC for children < 1 year.5 These ‘Berlin 
criteria’ for central-line-associated primary BSI and ventilator-associated pneumonia, consisting of 
clinical signs, and haematological and microbiological results, were developed because not all CDC 
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Table 5.   Late-onset bloodstream infection: Cox regression analysis  
with time-dependent variables 
 
General information 
 
No. of neonates                          742    
No. of patient days at risk a                         6713           
Range of patient-days / subject             2-110 
No. of bloodstream infections                         124   
 
                    Hazard Ratio       95%CI 
 
Univariate analysis 
 
Baseline variables b 
     Class of birth weight     1.79   1.45-2.17 
     Sex        1.00   0.70-1.43 
     Place of birth      1.95   1.30-2.93 
     Type of birth      1.56   1.07-2.27 
     Meconium-stained amniotic fluid    0.32   0.12-0.87 
     Premature rupture of membranes    0.66   0.38-1.16 
     Multiple birth      1.29   0.88-1.90 
Time-dependent variables 
     Enteral feeding      1.18    0.58-2.41 
     Parenteral feeding 
 Minimix      3.36   1.88-6.00 
Other       0.71     0.36-1.42 
     Ventilation     
Mechanical      0.75   0.53-1.07 
      Other         1.55   1.05-2.30 
     Urinary catheter      0.54   0.28-1.04 
     Intravenous catheter 
 umbilical vein      1.34   0.91-1.98 
other central venous     0.93   0.57-1.51 
     Intra-arterial catheter   
peripheral artery     0.64   0.42-0.98 
umbilical artery     1.28   0.81-2.02 
     Pleural drain      0.96   0.42-2.18 
     Intravenous antibiotics     0.39   0.27-0.58 
 
Multi-variate analysis c 
 
     Class of birth weight      1.79   1.45-2.17 
     Parenteral feeding with Minimix      3.69   2.03-6.69 
     Intravenous antibiotics      0.38     0.26-0.56 
 
 
Early-onset infections were excluded from the analysis. When multiple episodes of sepsis occurred in a neonate, 
only the first episode was included in the analysis. 
a For infected neonates, only the admission days before infection were included; for non-infected neonates, all 
admission days were included. 
b When bivariate analysis was performed with class of birth weight combined with one other baseline variable, 
class of birth weight remained the only significant variable. 
c From baseline variables, only birth weight was included in the model, and all time-dependent variables were 
included. Non-significant variables were excluded from the final model. 
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Table 6.    Late-onset pneumonia: Cox regression analysis with  
time-dependent variables 
 
General information 
 
No. of neonates                         742    
No. of patient days at risk a                        7473           
Range of patient days / subject            2-88 
No. of pneumonias                              58   
 
              Hazard Ratio        95%CI 
 
 
Univariate analysis 
 
Base-line variables b 
     Class of birthweight     1.45   1.05-2.00 
     Sex       0.90   0.52-1.53 
     Place of birth     1.51   0.82-2.77 
     Type of birth     0.84   0.49-1.42 
     Meconium      0.84   0.26-2.71 
     Premature rupture of membranes   1.11   0.56-2.20 
     Multiple birth     0.67   0.35-1.27 
Time-dependent variables 
     Enteral feeding     0.56   0.26-1.19 
     Ventilation  
Mechanical     7.61   3.69-15.8 
      other method     0.35   0.16-0.78 
     Pleural drain     1.27   0.39-4.10 
     Intravenous antibiotics    0.64   0.37-1.11 
 
Multi-variate analysis c 
 
     Class of birthweight     1.37   1.01-1.85 
     Mechanical ventilation    9.69   4.60-20.4 
     Intravenous antibiotics    0.37     0.21-0.64 
 
 
Early-onset infections were excluded from the analysis. When multiple episodes of sepsis occurred in a neonate, 
only the first episode was included in the analysis. 
a For infected neonates, only the admission days before infection were included; for non-infected neonates, all 
admission days were included. 
bWhen bivariate analysis was performed with class of birth weight combined with one other baseline variable, 
class of birth weight remained the only significant variable. 
c From baseline variables, only birth weight was included in the model, and all time-dependent variables were 
included. Non-significant variables were excluded from the final model. 
 
 
criteria were accepted by local neonatologists, just as was the case in our NICU.  In a surveillance 
study on 677 neonates with an overall nosocomial infection rate of 13.2%, they found a good 
agreement with CDC criteria. We decided not to include haematological results, such as leukocyte 
count or C-reactive protein, in our definitions because the decision to start antibiotics for suspicion of 
infection is based on clinical signs and symptoms and not on haematological results. Our results cannot 
be compared with this study because early-onset infections (< 48 h after delivery) and infections 
occurring > 28 days of admission were not included, and two non-ICUs were also included. 
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Surveillance data are often analysed by logistic regression. A problem, however, is that in this type of 
surveillance study, data are censored, and in logistic regression, observation time is considered 
constant for every individual. Cox-regression presumes fixed base-line risk factors that are constant 
over time and the response variable is time to event. This is also not suitable for analysis of 
surveillance data as many risk factors can change over time. Since Cox regression is available with 
most statistical packages and easy to use, we have attempted Cox regression analysis with time-
dependent risk factors as dichotomous (present / not present) for the total period of admission or as a 
percentage of days present in the risk period. This approach, however, can lead to false conclusions. 
Cox-regression with time-dependent variables is a more accurate way to analyse prospectively 
gathered surveillance data, but two factors have to be kept in mind.36 Firstly, an assumption about the 
incubation time of infection has to be made. In our analysis we related the presence/absence of risk 
factors on day T - 1 to day T, because this is in agreement with NNIS definitions of device-associated 
infections.24 We realize that this assumption is not perfect, since incubation time, the time between 
infection and clinical signs, depends on many factors such as the dose and virulence of the infecting 
micro-organism and the immunity of the patient. Secondly, such analysis does not take cumulative 
effects into account. For example, for line-associated BSI there is certainly a cumulative effect, as it 
takes time for skin flora at the exterior of intravascular catheters to develop to high numbers and to 
reach the blood.37   
In a multi-variate analysis with Cox regression with time-dependent variables, we identified 
independent risk factors for nosocomial BSI and pneumonia. Birth weight in neonates is a risk factor 
for nosocomial infection in general, and mechanical ventilation is a well known risk factors for 
pneumonia.10-12,18,38 Parenteral nutrition is essential for treatment of  neonates (particularly premature 
neonates) in the NICU before full enteral feeding can be given. In our NICU, an all-in-one mixture, 
Minimix, prepared by the hospital pharmacy, is used. It is usually started on the second day of life and 
consists of  fixed proportions of carbohydrates, proteins, electrolytes, trace-elements, vitamins and 
lipids. The association between intravenous lipids and coagulase-negative staphylococcal bacteraemia 
has been described previously.39-40 In a rabbit model, it has been shown experimentally that lipid 
infusions promote the growth of coagulase-negative staphylococci.41 The use of intravenous antibiotics 
was protective factor in our study, probably as a consequence of the use of broad-spectrum antibiotics 
or combinations of antibiotics, which reduces the amount of sensitive bacteria.  
The results of our surveillance did not point to a striking risk factor for which an intervention study 
could be initiated. Based on the surveillance results, we intensified training for nurses with emphasis 
on critical procedures in mechanical ventilation and the care of intravascular catheters because BSI and 
pneumonia were the most frequently occurring nosocomial infections. One possible future intervention 
to reduce the incidence of nosocomial BSI in the NICU could be the use of silver-impregnated central 
venous catheters, which have been shown to reduce the incidence of catheter-related BSI in high-risk 
adult patients with 44%.42 Also special teams dedicated to the care of intravenous catheters can result 
in a significant reduction in incidence of catheter-associated BSI.43 
Utilization ratios of medical devices in the NICU of the VU University Medical Center were collected 
according to NNIS.24 Our local utilization ratios for mechanical ventilators and central venous lines 
were high, even when stratified for birth weight. One explanation may be that, due to shortage of 
nursing staff, almost all infants on our unit are discharged to regional (level-II) hospitals as soon as 
they no longer require ventilator support. The patient population therefore always comprises the most 
critically ill neonates, which creates a patient mix quite specific for our NICU. Possible other 
explanations are differences in treatment strategy, or variation in illness severity on admission. The 
latter can only be partly corrected for by stratifying data for birth weight. In the 1990s, two illness 
severity scores were developed and validated for neonates: the CRIB and the Score for Neonatal Acute 
Physiology (SNAP).  Both scores perform better as predictors of mortality than birth weight 
alone.31,44,45 For investigation of the relation of illness severity and risk of nosocomial infection, we 
decided to use the CRIB because its performance is comparable to SNAP, but it is easier to measure.45  
In a subcohort of 232 neonates with a birth weight < 1500 g or gestational age < 32 weeks, we found 
no relation between CRIB and the risk on pneumonia or BSI.  
There are several possible explanations for the high incidence of infection in our NICU. Firstly, it can 
partially be explained by the use of our local, more specific definitions of infection. This was 
confirmed in a retrospective subanalysis. Controversy exists whether a Ureaplasma pneumonia is a 
nosocomial infection or a maternally acquired infection, which becomes symptomatic > 48 hours after 
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birth.32-34 Secondly, the patient-nurse ratio in an intensive care setting is critical. If this ratio is 
unfavourable, it has been shown in several studies that adherence to infection control measures is 
reduced.46-49 During our surveillance, there were periods that the patient-nurse ratio was suboptimal. 
In conclusion, our newly designed definitions for nosocomial infection performed well in our NICU. 
However, the reliability of these new definitions would benefit from assessment in other units before 
they could be adopted more widely as standard definitions. Cox analysis with time-dependent variables 
proved to be useful to identify risk factors in relation to the time of infection onset. The risk factors 
that we identified were low-birthweight category, intravenous feeding with Minimix and mechanical 
ventilation. The use of intravenous antibiotics was a protective factor. Our local nosocomial infection 
rates were high, compared with those found in NNIS studies. This is, in part, a consequence of the use 
of more sensitive and specific criteria, and the high utilization ratios for central venous lines and 
mechanical ventilation in a critically ill patient population. Xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
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Summary  
 
A premature infant in the neonatal intensive care unit (NICU) developed a bloodstream infection caused 
by coagulase negative staphylococci (CoNS), sensitive to vancomycin. The infection persisted for three 
weeks, despite therapy with vancomycin and replacement of all intravenous catheters. The neonate died 
due to necrotizing enterocolitis which developed during the ongoing sepsis. We screened this strain and 
216 other strains of CoNS from cultures of blood obtained from neonates between 1997 and 2000 for 
hetero-resistance to vancomycin. Forty-eight isolates, including the strain that caused ongoing sepsis, 
proved hetero-resistant. All isolates were identified as Staphylococcus capitis, and were identical, just as 
their resistant stable subcolonies were, when they were genetically fingerprinted by Amplified-Fragment 
Length Polymorfism analysis. The heteroresistant phenotype of this endemic strain was confirmed by 
population analysis. We conclude that heteroresistance to vancomycin occurs in S. capitis and might be the 
cause of therapy failures in  NICUs. Moreover, heteroresistant strains can become endemic in such units.   
  
Chapter 3 
Introduction 
 
During the last two decades, coagulase-negative staphylococci (CoNS) have emerged as the leading cause 
of bloodstream infections and septicaemia in neonatal intensive care units (NICUs).11,12 Although 
bloodstream infections caused by CoNS do not cause excess mortality, they lead to increased rates of 
morbidity and longer hospital stays.7 Various independant risk factors have been identified for 
bloodstream infections caused by CoNS.6,13,21 In an ongoing surveillance project, we found that in the 
NICU of the VU University Medical Center more than 50% of bloodstream infections are caused by 
CoNS. Because the majority of these microorganisms are resistant to ß-lactam antibiotics, the treatment of 
choice in the NICU of the VU University Medical Center is vancomycin.  
Over the past 5 years, the reduced sensitivity of methicillin-resistant Staphylococcus aureus to vancomycin 
and the possible implications of this reduced sensitivity for therapy have generated much concern.8,17,33 In 
Japan, a homogeneously vancomycin-resistant  (MIC,  > 8 mg/liter) S. aureus strain emerged from an 
endemic methicillin-resistant S. aureus strain which was hetero-resistant to vancomycin.17 Hetero-
resistance is defined as the presence of >10-6 stable cell subpopulations of a strain that is apparently 
susceptible to vancomycin but for which the vancomycin MIC for the subpopulation of cells is greater than 
or equal to 8 mg/liter.17 
Decreasing susceptibility to vancomycin has also been described for CoNS.10,30,32,37 Although CoNS are 
less pathogenic than S. aureus, they are important causes of opportunistic infections in hospitalized 
patients. However, the true clinical significance of the hetero-resistant phenotype remains to be elucidated. 
Against staphylococci with heteroresistance to vancomycin, the effect of therapy with a combination of 
vancomycin and ß-lactam antibiotics can be either antagonistic or synergistic.1,16,19,37   
Routine laboratory techniques, such as the disk diffusion method and the E-test, fail to detect 
heteroresistance to vancomycin in staphylococci.3 This can best be detected by population analysis, which 
is not suitable for routine purposes.15 Recently, a convenient disk agar screening method for detection of 
heteroresistance to vancomycin was developed at the department of Bacteriology of the Juntendo 
University.18 Wong et al. used this method to study the clinical significance of vancomycin-heteroresistant 
staphylococci.37  
A case of ongoing sepsis caused by CoNS in a neonate who did not respond to vancomycin therapy 
prompted the present study. The aim of the study was to investigate whether heteroresistance to 
vancomycin might have played a role in this case of therapeutic failure. Furthermore, we screened more 
than 200 CoNS strains from cultures of blood from neonates in the VU University Medical Center NICU 
for the presence of heteroresistance. Heteroresistant strains were genetically typed to study their 
relatedness.  
 
 
Materials and methods 
 
Selection of  isolates for screening for hetero-resistance to vancomycin. At the department of Medical 
Microbiology and Infection Control of the VU University Medical Center, significant strains isolated from 
blood cultures are routinely stored at  -80 °C, for future reference. Isolates of CoNS from cultures of blood 
from neonates in the NICU were identified by scrutinizing laboratory records for the years from 1997 to 
2000. If more than one blood culture from a single patient was positive within 2 days and yielded two 
strains of CoNS  with identical antibiotic profiles, only one of the two strains was selected for screening. A 
total of 217 isolates were studied.  
Screening for heteroresistance. Screening for heteroresistance was performed essentially as described by 
Wong et al.37 Brain Heart Infusion (BHI) agar plates with 4 mg of vancomycin per liter were prepared in-
house. Isolates were cultured overnight at 37 °C on sheep blood agar. A sterile swab was dipped into a 
suspension of the strain, adjusted to a turbidity equivalent to that of a 1 McFarland standard, and used to 
inoculate two BHI agar plates containing vancomycin. A 30 µg aztreonam disk was placed on the BHI 
plate within 5 min of inoculation. The plates were read after 48 hours of incubation at 37 °C; strains with a 
zone of enhanced growth around the aztreonam disk were regarded as candidates for vancomycin 
heteroresistance.  
Testing the stability of vancomycin-resistant subcolonies. Five colonies from strains A, B and C that 
grew on BHI-agar containing 8 mg of vancomycin per liter were tested for stability of resistance. These 
colonies were subcultured five times on antibiotic-free sheep blood agar. Subsequently, resistance to 
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vancomycin was tested by plating 40 µl of a suspension with a turbidity equivalent to that of a 2 
McFarland standard on a BHI-agar plate containing 0, 2, 4, 8, or 16 mg of vancomycin per liter. 
Population analysis. Population analysis was performed with strains A, B and C and five subcolonies 
(subcolonies A1 to A5) from strain A after five passages on antibiotic-free agar.15 Furthermore, S. capitis 
strains isolated from neonates in 1999 (strain D) and 2000 (strain E) were investigated. For this purpose 
strains were cultured overnight in BHI-broth. Then, 50 µl of the bacterial suspension was transferred to 
prewarmed BHI-broth and incubated at 37 °C until the optical density at 578 nm was approximately 0.7. 
After adjusting the optical density to 0.3 (approximately 108 CFU/ml), 10-fold dilutions of cell 
suspensions were made with 0.9% sodium chloride. Fifty microliters of these dilutions was used to 
inoculate BHI-agar plates containing 0, 1, 2, 3, 4, 5, 6, 7, or 8 mg of vancomycin per liter or 0, 0.5, 1, 2, 4, 
8, 16, or 32 mg of teicoplanin per liter, with a spreader. Plates were incubated at 37 °C for 48 h and the 
colonies were counted. 
Identification of hetero-resistant CoNS-strains. Identification of heteroresistant strains was performed 
with the API Staph system (bioMérieux inc., Marcy-l’Etoile, France). 
Genetic fingerprinting of heteroresistant strains. Genotypic fingerprints were obtained by Amplified-
Fragment Length Polymorphism (AFLP) analysis. DNA was isolated as described previously.2 Purified 
DNA was aliquoted and stored at -20 °C. All procedures relating to the preparation of templates for AFLP 
analysis were performed essentially as described by Koeleman et al.22  Briefly, total cellular DNA (50 ng) 
was digested with the restriction enzymes EcoRI and MseI and restriction half-site-specific double-
stranded oligonucleotide adaptors were ligated to the restriction fragments. Restriction and ligation were 
carried out simultaneously (3 h, 37 °C). Amplification was performed with a combination of primers (Eco-
A and Mse-C) with one selective base. Primer Eco-A was fluorescently labeled with Texas red (Isogen 
Bioscience BV, Maarssen, The Netherlands). Amplification was performed in a Gene Amp PCR system 
9700 thermal cylcer (Perkin-Elmer) for 35 cycles of denaturation for 30 s at 94 °C, annealing for 30 s at 65 
to 56 °C, and DNA molecule extension for 1 min at 72 °C. In the first 12 cycles the annealing temperature 
was lowered 0.7 °C per cycle. Fluorescent amplified fragments were separated by polyacrylamide gel 
electrophoresis (Rapid Gel-XL-6, Amersham Life Science, Cleveland, Ohio, USA) according to the 
instructions of the manufacturer in a Vistra 725 automated DNA sequencer (Amersham Life Science). The 
gel images were processed with Gel Compar software (version 4.0; Applied Maths, Kortrijk, Belgium). 
Levels of similarity between fingerprints were calculated with the Pearson product moment correlation (r) 
and grouping was obtained by the unweighted pair group method with average linkages.  
All hetero-resistant strains and five vancomycin-resistant subcolonies from strain A, B, and C were 
investigated by AFLP analysis. For comparison, several different (reference) species of staphylococci  
were included.28 Reproducibility  was tested by repeat typing.  
 
 
Results 
 
Description of the clinical course of neonates from which strains A, B, and C were isolated. 
(1) Strain A. A summary of the clinical course for the neonate from which strain A was isolated is 
presented in Figure 1. Strain A was isolated in September 1998 from a neonate of 28 weeks of gestation 
(birth weight, 640 g), who was admitted to the VU University Medical Center NICU because of 
respiratory insufficiency. The neonate was treated with penicillin and amikacin for 6 days. On day 7 of 
life, the neonate’s clinical situation deteriorated and therapy was switched to meropenem. Blood cultures 
grew  
CoNS resistant to oxacillin but sensitive to vancomycin, as determined by the disk diffusion method. On 
day 9, treatment with vancomycin (20 mg/kg of body weight/day as one dose) was started. On day 16 of 
life the neonate’s clinical condition once again deteriorated; meropenem was added to vancomycin. Blood 
cultures were again positive for CoNS. The vancomycin MIC for this strain was 3 mg/liter, as determined 
by the E-test. The central venous catheter was removed, and peripheral venous and arterial catheters were 
changed on day 20, but blood cultures remained positive for CoNS. Ultrasound investigations were 
repeatedly negative for thrombi in the heart or elsewhere. On a few occasions during the septic episode, 
the trough levels of vancomycin in serum were too low (normal trough levels, 5 to 10 mg/liter) , but the 
peak levels in serum were always good (normal peak levels, 20-40 mg/liter). The neonate developed 
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necrotizing enterocolitis on day 27 and died on day 29. On autopsy, no intravascular thrombus was found. 
Postmortem cultures of intraperitoneal and pleural fluid grew Klebsiella pneumoniae.  
(2) Strains B and C. Strains B and C were isolated from neonates admitted to the VU University Medical 
Center NICU during the same period that neonate A was admitted. Neonate B had a septic episode caused 
by CoNS in the second week of life. He was treated with vancomycin for 7 days and recovered. Neonate C 
twice experienced sepsis caused by a strain of CoNS over an interval of 1 week during the second half of 
August and was treated with vancomycin for 6 and 8 days, respectively, with good results. In these 
neonates, trough and peak serum levels of vancomycin were also suboptimal on some occasions. 
Vancomycin and meropenem were also administered to these two patients simultaneously for a few days: 
for 4 days in neonate B and for 10 days in neonate C. 
Screening for heteroresistance.  
We screened 217 strains of CoNS from positive cultures of blood from 163 neonates admitted to the VU 
University Medical Center NICU between 1997 and 2000, including the strains that caused sepsis in 
neonates A to C described above (Table 1). Among the strains isolated in 1997, none was positive by the 
screening test. For the period from 1998 to 2000, about one-third of the bloodstream infections were 
caused by heteroresistant strains of CoNS that showed enhanced growth around the aztreonam disk on the 
screening plate. Over these years, we observed a significant increase of the diameter of enhanced growth 
around the aztreonam disk (Table 1); the meaning of this observation is unclear. Two isolates showed 
confluent growth on the screening plate but did not show enhanced growth around the aztreonam disk. 
Population analysis.  
Strains A to E possessed heterogeneous growth curves by population analysis with vancomycin and 
teicoplanin (Figure 2). The growth curves for strains A1 to A5 did not differ from those for strain A to E 
(data not shown). Strains A to E fulfilled the definition of vancomycin heteroresistance, having 
subpopulations resistant to 4 mg of vancomycin per liter at frequencies of 2.8 x 10-5, 1.8 x 10-4, 3.0 x 10-5, 
6.5 x 10-5 and 3.4 x 10-5, respectively.17 
Stability of vancomycin-resistant subcolonies. 
The heteroresistant phenotype was stable in all subcolonies tested. After five passages on antibiotic-free 
agar plates, the subcolonies still grew on a BHI agar plate containing 8 mg of vancomycin per liter. 
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Figure 1. Neonate A 
 Figure 1. Schematic overview of period of NICU admission of neonate A with ongoing sepsis caused by a S. capitis
strain heteroresistant to vancomycin. For detailed information: see the Results. Normal values for vancomycin are as 
follows: trough level in serum: 5.0 to 10.0 mg/liter; peak level in serum: 20.0 to 40.0 mg/liter. Abbreviations: PEN, 
penicillin; AMK, amikacin; MEM, meropenem; VAN, vancomycin. 
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Figure 2. Population analysis 
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Figure 2. Population analysis of five clinical isolates (strain A to E) of S. capitis that were positive by 
screening for inducible heteroresistance (for descriptions of the strains, see Materials and Methods) and 
two reference strains of S. capitis. Profiles for vancomycin (A) and teicoplanin (B) are shown. 
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Table 1.  Results of screening of strains of CoNS from 217 positive cultures of 
blood from 163 neonates from the NICU obtained between 1997 and 2000 
 
  
Blood cultures positive for CoNS       
 
Year Total No. No. (%) with             No. with      Mean (min-max) diam eter (cm)
             heteroresistant      heteroresistant     of enhanced growth around        
          CoNS         S. capitis   aztreonam disk on screening plate 
 
1997     58       0 (0)              
1998     49     14 (29)              14            1.8 (1.5-2.1)  
1999     59     14 (24)              14             2.0 (1.5-2.9)   
2000     51     20 (39)              20             2.3 (1.9-3.0)   
 
 
Neonates for which cultures were positive for CoNS 
 
Year Total No.    No. (%) infected with  
hetero resistant S. capitis 
 
1997      38         0 
1998      36       11 (31)  
1999      42       13 (31)  
2000      47       18 (36) 
 
 
Identification of heteroresistant strains of CoNS. 
All 48 strains positive by screening, including the three confirmed heteroresistant strains, were identified 
as S. capitis (Table 1). The two strains with confluent growth on the screening plate were identified as S. 
haemolyticus. 
Genetic fingerprinting of heteroresistant strains.  
AFLP analysis showed a good reproducibility and discriminatory power when the region from 50 to 500 
bp was tested (Figure 3). On the basis of the results of tests with various Staphylococcus species, a cutoff 
value of 90% for identical strains was determined. Strain A, B, and C, and the 5 stable vancomycin-
resistant subcolonies from each parent strain were identical (homologies, > 90%) and different from the 
two S. capitis reference strains (Figure 3). All 48 confirmed and presumptive heteroresistant S. capitis 
strains were identical (homologies, > 90%) when the region from 50 to 250 bp was tested (Figure 4). We 
concluded that clonal spread of a single heteroresistant S. capitis strain had occurred over a period of 3 
years. 
 
 
Discussion 
 
This study was initiated after the detection of a case of ongoing sepsis caused by CoNS in a premature 
neonate, as determined by several positive blood cultures. Treatment with vancomycin was not effective. 
The sepsis was caused by a strain of S.capitis, which was heteroresistant to vancomycin. Screening of 
more than 200 isolates of CoNS from cultures of blood from neonates in the VU University Medical 
Center NICU showed that this S.capitis strain had been endemic in the unit since 1998 and that it was the 
causative agent of about one-third of all cases of bacteremia caused by in the VU University Medical 
Center NICU.   
The heteroresistant phenotype of the isolate causing ongoing sepsis was not detected by methods routinely 
used in our laboratory, i.e. the disk diffusion method and the E-test (on Mueller-Hinton agar with an 
inoculum with a turbidity equivalent to that of a 0.5 McFarland standard). A recent study by Walsh et al.,36 
which was published after our study was conducted, showed that a modified E-test (with BHI agar and an  
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inoculum with a turbidity equivalent to that of a 2.0 McFarland standard) is the most sensitive and specific 
method for the detection of staphylococci with reduced susceptibilities to glycopeptides which can be used 
in the daily laboratory routine. 
Persistent staphylococcal bacteremia in premature neonates that does not respond to vancomycin therapy, 
despite the susceptibility of the bacteria to vancomycin, has been described in a series of 10 neonates by 
Tan et al.34 The isolates of that study were methicillin-resistant S. aureus (n=5), methicillin-sensitive S. 
aureus (n=2), and CoNS (n=3, the isolates were not further identified). A detailed evaluation of some of 
the neonates to establish a focus of infection was negative, so heteroresistance may have played a role in 
the persistence of the staphylococcal bacteremia. Addition of intravenous rifampin to the antibiotic 
regimen was effective in sterilizing cultures of blood from these neonates.   
Nosocomial transmission of endemic CoNS strains in a NICU, with the rate of endemicity being up to 
45% among all blood culture isolates, has been described before.20,24,35 Little is known about why certain 
strains become endemic and others do not. Sepsis caused by CoNS is the most frequent nosocomial 
infection in the VU University Medical Center NICU. Vancomycin therapy is instituted only if an 
oxacilin-resistant strain of CoNS is isolated from a blood culture, and the patient’s clinical deterioration 
cannot otherwise be explained. The frequent use of vancomycin in the NICU might have given the 
heteroresistant strain described here a selective advantage over other nonheteroresistant strains.4 However, 
in our screening we also identified two strains of S.haemolyticus which grew abundantly on the BHI agar 
plates with vancomycin. S. haemolyticus is known for its resistance to vancomycin.9,29 Nosocomial spread 
of S. haemolyticus in NICUs has been described before.23,26 The fact that in the VU University NICU those 
strains did not become endemic, indicates that other features of the endemic S. capitis strain may have 
facilitated its nosocomial spread.20  
Heteroresistance to vancomycin has been described in S. aureus, and it has been shown that it can be the 
predecessor of homoresistance.17 The mechanism of resistance to vancomycin in staphylococci is 
completely different from that in vancomycin-resistant enterococci. The vanA, vanB, and vanC genes have 
never been found in staphylococci, although experimentally the vanA gene has been transferred from 
enterococci to S. aureus.27 Although the precise genetic mechanism for vancomycin resistance in 
staphylococci awaits elucidation, it is considered that thickening of the cell wall peptidoglycan layer is 
responsible.14,31 Vancomycin is captured in the thickened cell wall and is prevented from reaching its 
targets on the cell membrane. 
Although the presence of subcolonies with reduced sensitivity to vancomycin may influence the clinical 
course of sepsis caused by CoNS,37 the true clinical significance of heteroresistant S. capitis must still be 
clarified. Neonate A died from necrotizing enterocolitis during ongoing sepsis caused by a heteroresistant 
S.capitis strain. The presence of necrotizing enterocolitis may explain why postmortem cultures of 
intraperitoneal and pleura fluid were positive for K. pneumoniae, which belongs to the normal intestinal 
flora. Although the cause of necrotizing enterocolitis is probably multifactorial and still unknown, 
infection-associated inflammatory mediators may play a role.25 Most of other conceivable causes for the 
failure of vancomycin therapy in this neonate, such as colonization of intravascular catheters or 
intravascular thrombi, were excluded. The levels of vancomycin in serum were sub-optimal on a few 
occasions; however, this was also the case for neonate B and C, who responded well to vancomycin 
therapy. It is well known that serum vancomycin concentrations in neonates cannot be reliably predicted.5 
Finally, it has been described that ß-lactam antibiotics may induce or enhance vancomycin resistance in 
staphylococci.1,37 The combination of vancomycin and meropenem could have enhanced the level of 
vancomycin resistance in S. capitis and might have contributed to the therapeutic failure. 
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Abstract 
 
In 1998, an outbreak of systemic infections caused by Bacillus cereus occurred in the neonatal intensive 
care unit of the VU University Medical Center, Amsterdam, The Netherlands. Three neonates developed 
sepsis with positive blood cultures. One neonate died, and the other two neonates recovered. An 
environmental survey, a prospective surveillance study of neonates, and a case control study were 
performed, in combination with molecular typing, in order to identify potential sources and transmission 
routes of infection. Genotypic fingerprinting by amplified-fragment length polymorphism (AFLP) showed 
that the three infections were caused by a single clonal type of B. cereus. The same strain was found  in 
trachea aspirate specimens of 35 other neonates. The case control study showed mechanical ventilation 
with a Sensormedics ventilation machine to be a risk factor for colonization and/or infection (odds ratio 
9.8; 95% confidence interval, 1.1 to 88.2). Prospective surveillance showed that colonization with B. 
cereus occurred exclusively in the respiratory tract of mechanically ventilated neonates. The epidemic 
strain of B. cereus was found on the hands of nursing staff and in balloons used for mechanical ventilation. 
Sterilization of these balloons ended the outbreak. We conclude that B. cereus can cause outbreaks of 
severe opportunistic infection in neonates. Typing by AFLP proved very useful in the identification of the 
outbreak and in the analysis of strains recovered from the environment to trace the cause of the epidemic. 
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Introduction 
 
Members of the genus Bacillus are aerobic spore-forming rods which are ubiquitous in nature.18 Despite 
their widespread distribution, even as normal skin flora, Bacillus spp. rarely cause infections. The 
exception is Bacillus cereus, which is a well-known cause of food poisoning and a dreaded cause of post-
traumatic endophthalmitis.18 B. cereus can also cause opportunistic infections, mainly in the 
immunocompromised host.5,18 Over the past 20 years, infections with this micro-organism in neonates 
have been reported occasionally.7,9,12 B. cereus, however, is also known as a cause of pseudo-
outbreaks.6,8,11 Differentiation between an outbreak and a pseudo-outbreak and determination of the source 
require careful analysis of patient data and accurate typing of the outbreak strain.  
Over the last several years, the isolation of Bacillus spp. from trachea aspirates of mechanically ventilated 
neonates in the neonatal intensive care unit (NICU) of our hospital had been common but had no apparent 
clinical implications. Between January and August 1998,  three neonates developed serious invasive 
infection with B. cereus, and 35 neonates were found to be colonized with this microorganism. We 
describe this outbreak, the identification of the outbreak strain through genetic typing by Amplified-
Fragment Length Polymorfism (AFLP), the risk factors for colonization, the vector of infection, and the 
measures taken to control the outbreak.      
 
 
Materials and Methods 
 
Microbiologic methods. B. cereus was identified as large aerobic, Gram-positive, catalase-positive, 
spore-forming rods growing as irregular hemolytic colonies on sheep blood agar. Genotypic fingerprints 
were obtained by AFLP.  DNA was isolated as described previously.3 Purified DNA was aliquoted and 
stored at -20 °C. All procedures relating to the preparation of AFLP templates were performed essentially 
as described by Koeleman et al .10 Briefly, total cellular DNA (50 ng) was digested with the restriction 
enzymes Eco RI and MseI, and restriction half-site-specific double stranded oligonucleotide adapters were 
ligated to all restriction fragments. Restriction and ligation was carried out simultaneously during 3 h at 37 
°C. Amplification of sets of restriction fragments was performed by PCR with a primer combination with 
one selective base (Eco-A and Mse-C). The Eco-A primer was Texas red fluorescently labeled (Isogen 
Bioscience BV, Maarssen, The Netherlands). Amplification was performed in a Gene Amp PCR system 
9700 thermal cycler (Perkin-Elmer) for 35 cycles: denaturation (30 s at 94 °C), annealing (30 s at 65 to 56 
°C) and DNA molecule extension (1 min  at 72 °C). In the first 12 cycles, the annealing temperature was 
lowered 0.7 °C per cycle. After denaturation (1 min at 95 °C, cooling on ice) fluorescent amplified 
fragments were separated by polyacrylamide gel electrophoresis (Rapid Gel-XL-6, Amersham Life 
Science, Cleveland, OH, USA) according to the manufacturer’s instructions in a Vistra 725 automated 
DNA sequencer (Amersham Life Science). Gel images were further processed with the Gel Compar 4.0 
software (Applied Maths, Kortrijk, Belgium). Levels of similarity between fingerprints were calculated 
with the Pearson product moment correlation (r), and grouping was obtained with the unweighted pair 
group method using average linkages. 
Strains. Typing of the following B. cereus isolates was performed: isolates from the three symptomatic 
cases as well as from 35 neonates that were asymptomatically colonized in the respiratory tract, isolates 
from balloons used for manual ventilation and from hands of medical staff, and other environmental 
isolates. In our laboratory, blood culture isolates are stored for future reference. Therefore, we were able to 
include control isolates obtained in previous years from blood cultures. These included one isolate from a 
neonate in January 1997 and 14 isolates from other patients. 
Study on the incidence of colonization with B. cereus. The incidence of colonization of newborn babies 
with B. cereus was determined retrospectively by reviewing laboratory work sheets from January 1997 
through January 1998. Although not instructed to mention the growth of colonies typical for Bacillus spp. 
on the laboratory work sheet, the majority of laboratory personnel did so on a routine basis. In this period, 
B. cereus isolates were not stored. In February 1998, all laboratory personnel were informed about the 
serious infections caused by Bacillus spp. in the neonates and instructed to report any growth of B. cereus. 
From that moment, the incidence of colonization was assessed prospectively, and B. cereus isolates were 
typed by AFLP and stored. 
Case control study on risk factors for colonization with B. cereus. To identify risk factors for 
acquisition of B. cereus, a case control study was conducted in April 1998. Because most isolates were 
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cultured from sputum specimens, our study focused on the respiratory tract and oral feeding. A case 
patient was defined as any patient admitted to the NICU between 7 January and 7 April 1998 from whom 
B. cereus was isolated from any site. Cases were identified by reviewing laboratory records. Risk factors 
for cases were recorded for the period preceding the first culture with B. cereus. Control patients, who 
stayed in the NICU during the same period and were negative for B. cereus in sputum, were selected 
randomly. Risk factors for control patients were recorded until the last negative culture. 
Surveillance of neonates. To establish the route of colonization, surveillance cultures were obtained from 
neonates that were present in the NICU in April and May 1998. Culture specimens were obtained two to 
three times per week from four sites: (1) umbilicus; (2) armpits; (3) anus, and; (4) trachea aspirate (if the 
neonate was mechanically ventilated) or throat (if the neonate was not mechanically ventilated). 
Surveillance of health care workers. Hand carriage with B. cereus was determined by printing the 
fingers of the dominant hand on a blood agar plate. Prints of fingers were collected from randomly 
selected members of the nursing staff of the NICU. For comparison, nursing staff members of other 
departments in the hospital were investigated by the same method. To determine the frequency of carriers 
of B. cereus outside the hospital, prints of fingers of randomly selected first year medical students were 
obtained. 
Environmental survey. In order to identify reservoirs of B. cereus in the NICU, environmental samples 
were obtained with sterile swabs premoistened with sterile saline. An initial survey was based on potential 
sources of B. cereus spores known from the literature.1,4,6,13,17 Based on the results of the case control 
study and the surveillance study, a second survey was directed at materials used in mechanical ventilation.  
Observation of procedures for cleaning and disinfection. All procedures for mechanical and manual 
ventilation were critically evaluated by an infection control practitioner, either by personal observation or 
by interviewing the nursing staff. Adherence to existing protocols for cleaning and disinfection of 
equipment used in intubation and mechanical ventilation was verified.  
Intervention. In the second weekend of July all Ambu balloons and Jackson-Reese balloons of  the unit 
were sterilized by autoclaving (4 minutes at 134 °C in a validated steam autoclave). From the moment of 
the intervention, the use of a balloon was restricted to one patient and the balloon was sterilized after 
discharge of the patient, before use in a new patient. 
Statistical analysis. Data for cases and controls were collected on standardized forms and analyzed with 
the SPSS statistical package version 7.5 and EXCEL version 4.0. For categorical variables odds ratios 
were calculated, and continuous variables were compared with Student’s t test. Whenever cells in a cross-
table contained zero and thus an odds ratio could not be calculated, 0.5 was added to every cell. Odds 
ratios with a 95% confidence interval not containing unity and mean differences with a 95% confidence 
interval not containing zero were considered statistically significant. 
 
 
Results 
 
Description of neonates with infections caused by B.cereus 
Salient features of cases are summarized in Table 1. 
Typing of strains 
The results of genotypic fingerprinting are shown in Figure 1. B. cereus strains isolated from the neonates 
who developed serious infection and from the 35 neonates who were colonized in the respiratory tract and 
isolates found in balloons used in manual ventilation and on the hands of some members of nursing staff of 
the NICU were closely related. Reference strains (NCTC 11143 and 11145 and ATCC 9139), strains 
isolated from other wards (N.6) and a strain isolated from  a dust sample in the NICU, differed markedly 
from the outbreak strain. It differed also from a strain isolated once before on the NICU in January 1997 
and from 14 other non-related clinical isolates of B. cereus from other wards in the hospital (1990 to 1997, 
data not shown).   
Incidence of colonization with B. cereus 
The incidence of colonization of mechanically ventilated neonates between January 1997 and January 
1999 is shown in Figure 2. Eighty-two percent of mechanically ventilated neonates became colonized 
during the first 5 days of life. The presumed vector of B. cereus was eliminated in the second weekend of 
July 1998; the incidence of colonization declined rapidly, and since September 1998 the epidemic strain 
has been isolated only once from a trachea aspirate.xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx x  
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Table 1. Salient features of the cluster of B. cereus infections  
 
 
 
Patient no 
 
1 
 
2 
 
3 
 
 
Birth date 
Place of birth 
 
 
11 January 1998 
VUmc 
 
11 February 1998 
VUmc 
 
11 March 1998 
At home 
Gender 
Gestational age (wk) 
Birth weight (g) 
 
Male 
28 5/7 
895 
Female 
26 4/7 
1000 
Male 
37 3/7 
2780 
Reason for admission 
to NICU 
IRDS (ventilator  
with HFOV), PDA 
IRDS (ventilator  
with HFOV) 
Perinatal asphyxia, 
persistent fetal circulation 
(ventilation with 
 HFOV and NO), 
hepatosplenomegaly 
 
Period of mechanical 
ventilation (day) 
 
0-12 0-33 0-16 
Day of colonization 
of respiratory tract 
with B. cereus 
 
5 5 14 
Day of infection 
 
11 12; 28 20 
Clinical picture 
 
Shock, DIC, hemorrhagic 
meningoencephalitis 
 
Sepsis; arthritis a Sepsis with diarrhea 
Cultures positive for 
B.cereus 
 
Blood, CSF, 
 trachea aspirate, 
 necrotic skin lesion 
 
Blood; 
 aspirate of knee a
Blood, CSF, tip of 
peripheral catheter 
Treatment 
 
Amoxicillin and 
cefotaxime 
 (1 day, until death) 
Meropenem and 
vancomycin (10 days); 
meropenem 
 (3 wk) a
Meropenem and 
vancomycin (21 and 7 
days, respectively) 
 
Outcome Died on day 12 Recovered; recovered a Recovered 
 
 
Abbreviations: VUmc, VU University Medical Center; IRDS, infant respiratory distress syndrome; PDA, persistent 
ductus arteriosus; DIC, diffuse intravasal clotting; HFOV, High Frequency Oscillatory Ventilation; CSF, 
cerebrospinal fluid; NO, Nitric Oxide 
 a Data for infections at day 12 and day 28, respectively 
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Table 2.   Risk factors for colonization and infection with B. cereus among patients 
                  in the Neonatal Intensive Care Unit 
          
Risk factor                   Cases    Controls     Odds ratio 
             (n = 22)   (n = 22)         (95%CI) a
                        or p-value 
       
General features 
    
   Mean duration of study (days)                  7.1    8.3          NS#
   Mean birth weight (gram)                      2018  2245          NS 
   Mean gestational age (wks)                    32 6/7  34 5/7          NS 
   Median Apgar score at 5 min                 8      8          NS 
   Way of delivery 
      Vaginal              13     14          NS 
      Caesarian section                9       8 
   Place of birth 
      VUmc b     12       9          NS 
      Other hospital                7     11 
      At home                  3       2 
 
Enteral feeding  
 
   Feeding 
      Breast milk                  8      13    0.40 (0.12-1.33) 
      Nenatal                   6        9    0.54 (0.15-1.92) 
      Nutrilon Premium                  3        9    0.23 (0.05-1.01) 
   Additives 
      Cornoil                  0        1             0.32 (0.01-8.25) c
      Dextrose                  0        0   
      Fantomalt                   1        1    1.00 
      Fortifier                   4        6    0.59 (0.14-2.48) 
 
Mechanical ventilation 
 
   Method 
      With endotracheal intubation            21      22     0.32 (0.01-8.25) 
      Without endotracheal intubation           4      10     0.27 (0.07-1.05) 
   Ventilation machine 
       Babylog               19      22     0.12 (0.01-2.55) 
       Sensormedics                  7        1     9.80 (1.09-88.2) 
       Infant flow                   4        1     4.67 (0.48-45.6) 
   Atomization with ventilation 
       Nitric Oxide      2        1     2.10 (0.18-25.0) 
       Ipratropium                  1        0                           3.14 (0.12-81.4) c
       Salbutamol                   0        0 
       Surfactant                  0        1               0.32 (0.01-8.25) c
   Humidifiers 
      Fischer Paikel                        19      22     0.12 (0.01-2.55) 
      Aquamod                   4        0     11.0 (0.55-216 ) c 
 
 
a Relative risk and 95% confidence interval (CI). # NS, not significant. 
b VU University Medical Center 
c Estimation of the odds ratio (see Methods) 
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Table 3. Colonization of fingers with Bacillus species (March 1998) 
 
 
 
Ward or group         No. of prints    No. (%) positive for  OR  (95%CI) a
of fingers      Bacillus species 
 
 
Neonatal Intensive Care Unit       30             11b (37%)    3.29 (0.92-10.0)  (NICU)   
 
Surgical Intensive Care Unit       12    1   (  8%) 
 
Traumatology ward        13        1   (  8%) 
 
Surgical gastroenterology ward         9    0   (  0%)        1.14 (0.33-3.98) (other wards) 
 
Surgical oncology ward          4    1   (25%) 
 
Plastic surgery and urology ward      11    2   (18%) 
 
Students         66    6   (  9%)        Reference-group 
 
a OR, odds ratio; CI, confidence interval.  
b Five of eleven were positive for the epidemical strain. 
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Figure 2. Epidemic curve 
Figure 2. Percentage of newly admitted mechanically ventilated neonates who became colonized with B. 
cereus  in the respiratory tract between January 1997 and January 1999. Balloons were sterilized by 
autoclaving starting from 14 July 1998. For January 1997 to January 1998, numbers were determined 
retrospectively by review of laboratory work sheets. For February 1998 to January 1999, numbers were 
prospectively determined. Jan, January; Jul, July. 
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Case control study 
Results of the case control study are shown in Table 2. General features and enteral feeding did not differ 
significantly for cases and controls. All cases and controls had been mechanically ventilated. Mechanical 
ventilation with the Sensormedics, a machine used for High Frequency Oscillatory Ventilation (HFOV), 
was the only risk factor for colonization. There were no significant differences in antibiotic treatment (data 
not shown). 
Surveillance of neonates 
During the surveillance period, 6 out of 32 neonates became colonized with B. cereus in the respiratory 
tract. These six neonates were all mechanically ventilated at that moment. Trachea aspirate was the first 
specimen from which B. cereus was isolated in every one of them. In one neonate, 3 days after 
colonization of the respiratory tract was assessed, a culture of the armpits grew B. cereus on only one 
occasion. Cultures of anus and umbilicus remained negative. The other mechanically ventilated neonates 
and neonates that were not mechanically ventilated remained negative for B. cereus. 
Surveillance of nursing staff 
Results are shown in Table 3. The percentage of carriers of B. cereus was higher, although not statistically 
significant, among  nursing staff of the NICU compared to other wards and to students. From the prints of  
fingers from the nursing staff of the NICU, both the strain of B. cereus found in neonates and non-related 
strains were isolated. For nursing staff of the other wards, only miscellaneous strains were found.  
Environmental culture survey 
Results of the two culture surveys are shown in Table 4. In the initial survey, only a sample of dust on a 
baseboard was positive for B. cereus. This strain was not related to the epidemic strain (Figure 1). The 
culture survey of materials used in mechanical ventilation identified manual ventilation balloons as the 
possible vector.   
Observation of procedures for cleaning and disinfection 
Mechanical ventilators were cleaned and disinfected according to standard procedures. Laryngoscopes and 
McGill forceps were disinfected with 70% alcohol before use. Balloons for manual ventilation were 
regularly cleaned manually with water and soap. 
Intervention 
The result of the intervention is shown in Figure 2. In July and August, after the intervention (sterilization 
of balloons), five new cases of colonization with the epidemic strain of B. cereus occurred. Cultures of 
prints of fingers of 15 randomly selected members of nursing staff of the NICU, performed in August 
1998, revealed one person who was positive for the epidemic strain of B. cereus. 
 
 
Discussion  
 
In this article, we describe an outbreak caused by B. cereus in a NICU, confirmed by molecular genetic 
fingerprinting. Contaminated balloons, used for manual ventilation, were found to be the vector of the 
microorganism, and introduction of routine sterilization of these devices ended the outbreak. Because of 
the widespread distribution of B. cereus, including as skin flora, the hospital environment can contain 
spores of B. cereus.1,4,13,16 Although this microorganism is known to cause invasive infections in 
immunocompromised hosts, it is often considered a contaminant when it is cultured from clinical 
specimens. Caution in the interpretation of positive culture results is also dictated by the reports on 
pseuodo-outbreaks due to contamination of equipment or even disinfectants.8,11 For maternity units and 
NICUs, dissemination of B. cereus has been described previously, with and without apparent cases of 
infection.2,7,20
A cluster of three cases of serious systemic infection (with positive cultures of blood, cerebrospinal fluid 
and synovial fluid)  within a period of 3 months prompted our investigation. Colonization of the 
respiratory tract of neonates with B. cereus had been a common finding over the last year. The regular 
isolation of B. cereus from tracheal aspirates was not viewed as a cause of concern because infections 
caused by B. cereus were not regularly seen; in previous years, infection had been reported only once in 
January 1997. We determined that B. cereus had been isolated regularly throughout 1997 and that 
approximately one-third of newly admitted neonates became colonized during their stay. The clonal nature 
of the strains that caused the cluster of invasive infections in 1998 and of the strains found in colonized 
infants was confirmed by  
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AFLP. This recently developed technique has a high degree of reproducibility and excellent discriminatory 
power.15 The routine protocol used in our laboratory for various bacterial species (digestion with EcoRI 
and MseI and PCR with a primer combination with one selective base, Eco-A and Mse-C) proved easily 
applicable and useful for typing of B. cereus.10
We can only speculate about the cause of this outbreak and the serious infections caused by this 
microorganism. It may have been due to the introduction of a more virulent strain of B. cereus in the unit. 
Little is known, however, about virulence factors for B. cereus. We observed that the epidemic strain 
produced hemolysin on blood agar, a factor which is associated with virulence in other bacterial species. 
Hemolysin production, however, is a common feature of B. cereus, and thus it can not explain the 
virulence of the epidemic strain. Most of the neonates admitted to our NICU are preterm babies and 
therefore immunocompromised, but no clear changes in the general characteristics of the patients admitted 
to the NICU occurred over the previous year. A case control study for colonization with B. cereus 
identified some interesting facts. Firstly, well-known risk factors for nosocomial pathogens in neonates, 
such as lower birth weight, lower gestational age, and longer duration of hospitalization, did not appear 
associated with colonization. Secondly, the Sensormedics machine, which is used for intensive mechanical 
ventilation (e.g., HFOV), was identified as a significant risk factor for colonization. A prospective 
surveillance of  newly admitted neonates also pointed to mechanical ventilation as a risk factor for 
colonization. Therefore, culture specimens were obtained from most materials used in mechanical 
ventilation. The probable cause of colonization of neonates with B. cereus was identified when the interior 
of the outlet of several balloons used in manual ventilation proved to be culture positive. AFLP typing  
 
Table 4. Environmental culture survey 
 
Culture specimen Remarks No. of 
cultures 
Positive for
B. cereus 
 
Initial survey 
 
   
Items situated in incubators  
of 2 colonized neonates  
e.g. toys, mattress 11 0 
Other items in NICU e.g. disposable paper napkins, towel, curtains, nurse’s 
uniform, five ventilator grids, dust samples, two 
cultures of Miele washing machine 
32 1a
Selected items from the 
kitchen 
e.g. tap water, 24 h old and freshly made drip feed, 
filtration paper 
9 0 
Bottles containing alcohol 
70% or soap 
 
 7 0 
With reference to case-
control study and 
surveillance of neonates 
 
   
Two Sensormedics ventilators  8 0 
Sensormedics used in culture 
positive neonate 
Including disposable hose set 11 0 
Materials used in intubation e.g. MgGill forceps, laryngoscopes, Silcospray 9 0 
Three Aquamod humidifiers One culture of water reservoir and two heating 
elements per humidifier 
9 0 
Randomly selected Ambu-
balloons b
 16 2 
Randomly selected Jackson-
Reese balloons b
The three positive balloons and one negative balloon 
were also positive for coagulase-negative 
staphylococci 
11 3 
a Dust on baseboard. 
b Specimens were obtained from the interior of  the outlet of the balloon. 
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showed that the strains isolated from these balloons were identical to those found in both colonized and 
infected babies. 
After intubation, neonates are manually ventilated before being connected to the mechanical ventilator, 
during transport or during cleaning of the ventilator. Most neonates became colonized within the first 5 
days of life, and so it is possible that B. cereus was blown in the respiratory tract during manual ventilation 
before connecting the neonate to the ventilation machine. All three neonates who developed systemic 
infection were mechanically ventilated with the Sensormedics machine. Abrasions of the trachea caused 
by the oscillating tube during HFOV with this machine may have served as a porte d’entrée. Indeed, 
sanguinary trachea aspirates are common with this type of mechanical ventilation. 
The exterior of the balloons was regularly cleaned with detergent. This method is insufficient to kill spores 
of B. cereus; spores can even survive in 70% alcohol.8,14 The interior of the balloons was not reached, and 
so the spores were also not removed mechanically. After the sterilization of the balloons by autoclaving in 
July, still five new cases of colonization occurred. This was probably due to person-to-person transmission 
through the hands of health care workers. In September all trachea aspirates were free of B. cereus. 
In summary, we provide evidence for a true outbreak of invasive infections caused by B. cereus in a 
NICU. We conclude that colonization of neonates with this microorganism should be prevented. 
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Summary 
 
Between August and November 1997, a nosocomial outbreak caused by gentamicin-resistant 
Klebsiella pneumoniae occurred in the neonatal intensive care unit (NICU) of the VU University 
Medical Center, Amsterdam, The Netherlands. Thirteen neonates became colonized and three of them 
became infected. Comparison of the isolates by Amplified-Fragment Length Polymorfism (AFLP) 
revealed clonal similarity for isolates of eight neonates  (homology > 90%). Cultures from 
environmental specimens were negative for gentamicin-resistant K. pneumoniae. A case-control study 
was conducted to identify risk factors associated with acquistion of gentamicin-resistant K. 
pneumoniae. Risk factors were lower gestational age and birth weight. These neonates need more care 
and handling an may therefore be more at risk for colonization. Length of stay on the NICU was 
significantly longer for cases, but mean time until colonization (6.3 days) was shorter than the total 
length of stay for controls (9.5 days). No single member of the medical or nursing staff was 
significantly more involved with cases than with controls. The outbreak was stopped by replacing 
gentamicin by amikacin as the antibiotic of first choice whenever the use of an aminoglycoside 
antibiotic was indicated.xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx   
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Introduction 
 
Gram-negative rods, like Klebsiella spp. are recognized causes of nosocomial infections.1-12  
Widespread use of antibiotics often leads to the selection of multiple antibiotic-resistant organisms. 
Klebsiella pneumoniae, which is naturally resistant to ampicillin and amoxycillin, is also increasingly 
resistant to cephalosporins through the production of extended-spectrum β-lactamases. Genes encoding 
for these enzymes are located on transferable plasmids that often carry other resistance factors, 
including resistance to aminoglycosides.13    
Almost 75% of nosocomial outbreaks caused by K. pneumoniae are traced to person-to-person 
transmission by direct contact and 25% to common sources.4 Several investigations have shown that 
healthcare workers commonly carry K. pneumoniae on their hands, and that carriage can last for 
several weeks, even when appropriate hand disinfection is practiced.14-15 Though reservoirs in the 
hospital environment have been found in several studies, in many outbreaks an initial source was never 
identified.16-18 The main reservoir is thought to be the lower digestive tract of colonized patients.3 
The present report describes a nosocomial outbreak of gentamicin-resistant K. pneumoniae in the 
neonatal intensive care unit (NICU) of our university hospital. A case control-study was conducted to 
identify risk factors for the acquisition of gentamicin-resistant K. pneumoniae. Despite several 
preventive measures, new cases still occurred. The outbreak was controlled by a change in antibiotic 
policy, whereby gentamicin was replaced by amikacin. 
 
 
Patients and Methods 
 
Microbiologic methods. Isolates were identified as Klebsiella spp. with the VITEK-system 
(bioMérieux, Vitek Inc, Hazelwood, USA). An additional  indole test was performed; when the strain 
was negative in this test it was identified as K. pneumoniae . The VITEK also routinely produced a 
susceptibility pattern for amoxycillin, amoxycillin+clavulanate,  piperacillin, imipenem, cephalotin, 
ceftriaxone, gentamicin, amikacin, norfloxacin, ciprofloxacin, nitrofurantoin, and cotrimoxazole. 
Resistance to gentamicin was defined as minimal inhibitory concentration > 16 μg/mL. Fingerprinting 
was performed by Amplified-Fragment Length Polymorfism (AFLP).19-21 DNA was isolated as 
described previously.22 Purified DNA was aliquoted and stored at –20 °C. All procedures relating to 
the preparation of AFLP templates were performed essentially as described by Janssen et al. and Vos 
et al.19-20  Briefly, total cellular DNA (50 ng) was digested with the restriction enzymes EcoR1 and 
Mse1 and restriction half-site-specific double stranded oligonucleotide adaptors were ligated to all 
restriction fragments. Restriction and ligation was carried out simultaneously during 2 hours at 37 °C. 
Amplification of sets of restriction fragments was performed by PCR with a primer combination with 
one selective base (Eco-A and Mse-C). The Eco-A primer was Texas Red fluorescently labelled 
(Isogen Bioscience BV, Maarssen, The Netherlands). Amplification was performed in a Gene Amp 
PCR system 9600 thermal cycler (Perkin-Elmer) during 35 cycles: denaturation (30 s at 94 °C), 
annealing (30 s at 65-56 °C) and DNA molecule extension (1 min  at 72 °C). In the first 12 cycles the 
annealing temperature was lowered 0.7 °C per cycle. After denaturation (1 min 95 °C, cooling on ice) 
fluorescent amplified fragments were separated by polyacrylamide gel electrophoresis (Rapid Gel-XL-
6, Amersham Life Science, Cleveland, OH, USA) according to the manufacturer’s instructions in a 
Vistra 725 automated DNA sequencer (Amersham Life Science, Cleveland, OH, USA). Gel images 
were further processed with the Gel Compar 4.0 software (Applied Maths, Kortrijk, Belgium). Levels 
of similarity between fingerprints were calculated with the Pearson product moment correlation (r) and 
grouping was obtained with the unweighted pair group method using average linkages (UPGMA). 
Case-control study. A case was defined as any neonate admitted to the NICU from which the 
epidemic strain of gentamicin-resistant K. pneumoniae  was cultured from any clinical site (n=8). For 
each case 2 neonates treated for at least 24 h on the same ward during the same period of time were 
randomly selected as controls. Controls had at least one negative culture of K. pneumoniae of sputum, 
throat, anus or perineum. Assessment of risk factors was made for cases in the period until the first 
positive culture. For controls the period of investigation was the period until the last negative culture.  
The following risk factors were recorded from the hospital records for case and control neonates: 
gender, place and mode of birth, gestational age, birth weight, total length of stay and for cases length  
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of stay on the NICU until colonization with K. pneumoniae,  type and duration of mechanical 
ventilation and use of intravascular catheters. Because person-to-person spread is a very important risk 
factor in outbreaks with Gram-negative bacteria, we tried to identify members of medical and nursing 
staff who were significantly more involved with cases than with controls. This was done by reviewing 
the medical records of cases and controls; any member of the medical and nursing staff who had 
written a report in the medical or nursing records was recorded. We also carried out the same 
procedure for radiologists performing ultrasound examinations in the NICU, because, by personal 
observation, we noticed that transducers were not always disinfected in between examinations of 
successive neonates.     
Surveillance and environmental cultures. Environmental samples of reusable materials used in 
intubation and of the coupling gel used in ultrasound examinations were obtained with sterile swabs 
premoistened with sterile saline. Surveillance  cultures of neonates  from: (1) sputum/bronchial lavage  
 
Table 2. Patient characteristics 
 
      Cases (n=8)    Controls (n=16) 
   
Gender:    - male                        3   13   * 
- female                        5     3 
Place of birth:   - our hospital                  7            6  * 
- other hospital                  1    10 
Mode of birth:   - Caesarian section                          3     9  
     - vaginal               5        7 
Gestational age (weeks):                    29   34   * 
Birth weight (g):                   1155        2210   * 
Length of stay (days):  - total           22.4           9.5   *   
- before positive culture              6.3     
    
* p < 0.05 
 
 
 
Table 3: Risk factors* 
                   Cases (n=8)  Controls (n=16)   
 
 
Mechanical ventilation: - with intubation      9.6            6.1  
(day/patient)   - CPAP            2.0    1.5  
 
Intravascular catheters: - peripheral venous line          7.9    8.3  
(day/patient)   - peripheral arterial line          5.8      4.2   
- umbilical venous line          5.9    3.7  
- umbilical arterial line         2.6    1.9  
 - Silastic line        1.5    0.6  
 - other central venous line    0.0    0.8      
Use of gentamicin     8    15 
(no. of patients) 
 
              highest OR            95%CI 
 
 
Hospital staff:   -  medical staff            9.0         0.89  -   91.2 
(contact with   - nurses           9.0          0.75  - 107.3 
cases and controls)  - radiologists        2.4          0.37  -   15.4 
 
* none of the risk factors was significantly related with acquisition of gentamicin-resistant K. pneumoniae 
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(in case of a mechanically ventilated neonate) or throat (in case there was no mechanical ventilation), 
and (2) anus, were obtained by sterile swabs. Swabs were smeared on a McConkey agar plate loaded 
with gentamicin (16mg/L).   
Statistical methods. Cases and controls were compared for presence of risk factors. Odds ratios (OR) 
and 95% confidence intervals (95%CI) were calculated. For differences in mean value for certain risk 
factors and patient characteristics a Student t-test was performed. XXXX 
 
 
Results 
 
Description of outbreak and control measures (Figure 1 and 2) 
The outbreak occurred on the neonatal intensive care unit (NICU) at the VU University Medical 
Center in Amsterdam, The Netherlands, from September to November 1997. The NICU of our hospital 
consists of two separate units. Unit 1 accomodates incubators with intensive care facilities, and unit 2 
accomodates nine incubators with high care facilities. Maximal occupation is 14 of the 20 incubators.  
The average length of stay is 10 days, after which the majority of neonates is transferred to medium 
care neonatal wards of community hospitals for further treatment and follow-up.  
The index patient was a female premature neonate with a gestational age of 31 weeks and a birth 
weight of 970 g. After admission to the NICU she was intubated for one day and one week later again 
for one day because of exhaustion caused by sepsis. After two and a half weeks a gentamicin-resistant 
K. pneumoniae strain was isolated from a sputum specimen. 
In the following two months another 12 neonates became colonized (Table 1), both in Unit 1 and Unit 
2. The majority of cases (nine out of thirteen neonates) were colonized in sputum. The urinary tract 
was also a frequent site of colonization . Three neonates became infected with gentamicin-resistant K. 
pneumoniae; two neonates developed pneumonia and one infant developed sepsis. She died six days 
later. 
Although nursing staff was aware of the importance of strict hand hygiene (infection control 
practitioners teach infection control issues on a 2-3 monthly basis), this topic was once again brought 
to the attention of medical and nursing staff. Whenever transportation of the neonate was possible, new 
cases were cohort isolated. Despite this control measures new cases with gentamicin-resistant K. 
pneumoniae still occurred in the following two months. 
During the first two weeks of November five neonates became colonized with gentamicin-resistant K. 
pneumoniae within 48 hours after admission (Figures 1 and 2). Because of this sharp rise in the 
number of new cases, a change in antibiotic policy was instituted: gentamicin was abandoned and was 
replaced by amikacin. 
Typing 
From the 13 colonized patients, isolates of 9 were successfully typed with AFLP (Figure 3). For eight 
isolates DNA-patterns showed a homology of more than 90%, which is indicative of similarity.  
Case-control study 
The characteristics of neonates included in the case-control study are shown in Table 2. Cases had a 
significantly lower gestational age and a significantly lower birth weight. Total length of stay was 
more than two times longer for cases compared with controls, but the mean length of stay for cases 
until colonization with gentamicin-resistant K. pneumoniae was shorter. As can be seen in Table 3, no 
risk factors for colonization were identified. Also, we were not able to identify members of staff or 
consulting radiologists who were significantly more involved with cases.   
Surveillance and environmental cultures 
Environmental cultures were all negative for gentamicin-resistant K. pneumoniae.The effect of the new 
policy was assessed by weekly surveillance cultures. Specimens were obtained from : (1) sputum or 
throat, because most cases were colonized in sputum and (2) anal swab, because gastrointestinal 
colonization has been shown to be an important reservoir of resistant Gram-negative rods.3 After 
abandoning gentamicin as first choice aminoglycoside and replacing it by amikacin, surveillance 
cultures in the following week revealed only one new neonate who had become colonized with a 
gentamicin-resistant K. pneumoniae. He had been admitted to the NICU a week before. The following 
two weeks no new cases occurred; the last surveillance cultures from all neonates were negative for 
gentamicin-resistant K. pneumoniae, so it was decided to stop surveillance. Up to the moment of 
writing (May 1999) no gentamicin-resistant or amikacin-resistant K. pneumoniae have been isolated. 
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Figure 1. Course of the outbreak 
 
 
 
 
 
 
 
Discussion 
 
During the last decades, Klebsiella spp have become a major cause of nosocomial infection. Especially 
in university hospital settings, outbreaks are caused by strains resistant to many antibiotics, e.g. 
aminoglycosides.  Jarvis et al. reviewed 24 nosocomial outbreaks caused by K. pneumoniae and found 
that over 50% of outbreaks occurred in NICUs.4 This high percentage can be explained by the 
susceptibility of this population of patients to colonization and infection, the widespread use of 
antimicrobial agents on these units, frequently overcrowded conditions, and the frequent handling of 
these patients by medical personnel.  
In this outbreak, epidemic gentamicin-resistant K. pneumoniae  were typed by Amplified-Fragment 
Length Polymorfism, a new technique which combines restriction fragment length polymorfism 
(RFLP) and polymerase chain reaction (PCR).19 Although isolates of all 13 cases were collected, 
technical problems and shortage of personnel resulted in only 9 isolates succesfully fingerprinted. 
Eight isolates were considered identical because they showed a homology exceeding 90%. Because 
this was considered sufficient evidence for nosocomial spread, no effort was made to type the other 
four isolates. 
The outbreak was controlled by a change in antibiotic policy in which gentamicin was replaced by 
amikacin. Although some studies have not found a significant relation between the use of antibiotics 
and the emergence of resistant bacteria, the selective pressure of the abundant use of gentamicin (23 of 
the 24 neonates  included in our case-control study were given gentamicin for various reasons) in the 
ward proved to be an important factor in this epidemic. Cephalosporins were never used as first-line 
antibiotics in our unit, so this was not a contributive factor for the selection of this gentamicin-
resistant, but cephalosporin-sensitive, strain of K. pneumoniae.  Environmental cultures from reusable 
materials used in intubation were performed because in the majority of cases the outbreak strain was 
isolated from sputum. Also the transducer used in ultrasound examinations, which has been described 
previously as an environmental source of K. pneumoniae,12 was investigated. Nevertheless, all 
environmental cultures were negative for gentamicin-resistant K. pneumoniae. Our case control study 
Figure 1. ?, Hospital admission before colonization; ?, Infection with gentamicin-resistant K. pneumoniae,  
                ?, Colonization with gentamicin-resistant K. pneumoniae. 
Change of 
antibiotic policy
August September October November December
August September  October   November      December 
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could not identify persons who were significantly more involved with cases, therefore culture of 
fingerprints from members of staff was not performed. 
The mean length of stay in our NICU has been constant over the past years (approximately 10 days). 
The patients colonized/infected with the gentamicin-resistant K. pneumoniae strain stayed longer on 
the NICU, but became colonized within one week (Table 2). Together with the finding of lower birth 
weight and lower gestational age as risk factors, this indicated that a possible factor favouring 
colonization with the epidemic strain was a greater need for care and handling of these smaller 
neonates.   
Though cohorting has proved to be a valuable control measure to prevent spread of gentamicin-
resistant K. pneumoniae,1  we were not able to do this in our NICU for two main reasons. Firstly, 
neonates were sometimes in such critical condition that transportation to the other unit was not 
possible. Secondly, at the time of the outbreak there was a shortage of nursing staff. The latter is also 
known to be an important factor in reduced adherence to protocols for hand disinfection by hospital 
personnel.23 Because the neonate within the incubator is essentially barrier nursed if strict hand 
disinfection is performed by medical and nursing staff, measures like using aprons and gloves were 
omitted. Surveillance of resistant Gram-negative bacteria is not routinely performed in the NICU of 
our hospital and it maybe that the cases were merely the tip of an iceberg. Hambræus et al. found that 
in a NICU of the university hospital of Uppsala, eight of the nine circulating phage patterns of K. 
pneumoniae were introduced by infants colonized on admission.6 In some NICUs every neonate that 
comes from an other ward/hospital is isolated until surveillance cultures are negative for multi-
resistant bacteria.3 In other NICUs surveillance is performed on anal swabs on a weekly basis in order 
to identify new strains of resistant bacteria. When aminoglycoside resistance is discovered the 
antibiotic concerned is immediately replaced by another. The fact that gentamicin-resistant K. 
pneumonaie disappeared from the ward favours the concept of rotating antimicrobial agents in NICUs 
to prevent selection of aminoglycoside-resistant bacteria. However the first goal must be to diminish 
the selective pressure, by optimizing the use of these antibiotics. Because of the nonspecific 
symptomatology of infection in neonates, improper use of antibiotics in the NICU cannot be avoided 
completely. 
 
 
Figure 2. Epidemic curve 
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Figure 2. Ten neonates became colonized (C) and three infected (I) with gentamicin-resistant K. pneumoniae.  
Change of antibiotic policy began on November 13th. 
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Abstract  
 
Objectives. Varicella-zoster virus (VZV) can cause severe disease in premature neonates. The fetus 
receives protective maternal VZV-immunoglobulin G (IgG) mainly in the third trimester of pregnancy. 
Therefore, premature neonates are considered at risk for VZV infection. Administration of varicella-zoster 
immunoglobulin (VZIG) within 96 hours after exposure effectively prevents severe illness in susceptible 
patients. The objectives of this study were to define the major determinants of the neonatal VZV-IgG titer 
and to determine the half-life of transplacentally acquired VZV-IgG. Guidelines provided by the Centers 
of Disease Control and Prevention (CDC) for the use of VZIG in (premature) neonates were evaluated. 
Methods. VZV-IgG titers were measured in sera of 221 neonates and 43 mothers using a quantitative 
enzyme-linked immunosorbent assay. In 27 neonates VZV-IgG titers were followed for up to 14 weeks.  
Results. In a linear regression model, the maternal antibody-titer was the major determinant of the neonatal 
titer (β=0.89); gestational age was only of minor importance (β=0.18). The median half-life of VZV-IgG 
in neonates was 25.5 days (range: 14.6-76.0 days). In the first weeks of life, major fluctuations of the 
VZV-IgG titer occurred in more than 50% of the neonates. The predictive value of CDC guidelines for 
identification of neonates who should receive VZIG in case of exposure to VZV was poor: positive and 
negative predictive values were 0.80 and 0.43, respectively.  
Conclusions. The neonatal VZV-IgG titer is predominantly predicted by the maternal VZV-IgG titer, 
whereas birth weight and gestational age are much less predictive than previously reported. 
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Introduction 
 
Varicella (chickenpox) is a highly contagious disease caused by varicella-zoster virus (VZV), a ubiquitous 
human α-herpesvirus.1,2 VZV is transmitted by direct contact, droplet, or airborne spread of vesicle fluid or 
secretions of the respiratory tract of patients with chickenpox or the vesicle fluid of patients with herpes 
zoster.3-6 The attack rate among susceptible household contacts is approximately 90%,1,2 but the risk of 
transmission in the hospital is probably lower.7 This usually self-limiting disease can cause serious 
morbidity and even mortality in premature and critically ill neonates.8-11 During pregnancy, protective 
maternal antibodies are transferred to the fetus. It is generally accepted that this transfer occurs mainly in 
the third trimester of pregnancy and therefore that premature neonates may not have acquired enough 
maternal antibodies to be protected.12-16 
Infected individuals start shedding the virus via the respiratory tract up to 5 days before the onset of 
symptoms.6 In addition, VZV-immunoglobulin G (IgG)-positive individuals may play a role in spreading 
the virus.17 Therefore, unintentional and inadvertent exposure of neonates cannot be completely prevented. 
For preventing such exposure, contact between neonates and siblings is avoided as much as possible, and 
nonimmune hospital staff are vaccinated. 
Introduction of VZV on pediatric and neonatal wards occurs regularly.3,9,11,18-24 Administration of 
varicella-zoster immunoglobulin (VZIG) within 96 hours after exposure has proved to be effective in 
preventing severe illness in seronegative patients.25 In our hospital, all neonates in the neonatal intensive 
care unit (NICU) are tested for VZV-IgG within 96 hours after exposure, regardless of maternal history, 
because the reliability of the maternal history for VZV is still uncertain.26-28 If neonates test negative, then 
VZIG is administered. 
The Centers for Disease Control and Prevention (CDC) recommends administering VZIG to exposed 
premature neonates with a gestational age < 28 weeks and/or a birth weight of < 1000 g, regardless of 
maternal history.16 Premature neonates of > 28 weeks of gestational age who are born to immune mothers 
are considered to have acquired enough maternal antibodies to be protected from severe disease and 
complications. 
To identify determinants of neonatal VZV-IgG levels, we measured VZV-IgG titers in 221 neonates and in 
43 mothers. The utility of CDC guidelines was evaluated. In addition, we determined the half-life of VZV-
IgG in 30 neonates by repeated measurements during the first 3 months after birth. 
 
 
Methods  
 
Study population. All neonates who were admitted to the NICU from April 1995 until February 2000 and 
 were tested for VZV-IgG because of possible exposure to the virus were identified retrospectively by 
review of laboratory records (n=157). To study the half-life of transplacentally acquired VZV-IgG in the 
neonate and the relation between the neonatal and maternal VZV-IgG titer, we studied 64 neonates and 43 
mothers prospectively. After informed consent was obtained from the mother, serum samples from mother 
and neonate were obtained within the first week after delivery. If the serum of the child tested positive for 
VZV-IgG, then permission was asked to obtain follow-up samples. Samples were obtained as close as 
possible to the following schedule: every week during the first month of life, every second week during the 
second month, and once a month during the following 4 months. The research protocol was approved by 
the local ethical committee. 
The following information was obtained from the medical records: gender, gestational age, birth weight, 
postnatal age (days) at which the serum sample was taken, multiple birth, and volume and type of 
transfusions administered before the serum sample was taken. Gestational age was calculated by menstrual 
history or, in case of irregular cycle, by ultrasound data obtained during the first trimester of pregnancy.  
Serological assay. Serum samples (100 µL) were tested for VZV-IgG quantitatively with an automated 
enzyme-linked fluorescent immunoassay (Vitek Immuno Diagnostic Assay System [VIDAS], bioMérieux, 
France). In international literature the sensitivity of VZV-IgG enzyme-linked immunosorbent assays has 
been reported to vary between 86% and 98%.16,29 Results of VZV-IgG enzyme-linked immunosorbent 
assays and the traditionally used fluorescent antibody to membrane assay are comparable.30 According to 
the manufacturer of the VIDAS-assay, sensitivity and specificity of the test are 99.7% and 97.6% 
respectively. Results are presented as the ratio (X) of the fluorescence value of the sample over that of a 
standard. Results are to be interpreted as follows: X < 0.60: negative; 0.60 < X < 0.90: equivocal; X  >
 72
Varicella zoster virus 
Table 1. General characteristics of study population  
 
Characteristic                       N (at risk*) 
 
Mothers              43   
Neonates    Total       221 
    Included in follow-up study   30  
    Duration of follow-up (d) Mean   52 
           Median   47 
           Range 15-98 
Ethnic background  White       171 
        Nonwhite          50 
Birth    Single birth       181 
       Multiple birth         Twins (17)       34 
              Triplets (2)           6 
Birth weight (g)    < 1000           35    (35) 
    1000-1499        72    (  9) 
    1500-2499        54    (  0) 
    > 2500          60    (  0) 
Gestational age (wk)  <28          23    (23) 
    28-31         85    (21) 
    32-36         66    (  0) 
    >37         47    (  0) 
Postnatal age at first   0-3       127 
time of serum    4-7         42 
sampling (d)   8-14         16 
    15-21         12  
    22-28           8 
    28-70         16 
Transfusion(s) before   Yes         76 
first sample   No       145 
VZV-IgG titer   Positive      167 
       Negative        54  
 
 a According to CDC 16
 
 
Table 2. Neonatal VZV-IgG titer in relation to maternal VZV-IgG titer 
 
Neonatal VZV-IgG titer  
 
                  At risk*             Not at risk *  
     
    Positive Negative Positive Negative 
Maternal VZV-IgG titer 
  Positive         9       1 †      32        2 †     44   
  Negative         0       2        0        5            7 
 
     9       3      32       7  51 
 
Predictive value of maternal VZV-IgG titer: 
Positive predictive value (not at risk) :  41/44 = 0.94 
Negative predictive value (at risk):   7/7 = 1.00 
 
* According to the CDC 16, † Clinical information for these neonates is in ‘Results’    
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Table 3. Neonatal VZV-IgG titer in relation to CDC criteria 16 
 
 
   Neonatal VZV-IgG titer 
      Positive Negative 
 
            Not at risk       142          35    177 
According to CDC: 
      At risk    25         19      44  
 
167         54    221 
Predictive value of CDC-criteria: 
 
Positive predictive value (not at risk):  142/177 = 0.80 
Negative predictive value (at risk):    19/44  = 0.43 
 
 
 
0.90: positive. Cutoff values are stored in the VIDAS testing machine and are deduced from test values of 
the standard. Because of the use of the standard as an internal control, the results of various runs are 
comparable. We considered equivocal results as negative.   
Calibration of the VZV-IgG assay. The VIDAS VZV-IgG assay was calibrated with the International 
Standard from the World Health Organization containing 50 International Units (IU) of VZV-IgG. The 
standard was dissolved in 1 mL of sterile water. A two-fold dilution series was tested twice in two runs 
with 2 different kits with different lot numbers (total = 4 series). 
Estimation of the half-life of VZV-IgG in neonates. The half-life of VZV-IgG was estimated using the 
titers from neonates with positive VZV-IgG titers at birth. The half-life was calculated using the VZV-IgG 
titer of the first and the last serum sample from each child.  
Study on mother-child serum pairs: linear regression model of neonatal anti-Varicella IgG titer. 
Data obtained from 51 neonates, for which a maternal titer was available, were included in a linear 
regression model. Among those 51 neonates were 8 twins; therefore 43 mothers contributed to 51 
serumpairs. The following variables were entered in the model: maternal VZV-IgG titer, gender, 
gestational age, age on day of serum sample, transfusions of packed cells, filtered erythrocytes, 
thrombocytes or fresh-frozen plasma, multiple birth and the ethnicity of the mother (white or not). Birth 
weight was not entered because this variable was multicollinear with gestational age (r = 0.90). Two 
multivariate linear regression models are presented: a model in which all variables are entered and a 
stepwise model in which nonsignificant variables are withdrawn. Because the partial regression-
coefficients have different dimensions, we use the standardized coefficient β. This is a regression 
coefficient without dimension which is calculated as follows: β = regression-coefficient (X) x (standard 
deviation of X [SX] / standard deviation of outcome variable [neonatal titer]). Therefore, β depicts the 
relative influence of each separate variable.     
Theoretical influence of transfusions of blood products containing various amounts of VZV-IgG 
antibodies and of blood withdrawal. Because blood products contain various amounts of plasma, 
neonatal VZV-IgG titers could be influenced by transfusions. The intensive monitoring of the clinical 
condition of the neonate requires frequent withdrawal of blood samples. Therefore, we calculated the 
theoretical effect of transfusions and  blood withdrawal on VZV-IgG titers in two fictitious neonates of 
gestational age and birth weight of 26 weeks and 877 g, and 38 weeks and 3409 g, respectively. Their 
extracellular volume (ECV), in which VZV-IgG is distributed, was calculated as 500 mL and 1500 mL.31
Predictive value of CDC guidelines and predictive value based on maternal titer. The predictive value 
of the CDC criteria was calculated for the total study population (n=221).16 The predictive value of the 
maternal titer was calculated for the subset of 51 neonates for which a maternal titer was available. 
Positive predictive value (PPV) was defined as the percentage of neonates with a positive VZV-IgG titer, 
predicted correctly by CDC criteria and the maternal titer, respectively. Negative predictive value (NPV) 
was defined as the percentage of neonates with a negative VZV-IgG titer (at risk), predicted correctly. 
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Figure 1 
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Figure 1. Results from follow-up study of VZV-IgG titers in 27 premature neonates. # Horizontal line indicates 
cutoff value (0.139 IU/mL). 
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Figure 2. Correlation of neonatal VZV-IgG titers with gestational age (n = 221). Rsq, R2 = correlation 
coefficient. Neonatal serum samples were obtained on day 0 to 70 of life. # Horizontal line indicates cutoff 
value (0.139 IU/mL). 
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Figure 3 . Correlation of neonatal VZV-IgG titer with corresponding maternal VZV-IgG titer (n=51). Rsq, R2 = 
correlation coefficient. Neonatal serum samples were obtained within the first week of life. 
# Horizontal and vertical line indicate cutoff value (0.139 IU/mL). 
 
 
Statistical analysis. Analysis was performed with the SPSS Statistical Package version 9.0 (SPSS Inc. 
Chicago, IL), EXCEL 4.0 (Microsoft, Redmond, WA), and Lotus-123 version 2.01 (IBM Software Group, 
Cambridge, MA). p < 0.05 was considered significant. 
 
 
Results 
 
Study population  
We included 221 neonates in the study. General features of the study population are presented in Table 1. 
Twenty-five percent of neonates had a negative VZV-IgG titer. In the prospectively recruited cohort of 64 
neonates, a maternal serum sample was not available in 13 cases. 
Calibration of the VIDAS  
Serial measurements of VZV-standard dilution samples showed an  excellent reproducibility of the test 
(fitted calibration curve: R2 = 0.993). 
Estimation of the half-life of maternally acquired VZV-IgG antibodies 
Results are shown in Figure 1. For all neonates taken together (n = 27), the median half life of VZV-IgG 
was 25.5 days (range 14.6-76.0 days). In 15 neonates with continuous and regular decreasing VZV-IgG 
titers, the median half-life was 21.4 days. In 12 neonates, at some time points, the titer was higher than at 
previous time points. The increases occurred mainly during the first weeks of life. During the follow-up 
period, transfusions of blood products were administered to neonates with regularly as well as irregularly 
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decreasing titers. In 3 cases, the last VZV-IgG titer (on day 5, 16, and 16 of life, respectively) was higher 
than the first; these 3 cases were excluded from the half-life calculations.  
Linear regression model of factors that influence neonatal VZV-IgG titer  
Results are shown in Figures 2 and 3. In a crude analysis of correlation (Figure 2), gestational age was a 
poor predictor of neonatal VZV-IgG antibody titer (R2  = 0.07). This was also the case for birth weight (R2 
 = 0.06). In contrast, maternal VZV-IgG titer (Figure 3) correlated well with neonatal VZV-IgG titer (R2 = 
0.72). This was also the case for neonates who were at risk according to the CDC guidelines. The linear 
regression model, in  which all variables were entered, explained 85% of variance of neonatal VZV-IgG 
titer, and the maternal titer was the major predictor of the neonatal VZV-IgG titer (β = 0.90, p < 0.01). 
Less important predictors were gestational age (β = 0.17, p = 0.02), and the ethnic background of the 
mother (β = 0.12, p = 0.05). In the stepwise linear regression model, explaining 84% of variance in 
neonatal VZV-IgG titer, gestational age (β = 0.18, p < 0.01), day of sampling serum (β = -0.17, p < 0.01) 
and the ethnic background of the mother (β = 0.15, p = 0.01) were included, but the maternal titer 
remained the single most important predictor of the neonatal titer (β = 0.89, p < 0.01).  
Three neonates had a negative VZV-IgG titer, despite a positive titer of the mother (Table 2, Figure 3). 
The first was a male neonate of gestational age 31 6/7 weeks and birth weight 1855 g; the other two were 
male twins with a twin-to-twin transfusion syndrome, of gestational age 28 5/7 weeks, and a birth weight 
of 766 and 1040 g, respectively.  We could not identify any particular features that could explain the 
discrepancy between maternal and neonatal VZV-IgG titer.   
Theoretical influence of transfusions and blood sampling 
In the simulation model, withdrawal of blood samples varying between 0 and 100 mL and administration 
of various volumes (0-50 mL) of transfusions with different VZV-IgG titers (0.5, 0.16, 0.12, and 0.05 
IU/ml, respectively) were evaluated. In general, withdrawal of blood and blood transfusions had little 
effect on neonatal VZV-IgG titers. Only in the simulation of a very premature neonate (gestational age of 
26 weeks) with a VZV-IgG titer approximately at the cutoff point did transfusions with a volume of > 20 
mL of blood products containing a high titer of VZV-IgG (0.5 IU/mL) or withdrawal of > 50 mL of blood 
affect the serostatus, changing it from negative to positive and positive to negative, respectively.  
Predictive value of CDC criteria and predictive value based on the maternal titer  
The predictive value of the CDC guidelines is shown in Table 3. Because 57% of the neonates who were 
at risk according to CDC criteria tested positive for VZV-IgG, the NPV of these criteria was very low 
(0.43). The PPV was higher (0.80). The PPV and NPV of the maternal titer were significantly better, 0.93 
and 1.0 respectively (Table 2).   
 
 
Discussion  
 
In the Netherlands, 98% of young adults is positive for VZV-IgG.32 Vaccination against VZV is not 
routinely performed. Because of this high seroprevalence, the majority of neonates acquire anti-VZV-IgG 
antibodies during gestation. In our study population, the maternal titer was the single most important 
predictive factor of neonatal VZV-IgG titers. The generally accepted hypothesis that very premature 
neonates have not acquired sufficient maternal antibodies to be protected from VZV could not be 
confirmed: 57% of premature neonates who were at risk according to the CDC guidelines had sufficient 
levels of VZV-IgG. The subanalysis of mother-child serum pairs showed that 2 very premature neonates 
(at risk according to CDC) had the highest VZV-IgG titer. In our opinion, CDC recommendations as to 
which neonates should receive VZIG in case of exposure to VZV, are not universally applicable. From our 
data, it seems impossible to predict the serostatus of a premature neonate on the basis of gestational age or 
birth weight alone. Possibly, the utility of the CDC definitions of which neonates are at risk for VZV 
should be defined for different populations, according to the prevalence of VZV-IgG in women of child-
bearing age. Our finding that almost 25% of neonates tested negative for VZV-IgG is most likely due to 
the fact that 52 of 221 neonates were tested at a postnatal age of > 1 week and that there was 
overrepresentation in our study population of neonates from immigrant mothers. Seroprevalence of VZV-
IgG positivity in (sub)tropical regions is known to be much lower than in regions with more temperate 
climates.33,34 In fact, both factors had a small but significant predictive value in the linear regression 
model. 
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Mendez et al. found that 10 out of 12 neonates with a gestational age < 30 weeks had a positive VZV-IgG 
titer.35 In another study, 23 premature neonates (gestational age: 22-31 weeks), born from VZV-IgG 
positive mothers, were tested for VZV-IgG with two serological assays; 17 of the 23 tested positive with at 
least one of the two VZV-IgG assays.23 Also, for IgG antibodies directed against other viruses, it was 
shown that the maternal titer is the most important predictor of the neonatal titer, although there is a small 
but significant difference between mature and premature neonates.36,37  
In healthy adults, the half-life of IgG antibodies is 21 days.38 The median half-life in our premature 
neonates was 5 days longer, although the subgroup with regular decreasing titers had a mean half-life 
almost equal to that of adults. In the first weeks of life, when the neonates are intensively treated, major 
fluctuations of the VZV-IgG titer occurred in 44% of the neonates. We could not explain these fluctuations 
by administration of blood products, because blood products were also given to neonates who showed a 
steadily decreasing VZV-IgG titer.  
In (premature) neonates, there are many factors (with opposite effects) that, in theory, can affect the 
neonatal VZV-IgG titer. Some of those factors cannot be measured and therefore could not be entered in 
the linear regression model. The neonatal VZV-IgG titer at birth is determined by the amount of maternal 
antibodies received during gestation as well as by the extracellular volume (ECV) in which these maternal 
antibodies are distributed. The ECV of neonates varies from 59% of total body weight at 24 weeks of 
gestation to approximately 44% at term and is approximately 30% 6 months after birth.31 However, 
because of growth, the absolute ECV increases, which  results in a steady increase of distribution volume. 
Second, at birth, a physiologic hemo-concentration occurs but resolves in a few days.39 Third, compared to 
the circulating blood volume, relatively large amounts of blood may be withdrawn for investigation, 
especially in the first weeks of life. In our NICU, in critically ill neonates, sometimes > 50% of blood is 
withdrawn in the first weeks of life; this is approximately 12% of ECV.25 Finally, administration of 
multiple transfusions of blood products is common.40 Through transfusions, seronegative individuals can 
become temporarily seropositive for VZV-IgG.41 Because of the high seroprevalence of VZV-IgG in the 
Netherlands, it is reasonable to assume that most  transfusions will contain a certain amount of VZV-IgG. 
We showed in a theoretical model that only large volumes of transfused blood products or of blood 
withdrawals influence the VZV-IgG titer and only in very low birth weight neonates.     
In our hospital, measurement of the VZV-IgG titer can be accomplished within a few hours. Therefore, it 
is always possible to identify neonates who are at risk for VZV and should receive VZIG within the 96 
hours period after exposure to VZV. VZIG cannot prevent the development of varicella, but it prevents 
serious life-threatening disease. Neonates lack optimal cellular responses to VZV. Therefore, it is possible 
that very premature neonates may benefit from boosting VZV antibody titers, even if they have 
measurable VZV-IgG titers at birth. So far, however, the effect of such boosting has not been studied. 
Therefore, until additional research is conducted, it may still be justifiable to provide passive antibodies to 
the very low birth weight infant. 
 
 
 
Conclusion  
 
We showed a large variability in neonatal VZV-IgG titers, which is predominantly determined by the 
maternal VZV-IgG titer. More than 50% of our premature neonates of < 28 weeks gestation and/or birth 
weight of < 1000 g, showed a measurable VZV-IgG titer. With a few exceptions, the maternal titer of 
VZV-IgG predicted the neonatal titer very well. The only means of determining whether a neonate is at 
risk for VZV infection with certainty is by actually measuring his or her VZV-IgG titer.  
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Abstract 
 
Mannose Binding Lectin (MBL) plays an important role in the innate immune response. Three alleles 
in the MBL-gene, and one allele of the promotor independently cause low serum MBL levels 
compared to the wild type. We investigated the relation between MBL genotype and the occurrence of 
nosocomial infection in neonates in the neonatal intensive care unit (NICU). Prospectively gathered 
information on nosocomial infection of 742 neonates was available from a recently performed 
surveillance study in our NICU. DNA was isolated from Guthriecards of a subgroup of 204 of the 
neonates that stayed on the NICU for at least 4 days. After a pre-PCR of the MBL-gene on blood spots 
on Guthriecards, mutations were analysed by allelic discrimination by real-time PCR for 6 mutations 
in the MBL-gene. For 186 neonates an MBL-genotype could be determined. Forty-one of these 
neonates had developed sepsis. In 25/41 cases blood cultures grew coagulase negative staphylococci 
(CoNS). Pneumonia occurred 29 times, with various causative organisms. We found no relation 
between MBL genotype and risk for nosocomial sepsis or pneumonia, even after correction for birth 
weight. Possibly, this is due to an insufficient correlation between genotype and concentration of 
functional MBL. In addition, the majority of bloodstream infections in the NICU is caused by CoNS, 
to which MBL binds poorly. 
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Figure 1. Function / structure of Mannose Binding Lectin (MBL) and MBL-gene 
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Figure 1. Mannose Binding Lectin. Genetics, function and structure 
Normal function. Mannose Binding Lectin (MBL) is produced in the liver and is encoded by the MBL-2 gene 
on chromosome 10q21. The MBL-2 gene consists of 4 exons which encode for the four components of the 
MBL-subunit: (1) a cysteine rich region, (2) a collagenous domain, (3) a neck region and (4) a carbohydrate 
recognition domain. Three MBL-subunits are entwined to a MBL-structural unit. Two to six structural units are 
combined to higher MBL-polymere structures. Circulating MBL-polymers can bind to repeating sugar-groups 
on the outer membrane of various microorganisms (viruses, bacteria, parasites, yeasts); those repeating sugar 
groups do not exist on human cells. On binding, MBL-associated Serine Protease (MASP) is activated through 
conformation changes in the molecule, which activates the complement system to produce activated C3b,  
which opsonizes the microorganism. Eventually, this opsonization promotes the elimination of the 
microorganism by complement receptor-bearing cells.  
Consequences of mutations in the MBL-gene. Three point mutations in exon-1 (haplotype B, C, D), lead to 
deficient MBL subunits, which can not combine to a MBL-structural unit, and thus to MBL-deficiency. Each 
mutation leads to a rather similar phenotype. Homozygous mutants have an almost undetectable MBL and 
heterozygotes (wild/mutant) have about 10% of detectable MBL compared to wild-type homozygotes, and the 
MLB molecule consists mainly of monomeric triplet units. Furthermore several mutations are possible in the 
promotor region in which a homozygous X mutation also leads to a almost undetectable MBL. Through a 
linkage disequilibrium are only 7 haplotypes: HYPA, LYPA, LYQA, LXPA, LYPB, HYPD, LYQC.   
 
 
Introduction 
 
The immune system comprises two separate systems. Firstly, there is the evolutionary old and 
aspecific innate immune system, consisting of different protein systems, among which the complement 
system and Mannose Binding Lectin (MBL). Secondly, there is the more specific adaptive immune 
system, which is composed of the white range of blood cells. The latter is more effective but is time-
delayed. If the adaptive immune system is not compromised, the innate immune system is of minor 
importance.1 However, if the adaptive immune system is compromised the influence of MBL-
deficiency becomes apparent.2,3  
MBL is a Ca2+-dependent collagenous lectin, and has a bouquet-like structure which recognizes 
patterns of, and can bind to, repeating structures of polysaccharides on the surface of many micro-
organisms (Figure 1). It functions as an ante-antibody, which means that it opsonizes micro-organisms 
before specific IgM can be produced.4 Subsequently, an MBL-associated serine protease (MASP-2), 
which is functionally analogous to C1-esterase, activates the complement cascade leading to killing of 
the micro-organism.   
The structure of the MBL-monomere is encoded by the MBL-2 gene on chromosome 10 (Figure 1). 
Functional MBL consists of a polymer of various MBL-monomers, which impresses as a bundle of 
tulips. Three single-base pair substitutions in exon-1 of this gene give rise to three mutant-alleles (B, 
C, D) leading to failure of assembly of the functional MBL-multimer. These polymorphisms occur in 
about one third of the human population and the frequency of occurrence of different polymorphisms 
is related to various ethnic groups.5 The heterozygous polymorphisms reduce the amount of functional 
MBL 5-10 fold, whereas the homozygous mutations lead to almost undetectable MBL-titers.5 
Furthermore, a number of base-pair substitutions of the promotor-region of the MBL-2 gene are 
described, leading to several promotor variants, some of which decrease the functional MBL serum 
level significantly.5 
The incidence of nosocomial infection in the neonatal intensive care unit is high.6 The most important 
risk factor in this patient category is a low birth weight 7,8, a risk factor that is in part a reflection of the 
more intensive treatment, e.g. with intravascular catheters and mechanical ventilation, that smaller 
preterm neonates require compared to heavier neonates. Furthermore, the adaptive host defence to 
infection of, especially preterm, neonates is impaired for several reasons.9-14 Therefore, MBL-
deficiency may be a risk factor for infection in this patient category.  
We investigated the influence of MBL-genotype on the risk on nosocomial infection by determining 
the MBL-2-genotype of 204 neonates for which nosocomial infections had been prospectively 
registrated in a previous study.15  
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Materials and Methods 
 
Surveillance study. In 1998-2000, we performed a prospective study on nosocomial bloodstream 
infection and pneumonia on 742 neonates admitted to the neonatal intensive care unit of the VU 
University Medical Center, using local infection definitions, consisting of clinical and microbiological 
data.15 Several potential baseline risk factors for nosocomial bloodstream infection and pneumonia 
were recorded. Neonates that stayed for at least 4 days in the NICU were eligible for inclusion in the 
study on MBL.  
Retrieval of patient material. The study was approved by the local ethical committee. Parents of 
eligible neonates were asked for permission (informed consent) to use the Guthriecard of their child 
for DNA-isolation and MBL-gene analysis.  
In the Netherlands, in the first week after birth, a blood sample of neonates is collected by heel 
puncture on a Guthriecard. These are investigated at the National Institute of Public Health and the 
Environment (Bilthoven, the Netherlands) for certain congenital diseases, and subsequently stored for 
five years. 
 
Investigation of single nucleotide polymorphisms (SNP) of neonatal DNA from Guthriecards.16  
In summary, the procedure was as follows.  
Isolation of DNA. Blood was eluted from Guthriecards by soaking three discs from each card in Tris 
EDTA buffer (10 mM Tris-HCL pH 8.3 + 1 mM EDTA ) and then incubated for 10 minutes at 56 °C. 
Subsequently, samples were centrifuged at 13000 rpm for 10 min. The resulting supernatant was 
isolated with QIAamp according to the manufacturer’s instructions and eluted in 100 μl eluation 
buffer. DNA samples were frozen at –20 °C until use. 
Polymerase Chain Reaction (PCR). For the PCR a nested approach was chosen because the DNA 
amounts obtained from the Guthriecards were too small for direct detection of SNPs. A pre-PCR with 
two primers flanking the MBL-2 gene was performed for amplification of a DNA segment containing 
all 6 SNP targets. After this, SNP analysis was performed using six different real-time PCR allelic 
discrimination TaqMan assays.14 Each assay consists of nonlabeled forward and reverse primers 
combined with two fluorescent TaqMan oligonucleotide probes, differently labelled for wild-type and 
mutation. Because of the close proximity of the mutations in exon-1, these were enclosed in one 
primer pair. Oligonucleotides corresponding to wild type promotor variants L, Y and P, and the wild-
type structural gene A, were labelled wit VICTM. Oligonuclotides corresponding to mutation promotor 
variants H, X, Q, and the mutation haplotypes of the structural gene B, C and D were labelled with 
FAM (6-carboxy-fluorescin). Endpoint detection was performed on the ABI Prism 7000 instrument 
and results were analysed with the sequence detection software v1.01 of Applied Biosystems.  
Deduction of MBL-genotype from results of SNP. In theory there are 26 = 64 possible combinations 
for 6 SNPs, but because of a strong linkage disequilibrium between promotor and exon, there are only 
7 well-known haplotypes: the promotor variants with a wild type structural gene; HYPA, LYPA, 
LYQA, LXPA, and the haplotypes with a mutant structural gene; LYPB, HYPD, LYQC.17 Every 
individual expresses two MBL-haplotypes. From the results of the SNPs the genotypes were deduced 
to those 7 haplotypes. 
Analysis of effect of MBL-genotype on risk on nosocomial infection. Genotypes were stratified in 6 
combined promotor-exon groups (YA/YA, YA/XA, XA/XA, YA/O, XA/O and O/O) and in 3 exon 
groups (A/A, A/O, O/O).18,19 The infection risk was investigated for (1) bloodstream infection, (2) 
pneumonia and (3) combination of both infections. Analysis was performed by multiple logistic 
regression with potential risk factors for nosocomial infection that had been evaluated in the 
surveillance study that had previously been performed in the NICU of the VU University Medical 
Center15:  birth weight category (< 1000g, 1000-1499 g, 1500-2499g, >=2500g), gender,  place of birth 
(VU University Medical Center or elsewhere), type of birth (Caesarian section or vaginal), presence of 
meconium-stained amniotic fluid, premature rupture of membranes (>24 h before delivery) and 
multiple birth. Statistical analysis was performed with SPSS version 12.0. (Chicago, Illinois, USA). 
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Figure 2.  Results from informed consent procedure and patients included in the 
study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
Response and retrieval of DNA specimens 
Parents of 512 neonates were asked for informed consent for this study. Results for response-rate and 
retrieval of Guthriecards is shown in Figure 2. Finally, 204 Guthriecards were investigated. 
SNP analysis 
After pre-PCR, the DNA-yield of 188/204 cases was sufficient for further analysis. In general, the 
results for estimation of SNPs were good. In 11 of the 6x188= 1128 SNP-estimations no result was 
obtained. Of these 11 genotypes with missing information, in most cases the MBL-genotype could still 
be deduced. In 1/188 DNA specimens, the combinations of SNPs could not be translated into known 
haplotypes according to Garred and Neth.18,19 This specimen had the combination L/H-Y/X-P/P-A/A-
no result-A/A. Furthermore, there was 1/188 combinations of SNPs for which each single SNPs was 
estimated but was not translatable in the seven well known haplotypes. Therefore, 188-2 = 186 MBL-
Requests for informed consent 
n = 512 (100%) 
 
Deceased:                         34 
BSI:                           128 
Pneumonia:                      63 
Sepsis and pneumonia:  170 
Non-response 
n = 193 (37.7%) 
 
Deceased:                         12 
BSI:                                  48 
Pneumonia:                      18 
Sepsis and pneumonia:    59 
Response 
n = 319 (62,3%) 
 
Deceased:                         22 
BSI:                                  80 
Pneumonia:                      45 
Sepsis and pneumonia:   111 
No informed consent  
n = 13 (4.0%) 
 
Deceased:                         1 
BSI:                                  6 
Pneumonia:                      0 
Sepsis and pneumonia:     6 
Informed consent 
n = 306 (96.0%) 
 
Deceased:                         21 
BSI:                                  74 
Pneumonia:                      45 
Sepsis and pneumonia:   105 
Guthriecard not found 
 = 102 (33.3%) 
 
Deceased:                      18            
BSI:                                31           
Pneumonia:                    15           
Sepsis and pneumonia:   33    
Guthriecard found and 
investigated 
n = 204 (66.7%) 
Not sufficient DNA isolated 
 
n = 16 (7.8%) 
MBL genotype identified 
n = 186 (98.9%) 
 
Deceased:                         3 
BSI:                                 41 
Pneumonia:                     29 
Sepsis and pneumonia:   62 
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genotypes were investigated in relation to infection risk; 35/186 (19%) neonates had 2 low-level MBL-
haplotypes (LXPA, LYPB, HYPD or LYQC), 69/186 (37%) had 1 low-level haplotype. 
Causative microorganisms of blood stream infection and pneumonia 
From the previous study, we retrieved results of bacterial cultures.13 These are shown in Table 1. 
Coagulase negative staphylococci were the most frequent cause of blood stream infection. There was 
no predominant causative microorganism for pneumonia. 
MBL-genotype and infection risk 
In a univariate analysis, as well as in a multiple analysis with other baseline risk factors for nosocomial 
infection, we found no relation between the MBL-genotype of the neonates and the risk of infection. 
Birth weight was the only  significant risk factor for nosocomial infection (Table 2). 
 
 
Table 1. Causative organisms of infection 
 
     Causative organism      n 
 
Bloodstream infection Coagulase negative staphylococcus    25 
 Bacillus cereus             3 
 Staphylococcus aureus           3 
 Streptococcus viridans           1  
 Enterobacter cloacae            1 
 Culture negative           8 
         41 
 
Pneumonia Ureaplasma urealyticum          4 
 Bacillus species            4 
 Mixed grampositive/negative flora         4 
Klebsiella species           3 
 Staphylococcus aureus            2 
 Haemophilus influenzae          1   
Enterobacter cloacae             1  
 Escherichia coli           1 
 Candida albicans           1 
 Culture negative/ no significant pathogens        8 
             29 
           
 
 
Discussion 
 
MBL is present in serum of preterm neonates and amniotic fluid, and the MBL  amount  increases with 
duration of gestation.20,21 It is also detectable in cord blood 22, but it is believed that there is no passive 
transfer of maternal MBL to the fetus.23 MBL increases in the first three months of life in response to 
environmental changes.24,25 Recurrent infection has been described in MBL-deficient infants.26 
We found no relation between MBL-genotype and the risk of nosocomial bloodstream infection and 
pneumonia in a population of neonates in the NICU, although the adaptive immune system in this 
patient category is functioning suboptimally. This is caused, for example by a lowered production of 
granulocyte colony-stimulating factor (G-CSF) leading to low number of neutrophils.27 Also, the 
phagocytic function of those neutrophils is impaired.10,11,14 Furthermore, there is an impaired 
opsonisation by IgG 28 and chemotaxis.12  
In contrast to our findings in preterm neonates, MBL-deficiency has been described as a risk factor for  
increased susceptibility to infection in adults and older children, especially when combined with 
another immunocompromising factor, such as chemotherapy or hematological malignancy.2,3,5,19,29-31 
MBL-variant alleles were also found to be a risk factor for acute respiratory illness in children between  
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6 and 17 months of age; in this period the protecting maternally acquired IgG antibodies have 
disappeared and the adaptive immune system is still immature.3 Therefore, the lack of a correlation in 
our patient population was unexpected. Recently, however, Ahrens et al also found no relationship 
between mutations in the MBL gene and sepsis in premature neonates, but a clear correlation with 
gestational age.32 No information on causative microorganisms of infection related to MBL genotype 
was provided. 
There are several hypotheses for the absence of relation between infection risk and MBL genotype in 
preterm infants requiring intensive care, despite their premature adaptive immune systems. Possibly 
the most important is the high prevalence of bloodstream infections caused by coagulase negative 
staphylococci (CoNS) in this patient group. It is known that MBL binds poorly to CoNS 33 and it is 
therefore likely that complement activation through MBL-binding is not effective in infections caused 
by these microorganisms, and hence, that MBL is not protective. Because the number of patients with 
infections caused by other microorganisms than CoNS is low in our study, a possible protective effect 
of MBL in such infections might not be detectable. Furthermore, MBL-genotype may not be suited as 
a good predictor of MBL-function in individual patients, because of significant individual variability in 
the correlation between genotype and MBL function.5 Even normal MBL levels can be associated with 
a non-functional MBL-system because of other deficiencies such as deficiency of MBL-associated 
Serine Protease 2.34 Recently, functional MBL pathway assays have been developed. These assays 
have led to a better understanding of  the relation between genotype and levels of functional MBL. It 
apears that, especially in heterozygosity, the amount of MBL in the circulation is less dependent on the 
genotype, than was previously anticipated.35,36 Only high molecular weight MBL activates the 
complement system efficiently. Therefore the MBL-function in heterozygous individuals may be 
highly dependent on the promotor-function of the wild type allele.36 
We inferred abnormalities in MBL levels from the different haplotypes that we determined by SNP 
analysis. The nested PCR approach that we applied on DNA recovered from Guthriecards was very 
efficient and permitted to determine MBL alleles in these neonates, after they had been dismitted from 
hospital and without the need to obtain new blood specimens. This was a great advantage. In one 
neonate the combination of SNPs did not belong to the 6 well known haplotypes, but more MBL 
haplotypes have been described recently.37 
We conclude that MBL genotype, confined to the six investigated haplotypes, does not seem to be 
correlated to risk of infection in preterm neonates in the NICU, where the majority of infections is 
caused by coagulase negative staphylococci. 
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General Discussion and Summary 
 
 
Nosocomial infections, also called hospital-acquired infections, arise as a consequence of admission to 
the hospital. In the hospital, the neonatal intensive care unit (NICU) is well known for its high 
incidence of nosocomial infections. This is caused by several factors. First, the patient population is 
highly susceptible to infection, due to a suboptimally functioning immune system. This applies to first-
line defence mechanisms, such as the skin (thin and fragile) and the airways (reduced coughing reflex), 
as well as second-line defences, for example the cellular immune system. Many invasive procedures 
and devices undermine the first-line defences even further, for example intubation for mechanical 
ventilation and intravascular catheters for administration of fluids and medicines. Secondly, neonates 
are easily colonized by hospital microbial flora that is more often resistant to various antimicrobial 
agents. This is, amongst others, because neonates are sterile at birth, and thereafter intensively cared 
for and treated, which involves frequent hand contacts with health care workers. Therefore, contact 
with hospital bacteria is frequent, and as a consequence these bacteria are easily spread with a chance 
that they become epidemic. The most effective preventive measure is a thorough disinfection of the 
hands before patient contact. An ongoing effort is necessary to maintain a high level of adherence to 
hand disinfection protocols by health care workers; especially in periods of understaffing there is a 
tendency to omit disinfection of hands preceding to patient contact. Thirdly, in the NICU antimicrobial 
agents are frequently used for treatment of infection and suspected infection; this harbours the risk of 
selection of (multi) resistant bacteria, which makes treatment of infection more difficult. 
 
In the second half of the preceding decade, the impression was that the occurrence of infections in the 
NICU of the VU University Medical Center, expressed as the number of infections per 1000 admission 
days, was high. We realized at that time, that little was known about the incidence of nosocomial 
infections in NICUs and on the specific risk factors for nosocomial infections in this patient 
population. There was no literature on Dutch NICUs and only few studies in the international 
literature. In addition, comparison with results of other studies was not possible because of the lack of 
standardized data from surveillance studies.  
 
To confirm the impression that the local incidence of nosocomial infection in the NICU was high and 
to identify risk factors, we proposed to start a prospective study. The most important problem for 
investigation of the endemic level of infection in the NICU is the lack of standardized infection 
definitions for neonates. To our neonatologists, the CDC definitions for children < 1 year were not 
acceptable for neonates. In chapter 2, the major problems for designing such definitions in this patient 
category are described. We designed infection definitions based on existing CDC definitions intended 
for children < 1 year, but adjusted to the specific subtle symptomatology of infection in neonates and 
the usual diagnostic work-up of infection in the NICU. These adjusted definitions were then used for a 
surveillance period of 29 months. During this period, 742 neonates, who stayed in the NICU for more 
than 24 hours, were surveyed. Base-line risk factors, time-dependent risk factors (for example 
mechanical ventilation and various intravascular catheters), and the occurrence of infection were 
recorded prospectively on a daily basis. 
Bloodstream infection and pneumonia were the most frequently occurring nosocomial infections. 
Through multivariate analysis, risk factors for infection were identified. The most important  risk 
factor for all infections was low birth weight. Obviously, the administration of intravenous antibiotics 
was a protective factor. Other major risk factors were mechanical ventilation for pneumonia and the 
administration of parenteral feeding for bloodstream infection. It is known that the latter promotes the 
growth of coagulase negative staphylococci, the most frequent cause of blood stream infections in the 
NICU. Compared to American NICUs participating in the NISS, the use of devices, such as central 
venous catheters and mechanical ventilation, was high, which is a reflection of differences in treatment 
strategies between Dutch and American NICUs. This difference influences this comparison. The 
incidence of infection was high in our NICU, however, even after correction for the difference in 
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frequency of utilization of invasive devices. This can partly be explained by the differences in 
definitions for infection. Our definitions are more suitable for neonates than CDC definitions used for 
all children < 1 year of age. In a random sample of the infections that we recorded, it was shown that 
some of these would not been have been identified by CDC definitions. 
 
In addition to the investigation of the endemic level of nosocomial infections in general, also the 
endemic level of infection and/or colonization with a specific bacterial species in the NICU can be 
investigated. An example is given in chapter 3. A neonate with a persistent infection with positive 
blood cultures with coagulase negative staphylococci over a period of three weeks despite treatment 
with vancomycin, was the reason to start an investigation. Eventually, this neonate died. With routine 
methods for measurement of antibiotic resistance in the medical microbiology laboratory, the CoNS-
strain appeared susceptible to vancomycin. All other possible causes for treatment failure were 
excluded; all intravascular catheters were changed and levels of vancomycin measured in the blood 
were not different from levels measured in other neonates treated with vancomycin. The strain was 
identified as Staphylococcus capitis; it was heteroresistant to vancomycin, which means that the 
bacterial population contains a vancomycin resistant subpopulation. Because the great majority of the 
population is sensitive, the resistant subpopulation remains unnoticed with routine laboratory methods, 
but could have been the cause of therapy failure. This finding was the reason to investigate more than 
200 CoNS strains from blood cultures from patients that been admitted to the NICU in the preceding 
three years, that were stored in the freezer. Forty-eight strains appeared heteroresistant to vancomycin 
and all these strains were identified as S. capitis. Genotyping of these strains with Amplified-Length 
Fragment Polymorphism (AFLP) showed that transmission of one S. capitis strain had occurred and 
that this strain had become endemic in the NICU. However, treatment of S.capitis infections with 
vancomycin in other neonates apparently did not cause major problems, since these infections 
remained unnoticed. It is difficult, however, to estimate retrospectively the true extent of the impact of 
infection with such heteroresistant strains in our NICU.  
 
Shortly before and during the surveillance period described in this thesis, two epidemics with a 
specific causative microorganism that required specific control measures occurred. These outbreaks 
were thoroughly investigated, to detect sources of cross-infection. In addition, understanding the 
causes of an outbreak often leads to a better understanding of the risk factors to which the patient 
population is exposed and hence, to improved infection control.  
  
In chapter 4, an outbreak caused by Bacillus cereus is described. This bacterium, which belongs to the 
normal flora of skin and mucous membranes and seldom causes infections in non-
immunocompromised hosts, caused serious infections in three neonates within a short period; one of 
them died as a consequence of infection. Genotyping of the three causative B. cereus strains showed 
that they were clonally related and that transmission of one strain in the NICU had occurred. This 
observation prompted an extensive investigation into the cause and source of this epidemic. In the 
preceding years, colonization of the airways of neonates with B. cereus had been a frequent 
observation in sputum specimens from the NICU, but this had never been paid much attention to 
because this bacterial species was considered colonisation or contamination.  
Bacillus species can survive in the environment as spores for long periods of time. A spore is a 
dormant structure for survival of the cell, in which DNA is stored in a resistant envelope and in which 
there is no cell metabolism or cell fission. Characteristic is the ability of these spores to survive various 
unfavourable circumstances that would be lethal to normal cells, such as dryness, very high 
temperatures, high or low acidity or radiation. Even chemicals, such as disinfectants are resisted by 
spores. Spores can survive for long periods, and regain viability under favourable circumstances. 
Therefore, also the hospital environment can become contaminated with spores of Bacillus species. 
Initially, B. cereus was isolated from only 1 of 32 environmental specimens, but this environmental 
strain was different from the strain that caused the infections. In a prospective study of 22 neonates, it 
was found that colonization with B. cereus solely occurred in the respiratory tract. The genotype of 
these colonizing strains was identical to the epidemic strain. Subsequently, several characteristics and 
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potential risk factors of these 22 colonized neonates were compared with those of 22 non-colonized 
neonates. Mechanical ventilation with a Sensormedics machine appeared to be a significant risk factor 
for colonization. This led to a new environmental study for the presence of B. cereus, this time of 
various materials used preceding or during mechanical ventilation in the NICU. Several balloons that 
were used for manual ventilation appeared to be contaminated with B. cereus spores, identical to the 
epidemic strain. It appeared that after use, these balloons were only cleaned superficially, which is 
insufficient to kill spores.  
After the identification of the balloons as a possible source of the epidemic strain of B. cereus, all 
ventilation balloons on the ward were autoclaved (heated at high temperatures with saturated steam, 
which kills spores effectively) and with this measure the source of colonization of neonates with B. 
cereus was eliminated and no new serious infections caused by this bacterium occurred anymore. 
Thereafter, regular sterilisation of these balloons was introduced as a routine infection control 
measure. Hence, this outbreak led to the recognition of a previously unidentified potential source of 
nosocomial infections in the NICU and to better infection control. 
 
The second outbreak is described in chapter 5. It was caused by a Klebsiella pneumoniae strain that 
was resistant to gentamicin. Since, at that moment, the empiric antibiotic regimen for serious neonatal 
infection on the NICU was a combination of ampicillin and gentamicin, this was a serious problem, 
because Klebsiella species are also naturally resistant to ampicillin. The first isolate was cultured from 
a routine sputum specimen. Thereupon, a K. pneumoniae strain with an identical antibiogram was 
isolated from a blood culture drawn from a sick premature neonate, who died 6 days later. Possibly, 
the delayed administration of effective antibiotic therapy had contributed to the death of this neonate. 
Thus, it was likely that transmission of a multiresistant K. pneumoniae strain had occurred. The 
infection control team drew renewed attention to thorough disinfection of the hands by health care 
workers between patient contacts as this had been the most probable route of transmission. Despite this 
action, another 4 neonates became colonized in the following 6 weeks, most frequently in sputum but 
sometimes also in urine. These colonized neonates were cohorted as much as possible, which means 
that they were treated and cared in the same room and by the same nurses, separated from non-
colonized neonates. Cultures from possible environmental sources were negative for gentamicin-
resistant K. pneumoniae. Genotyping of 8 gentamicin-resistant K. pneumoniae strains revealed 7 
identical strains, which was proof of transmission in the NICU. 
Preventive measures appeared insufficient as five other neonates became colonized shortly after they 
had been admitted to the NICU. Two of them developed pneumonia with this bacterium. At this 
moment, there was a shortage of nursing staff and because of this the workload was high. Investigation 
of whether certain factors increased the risk of becoming colonized or infected was done by comparing 
colonized neonates with those that were not colonized (case-control study). Low birth weight appeared 
the only significant risk factor. These neonates are more intensively treated and cared compared to 
heavier neonates, which involves more hand contacts. Eventually it was decided to ban the use of 
gentamicin on the ward to remove the selective advantage for this gentamicin-resistant bacterium. 
Gentamicin was replaced by amikacin, a related aminoglycoside with nearly the same spectrum but to 
which resistance is more difficultly developed. In the succeeding weeks, this intervention was 
monitored by frequent surveillance cultures of all admitted neonates. The intervention proved 
successful, as only one more patient became colonized with gentamicin-resistant K. pneumoniae.  
This second epidemic is an example of an outbreak that is not caused by a specific common source but 
by selection, and hence facilitated spread, of a single bacterial strain due to its antibiotic resistance.  
 
In the genesis of infection, the protective activity of the immune system of the patient is of major 
importance. In the neonate, the innate immune system and specific immune system are still developing 
and function suboptimally. This is especially true for premature neonates. We investigated two aspects 
of this complex system: transferred maternal humoral immunity [exemplified by maternally acquired 
antibodies against the varicella-zoster virus (VZV)] and a member of the innate immune system, the 
Mannose Binding Lectin (MBL). 
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During pregnancy, neonates acquire protective antibodies against VZV. This virus causes chickenpox, 
which can be a very serious disease in neonates. VZV can be inadvertently be introduced into the 
NICU by persons who are in  the incubation period of this infection. When this person is diagnosed 
with chickenpox, all neonates that have been in contact with this person are screened for the presence 
of maternally acquired VZV immunoglobulins. VZV-IgG immunoglobulins are administered to 
neonates with low or absent VZV immunoglobulins. This does not protect them from getting 
chickenpox, but it mitigates the severity of the disease. 
At the time of study, it was thought that preterm neonates (born at a gestational age < 37 weeks), and 
especially very preterm neonates (born at a gestational age < 28 weeks) would have acquired 
insufficient amounts of maternal VZV immunoglobulins to be protected from chickenpox, and that the 
titer would decrease faster to non-protective levels compared to term neonates. In chapter 6 we 
describe the investigation of blood specimens of 43 mothers and 211 neonates for the presence of VZV 
immunoglobulins. Furthermore, de VZV-IgG titer of 27 neonates was followed over time, by obtaining 
sequential specimens. We determined that the half-life of VZV immunoglobulins in preterm neonates 
was identical to that in older children and adults, but that significant variability occurs in the first 
weeks of life. In our study, the neonatal VZV-IgG titer was predominantly predicted by the maternal 
VZV-IgG titer and to a lesser extent by the gestational age. Actually, a significant proportion of 
neonates that were candidate for receiving VZIG, were VZV-IgG positive. In three cases the mother 
was VZV-IgG positive but her child tested negative. We were not able to explain these discrepancies.  
 
Mannose Binding Lectin (MBL) is a major component of the aspecific immune system. This serum 
protein is produced by the liver and can bind to the surface of various microorganisms, and, by doing 
so, activate the complement system which kills the microorganism. In some individuals, a change 
(mutation) of the DNA, which is involved in the production of MBL, causes a lowered production of 
MBL or the production of dysfunctional MBL. If other components of the immune system also act sub 
optimally, a low MBL titer is a risk factor for infection. Two examples are children of 6-17 months of 
age in which maternal immunoglobulins have disappeared and which have not developed their own 
immunity, and older patients treated with chemotherapy. We hypothesized that a low-level MBL in 
neonates would increase the susceptibility to nosocomial infection, because of the suboptimal function 
of other parts of the immune system in this patient category. In chapter 7 we describe a study with a 
subpopulation of 186 neonates from the surveillance study that is described in chapter 2. We 
investigated blood spots on Guthrie cards from these neonates for variance of the DNA region that 
encodes MBL. For this subpopulation as well, a low birth weight was the most important risk factor 
for infection. We found no relation between genetic variations in the MBL-gene and infection risk. 
This can partially be explained by the fact that MBL binds poorly to CoNS, which are the most 
frequent cause of infection in neonates in the NICU. Also, it was recently found that the MBL-
genotype is not perfectly correlated to the circulating and functional MBL titer; the latter is also 
influenced by other factors. We concluded that variation in the MBL genotype is not a good predictor 
for the infection risk in premature neonates. 
 
 
Epilogue 
 
The Neonatal Intensive Care Unit combines patients with a suboptimal immunesystem, frequent use of 
invasive procedures, intensive treatment, and frequent use of antibiotics, which makes it the ideal site 
for nosocomial infections to develop. 
We described specific infection definitions, which comprised the subtle, aspecific symptomatology of 
infection in neonates, with which we could study the epidemiology and risk factors of nosocomial 
infection, of which little was known when we started this PhD study. Birth weight proved to be the 
overwhelmingly most important base-line risk-factor for nosocomial infection. When studied in a 
multivariate manner, none of the other base-line factors, including MBL-genotype, appeared to play a 
major role as a risk factor in comparison to birth weight. Of the time-dependent variables, mechanical 
ventilation appeared an independent risk factor for pneumonia, and intravenous feeding an 
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independent factor for bloodstream infection. Cox-regression with time-dependent variables proved an 
appropriate method to study risk factors which can change during admission.  
Duration of pregnancy determines birth weight, and need for mechanical ventilation and parenteral 
nutrition. Hence, every effort directed at the prevention of preterm delivery will indirectly lead to less 
nosocomial infections in the NICU.  
The selective pressure from the frequently used antibiotics in the NICU, combined with the frequent 
hand contacts between health care workers and neonate, causes an high intrinsic risk of transmission of 
especially resistant microorganisms. Our halting of an outbreak of resistant K. pneumoniae illustrates 
how a change of antibiotic policy may be an excellent adjuvant to classical infection control measures.  
In the NICU, new medical devices/procedure are frequently introduced, without a thorough evaluation 
of their concomitant risk of infection. The outbreak of a Bacillus cereus strain, that was traced to  
balloons for manual ventilation, is a clear example of the continuous threat posed by medical devices 
to the natural defences of the human body. In addition, this outbreak illustrated that in an 
immunocopromised population every single bacterial species must be considered as a potential 
nosocomial pathogen. Indeed, we concluded that Bacillus cereus can cause serious infections in 
neonates and that it is mandatory to “be serious about B. cereus”. 
The contribution of genotypic fingerprinting in investigation of the above mentioned endemic or 
epidemic bacterial strains appeared indispensable. 
Finally, obviously, prematurity means a premature immune system. We found no relationship between 
the Mannose Binding Lectin genotype and the risk for nosocomial infection. This is probably caused 
by the weak correlation between MBL genotype and phenotype and possibly by the poor binding of 
MBL to coagulase-negative staphylococci, which are the most frequent cause of infection in neonates. 
In addition, the important role of birth weight as a baseline risk factor, may mask the effect of other 
factors. This means that much larger studies may be needed to uncover the role of other base-line risk 
factors than birth weight.  
Surprisingly, in contrast to general opinion, gestational age, and hence birth weight, was not the most 
important predictor of the neonatal VZV-IgG titer. Maternal protection, in this case provided by high 
maternal VZV-IgG titers, is the best there is for every neonate. 
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Algemene Discussie en Samenvatting 
 
 
Nosocomiale infecties, ofwel ziekenhuis-infecties, ontstaan als gevolg van een opname in het 
ziekenhuis. De neonatale intensive care unit (NICU) is van oudsher een afdeling in het ziekenhuis 
waar de nosocomiale infectiedruk hoog is. Dit heeft diverse oorzaken. Ten eerste is de 
patiëntenpopulatie erg vatbaar voor infecties als gevolg van het suboptimaal functioneren van de 
normale afweermechanismen. Dit geldt zowel voor de eerste verdedigingslinies, zoals de huid (dun en 
fragiel) en de luchtwegen (suboptimale hoestreflex), alsook voor tweede linies, bijvoorbeeld de functie 
van het cellulaire immuunsysteem. Bovendien wordt er veel gebruik gemaakt van invasieve technieken 
die de eerste verdedigingslinies nog verder ondermijnen, door bijvoorbeeld intubatie van de luchtpijp 
voor kunstmatige beademing en katheters in de bloedbaan voor het toedienen van vocht en medicijnen. 
Ten tweede worden neonaten gemakkelijk gekoloniseerd met ziekenhuisbacteriën die vaker resistent 
zijn tegen meerdere antibiotica. Dit komt o.a. doordat neonaten steriel ter wereld komen en omdat er 
sprake is van veel handcontacten met ziekenhuispersoneel bij de intensieve verzorging en behandeling. 
Mede hierdoor kunnen deze ziekenhuisbacteriën gemakkelijk van patiënt op patiënt worden 
overgedragen en ligt het gevaar van epidemieën op de loer. De meest effectieve maatregel om dit te 
voorkomen is een goede handendesinfectie voorafgaande aan patiëntcontact. Het vergt een 
voortdurende inspanning om het zich houden aan handendesinfectieprotocollen door 
ziekenhuispersoneel op een hoog niveau te houden; hoe drukker de werkzaamheden zijn hoe minder 
men de tijd neemt voor adequate handhygiëne. Ten derde worden in de NICU veelvuldig antibiotica 
toegediend voor de behandeling van infecties en bij het vermoeden van infectie, waardoor het gevaar 
van uitselectie van antibioticaresistente bacteriën reëel is en de behandeling van infecties moeilijker 
wordt. 
 
In de tweede helft van de 90-er jaren bestond de indruk dat het vòòrkomen van infecties in de NICU 
van het VU medisch centrum (VUmc), uitgedrukt in het aantal infecties per 1000 opnamedagen, hoog 
was. Wij ontdekten toen dat er weinig informatie voor handen was over de incidentie van nosocomiale 
infecties in NICUs en de specifieke risicofactoren voor nosocomiale infecties in deze patiëntcategorie. 
Er was geen literatuur over Nederlandse NICUs en maar weinig publicaties in de internationale 
literatuur. Bovendien bleek onderlinge vergelijking van deze studies niet mogelijk als gevolg van het 
ontbreken van gestandaardiseerde data van surveillance studies. 
 
Ter bevestiging van het vermoeden dat de lokale incidentie van nosocomiale incidentie in de NICU 
hoog was en met als doel risicofactoren voor infectie te kunnen identificeren werd een prospectieve 
studie gestart. Het belangrijkste probleem voor een onderzoek naar het endemisch niveau van infecties 
in de NICU is het ontbreken van gestandaardiseerde infectiedefinities voor neonaten. In hoofdstuk 2 
worden de belangrijkste problemen voor het ontwerpen van infectiedefinities voor deze 
patiëntcategorie beschreven. Wij ontwierpen infectiedefinities met als basis de bestaande CDC-
definities voor kinderen < 1 jaar, met aanpassing voor de specifieke subtiele symptomatologie bij 
neonaten en mogelijkheden tot aanvullende diagnostiek in de NICU. Deze aangepaste definities 
werden vervolgens gebruikt in een 29 maanden durende surveillance studie. In deze periode werden 
742 neonaten, die langer dan 24 uur waren opgenomen op de NICU, geobserveerd. Hierbij werden 
naast een aantal base-line risicofactoren, dagelijks de aan/afwezigheid van tijdsafhankelijke 
risicofactoren (bijvoorbeeld kunstmatige beademing met intubatie en diverse infuuslijnen) en het 
ontstaan van infecties prospectief geregistreerd. Sepsis (bloedbaaninfectie) en pneumonie 
(longontsteking) bleken de meest voorkomende infecties. Door middel van multivariate analyse 
werden een aantal risicofactoren voor deze infecties geïdentificeerd. De belangrijkste risicofactor voor 
alle infecties was een laag geboortegewicht. Het gebruik van intraveneuze antibiotica had uiteraard een 
beschermend effect. Een belangrijke risicofactor voor pneumonie was intubatie en voor sepsis het 
toedienen van intraveneuze voeding. Van dit laatste is bekend dat dit de uitgroei van coagulase 
negatieve staphylokokken (CoNS), de meest voorkomende verwekker van sepsis in de NICU, 
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bevordert. Ten opzichte van Amerikaanse NICUs was het gebruik van invasieve hulpmiddelen, zoals 
centraal veneuze lijnen en kunstmatige beademing, hoog, hetgeen onder andere veroorzaakt wordt 
door verschillen in behandelstrategieën tussen Nederlandse en Amerikaanse NICUs. Ook was het 
aantal infecties op de NICU van het VUmc hoog ten opzichte van Amerikaanse NICUs, zelfs als 
gecorrigeerd werd voor frequentie van gebruik van invasieve hulpmiddelen. Dit heeft deels te maken 
met het verschil van definities voor infectie. De door ons gebruikte definities zijn meer geschikt voor 
neonaten dan de door de CDC gehanteerde definities voor kinderen < 1 jaar. In een willekeurige 
steekproef van de door ons gevonden infecties werd aangetoond dat deze met behulp van de CDC 
definities niet gevonden zouden zijn. 
 
Naast het onderzoek van het endemisch niveau van infecties in het algemeen kan ook onderzoek 
gedaan worden naar het endemisch niveau van infectie/kolonisatie door specifieke bacterie-soorten in 
de NICU. Een voorbeeld hiervan is te vinden in hoofdstuk 3. De aanleiding voor dit onderzoek was 
een neonaat met persisterende infectie met een CoNS in diverse bloedkweken gedurende 3 weken, 
ondanks behandeling met vancomycine. Deze neonaat overleed uiteindelijk. Met de gebruikelijke 
gevoeligheidsbepaling in het medisch microbiologisch laboratorium was de CoNS-stam gevoelig voor 
vancomycine. Alle andere bekende oorzaken voor therapie-falen werden uitgesloten; alle intravasale 
catheters werden gewisseld en ook de vancomycine-spiegels gemeten in het bloed van deze neonaat 
bleken niet afwijkend van spiegels die werden gevonden bij andere met vancomycine behandelde 
neonaten. De stam werd geïdentificeerd als Staphylococcus capitis en bleek heteroresistent tegen 
vancomycine. Dit betekent dat er binnen de populatie bacteriën een kleine subpopulatie is die resistent 
is. Omdat de grote meerderheid gevoelig is wordt dit niet opgemerkt bij routine gevoeligheidsbepaling, 
maar bij een infectie zou dit wel tot therapie-falen kunnen leiden. In aansluiting op deze bevinding 
onderzochten wij meer dan 200 CoNS stammen die in de vriezer bewaard waren, uit bloedkweken van 
patiëntjes die op de NICU waren verpleegd in voorafgaande 3 jaar. Achtenveertig stammen bleken 
heteroresistent te zijn tegen vancomycine en allen bleken ook S. capitis. Door genotypering met behulp 
van Amplified-Length Fragment Polymorphism (AFLP) kon worden aangetoond dat er verspreiding 
van één S.capitis stam had plaatsgevonden en dat deze stam dus endemisch was geworden in de NICU. 
Echter, behandeling van de andere neonaten met een S.capitis infectie met vancomycine verliep 
ogenschijnlijk zonder grote problemen. Het was echter moeilijk om retrospectief de werkelijke invloed 
van infectie met zo’n heteroresistente stam vast te stellen. 
 
Kort voor aanvang van en tijdens de surveillance periode die in dit proefschrift beschreven wordt, 
deden zich in de NICU een tweetal epidemieën voor met een specifiek oorzakelijk micro-organisme en 
specifieke maatregelen die nodig waren om de epidemie te beëindigen. Deze epidemieën werden 
grondig bestudeerd, om de bron te achterhalen. Bovendien leidt kennis over de oorzaak van een 
epidemie tot een beter inzicht in de risicofactoren aan welke de patiëntpopulatie wordt blootgesteld en 
daarmee tot een betere infectiepreventie in de toekomst. 
 
In hoofdstuk 4 wordt een epidemie beschreven veroorzaakt door Bacillus cereus. Deze bacterie, die 
als normale flora van huid en slijmvliezen kan voorkomen en zelden infecties veroorzaakt in patiënten 
zonder afweerstoornissen, veroorzaakte binnen korte tijd bij drie neonaten een ernstige infectie; één 
neonaat overleed aan de gevolgen. Door genotypering van de drie stammen met behulp van AFLP 
bleek het steeds om een zelfde genotype te gaan en was er dus sprake van overdracht binnen de NICU. 
Dit was aanleiding tot een uitgebreid onderzoek naar de bron/oorzaak van deze epidemie. In de 
voorafgaande jaren was kolonisatie in sputum van neonaten met B. cereus een reeds bekend fenomeen, 
maar dit werd beschouwd als kolonisatie van de luchtwegen of als contaminatie.  
Bacillus species kunnen lange tijd in de omgeving overleven als spore. Een spore is een 
overlevingsstructuur voor de cel waarbij het erfelijk materiaal wordt opgeslagen in een resistent 
omhulsel zonder dat er sprake is van normale celstofwisseling of celdeling. Kenmerkend is het 
vermogen van een dergelijke spore om onder ongunstige omstandigheden te overleven die een normale 
cel niet zou overleven, zoals droogte, zeer hoge temperaturen, een lage of hoge zuurgraad, of straling. 
Zelfs chemicaliën, zoals desinfectiemiddelen, worden door een spore weerstaan. Sporen kunnen zeer 
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lange tijd overleven, en onder gunstige omstandigheden weer uitgroeien tot normale cellen. Ook de 
ziekenhuisomgeving kan dus met sporen van deze bacteriesoort besmet raken. 
Aanvankelijk bleek slechts 1 van 32 omgevingsmonsters positief voor Bacillus cereus, maar deze 
bleek echter van een ander genotype dan de stam die de infecties had veroorzaakt. In een prospectief 
onderzoek naar kolonisatie bij 22 neonaten bleek kolonisatie met B. cereus alleen in de luchtwegen op 
te treden. Het genotype van deze isolaten was identiek aan de epidemische stam die de infecties had 
veroorzaakt. Vervolgens werden de gegevens en risicofactoren van 22 gekoloniseerde neonaten 
vergeleken met die van 22 niet-gekoloniseerde neonaten. Mechanische beademing met een 
Sensormedics beademingsmachine bleek een significante risicofactor voor kolonisatie te zijn. Daarop 
werden weer omgevingsmonsters onderzocht op de aanwezigheid van B. cereus, ditmaal van allerlei 
materialen die gebruikt worden voorafgaand of tijdens kunstmatige beademing in de NICU. Diverse 
beademingsballonnen die werden gebruikt bij handmatige beademing bleken positief voor de 
epidemische B. cereus stam. Deze ballonnen werden na gebruik slechts oppervlakkig gereinigd; dit is 
onvoldoende om sporen af te doden.  
Na identificatie van de beademingsballonnen als mogelijke bron van de epidemische B. cereus werden 
deze vervolgens allemaal geautoclaveerd (verhitten tot hoge temperatuur door middel van verzadigde 
stoom, waardoor ook sporen gedood worden). Daarmee werd deze bron van kolonisatie van neonaten 
met B. cereus geëlimineerd en werden geen nieuwe ernstige infecties, veroorzaakt door deze bacterie, 
meer gezien. Nadien werd regelmatig autoclaveren van de ballonnen als standaard infectiepreventie 
maatregel ingevoerd. Samenvattend; deze epidemie heeft er toe bijgedragen dat een tot dan toe nog 
onbekende bron voor nosocomiale infecties in de NICU werd geïdentificeerd en heeft geleid tot een 
betere infectiepreventie. 
 
De tweede epidemie wordt beschreven in hoofdstuk 5. Deze werd veroorzaakt door Klebsiella 
pneumoniae die resistent was tegen gentamicine. Aangezien op dat moment bij verdenking op 
neonatale infectie empirisch antibiotische therapie gestart werd bestaande uit een combinatie van 
ampicilline en gentamicine, was dit een ernstige zaak, omdat Klebsiella species van nature ook 
resistent zijn voor ampicilline. Het eerste isolaat werd gekweekt uit een routine sputummonster. 
Vervolgens werd een K. pneumoniae stam met een identiek antibiogram geïsoleerd uit een bloedkweek 
van een zieke, te vroeg geboren, neonaat, die 6 dagen daarna overleed. Mogelijk had het vertraagd 
instellen van een adequate antibiotische therapie bijgedragen aan het overlijden van deze pasgeborene. 
Er was dus waarschijnlijk sprake van overdracht van deze resistente stam tussen patiënten. Door de 
afdeling Infectiepreventie werd hernieuwde aandacht gevraagd voor een goede handendesinfectie 
tussen patiëntcontacten, omdat overdracht via handen van ziekenhuismedewerkers de meest 
waarschijnlijke transmissieroute was. Desondanks raakten in de daaropvolgende 6 weken nog 4 
neonaten besmet, waarbij de K. pneumoniae meestal in sputum werd aangetroffen, maar soms ook in 
de urinewegen. Deze besmette neonaten werden zoveel mogelijk in cohort verpleegd, d.w.z. 
gezamenlijk in één ruimte door dezelfde verpleegkundigen, gescheiden van de niet-besmette neonaten. 
Kweken van mogelijke omgevingsbronnen waren negatief voor gentamicine-resistente K. pneumoniae. 
Genotypering van 8 gentamicine-resistente K. pneumoniae stammen leverde zeven identieke stammen 
op, waardoor overdracht op de afdeling bewezen werd geacht.  
De preventieve maatregelen bleken onvoldoende toen in één week tijd vijf neonaten kort na opname 
besmet raakten. Twee van hen ontwikkelden een longontsteking met deze bacterie. Op dat moment 
was er een hoge werkdruk op de afdeling als gevolg van gebrek aan verpleegkundig personeel. Door 
het vergelijken van gekoloniseerde neonaten met niet-gekoloniseerde neonaten (patiënt-controle 
onderzoek) werd onderzocht of bepaalde factoren een verhoogd risico op kolonisatie of infectie met 
zich meebrachten. Een laag geboortegewicht bleek de enige risicofactor. Deze neonaten hebben in 
vergelijking met zwaardere neonaten een intensievere verzorging nodig, met meer handcontacten. 
Uiteindelijk werd besloten om het gebruik van gentamicine op de afdeling te stoppen om zo het 
selectieve groeivoordeel voor deze gentamicine-resistente bacterie op te heffen. Gentamicine werd 
vervangen door amikacine, dat nagenoeg dezelfde werking heeft maar waartegen moeilijker resistentie 
ontwikkeling optreedt. Het effect van deze maatregel werd onderzocht door in de daaropvolgende 
periode frequent surveillancekweken van alle opgenomen neonaten af te nemen. Het bleek een 
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succesvolle interventie, want er werd nog bij één patiëntje een gentamicine-resistente K. pneumoniae 
gevonden, maar daarna niet meer. 
Deze tweede epidemie is een voorbeeld van een uitbraak die niet wordt veroorzaakt door een 
gemeenschappelijke bron, maar door selectie van een bacteriestam als gevolg van resistentie-
ontwikkeling, en daarmee een gemakkelijkere verspreiding.  
 
 
Bij het ontstaan van een infectie speelt de afweer van de patiënt een belangrijke rol. Bij neonaten zijn 
het aangeboren en het specifieke immuunsysteem nog volop in ontwikkeling en functioneren 
suboptimaal. Dit geldt met name voor premature neonaten. Wij onderzochten twee aspecten van dit 
complexe systeem; de humorale immuniteit verkregen via de moeder [met als voorbeeld de via de 
placenta verkregen moederlijke antistoffen tegen het varicella-zoster virus (VZV)] en een onderdeel 
van het aangeboren immuunsysteem, het Mannose Bindend Lectine (MBL).  
 
Tijdens de zwangerschap, worden VZV-antistoffen van de moeder door de placenta overgedragen naar 
de ongeboren baby. VZV veroorzaakt waterpokken; een ziekte die zeer ernstig kan verlopen bij 
pasgeborenen. Soms zijn personen die zich in de incubatieperiode van deze ziekte bevinden aanwezig 
geweest in de NICU. Dit blijkt dan achteraf, als deze persoon waterpokken krijgt. Vervolgens worden 
dan alle neonaten in de NICU die in contact met deze (toen al besmettelijke) persoon zijn geweest 
onderzocht op de aanwezigheid van beschermende van de moeder verkregen antistoffen. Neonaten met 
lage antistofspiegels of neonaten die geen antistoffen hebben krijgen deze dan via een infuus 
toegediend. Dit beschermt hen niet tegen het krijgen van waterpokken, maar het vermindert de ernst 
van de ziekte. 
Ten tijde van het onderzoek, leefde de gedachte dat er bij premature neonaten (geboren bij 
zwangerschapsduur <37 weken), en met name bij de vroeg-premature neonaten (geboren bij 
zwangerschapsduur < 28 weken), onvoldoende overdracht van VZV-antistoffen zou hebben 
plaatsgevonden om beschermd te zijn en indien er voldoende hoge spiegels waren, dat deze wellicht 
sneller zouden afnemen tot een niet-beschermend niveau. Zoals beschreven in hoofdstuk 6 
onderzochten wij het bloed van 43 moeders en 211 neonaten op de aanwezigheid van VZV-antistoffen. 
Tevens werd de VZV-spiegel van 27 neonaten, middels het afnemen van opeenvolgende 
bloedmonsters, vervolgd in de tijd. Het bleek dat de snelheid van verdwijnen van antistoffen (de 
halfwaardetijd) bij premature neonaten identiek was aan de snelheid die bij oudere 
kinderen/volwassenen wordt waargenomen, maar dat met name in de eerste levensweken 
schommelingen in de spiegel voorkomen. De hoogte van de neonatale VZV-antistoftiter werd in onze 
onderzoeksgroep voornamelijk bepaald door de hoogte van de spiegel in het bloed van de moeder en 
veel minder door de zwangerschapsduur. In drie gevallen bleek de moeder VZV-antistoffen te hebben 
en het kind niet. Dit konden wij niet verklaren.     
 
MBL is een belangrijk onderdeel van het aspecifieke immuunsysteem. Dit eiwit in het bloed wordt 
gemaakt door de lever en kan binden aan het oppervlak van diverse micro-organismen, en daarmee het 
complementsysteem activeren, waardoor de micro-organismen worden gedood. Echter bij sommige 
personen is er een verandering (mutatie) in het erfelijk materiaal dat betrokken is bij de aanmaak van 
MBL, waardoor er minder of niet goed werkend MBL wordt aangemaakt. Wanneer andere onderdelen 
van het afweersysteem ook minder goed werkzaam zijn, is een lage MBL spiegel een risicofactor voor 
infectie. Twee voorbeelden hiervan zijn kinderen van 6-17 maanden waarbij de antistoffen van de 
moeder verdwenen zijn en die nog geen eigen specifieke afweer hebben opgebouwd, en bij oudere 
patiënten die chemotherapie ondergaan. Wij hypothetiseerden dat een verlaagd MBL bij neonaten ook 
de vatbaarheid voor ziekenhuisinfecties zou kunnen verhogen, omdat bij deze patiëntjes diverse 
onderdelen van het immuunsysteem nog suboptimaal functioneren. In hoofdstuk 7 beschrijven wij een 
onderzoek bij 186 neonaten uit het in hoofdstuk 2 beschreven surveillance onderzoek. Van deze 
neonaten onderzochten wij het bloed van de hielprikkaart op variatie in het erfelijk materiaal dat 
codeert voor MBL. Ook in deze subgroep was een laag geboortegewicht de belangrijkste risicofactor 
voor infectie. Wij konden echter geen relatie aantonen tussen de genen die coderen voor MBL en de 
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kans op infectie. Dit kan deels worden verklaard doordat MBL slecht bindt aan CoNS, de meest 
voorkomende oorzaak van infectie bij neonaten in de NICU. Tevens is inmiddels gebleken dat 
mutaties in MBL-genen geen exacte voorspeller zijn van de hoeveelheid circulerend én functioneel 
MBL; de functie van dit eiwit wordt ook door andere factoren beïnvloed. Wij concludeerden dat 
variatie in MBL genen geen goede voorspeller is van het risico voor infectie bij premature neonaten. 
 
 
Epiloog 
 
De neonatale intensive care unit is een combinatie van patiënten met een suboptimaal functionerend 
immuunsysteem, frequent gebruik van invasieve procedures, intensieve behandeling, en een frequent 
gebruik van antibiotica, en is daarmee een ideale plaats voor het ontstaan van nosocomiale infecties. 
Wij beschreven specifieke infectiedefinities, waarin de subtiele, aspecifieke symptomatologie van 
infectie bij neonaten is opgenomen. Hiermee konden wij de epidemiologie van en risicofactoren voor 
nosocomiale infectie in deze patiënt categorie konden bestuderen. Over dit onderwerp was bij aanvang 
van dit promotie-onderzoek nog weinig bekend. Het geboortegewicht bleek met voorsprong de 
belangrijkste base-line risicofactor voor nosocomiale infectie. In een multivariaat onderzoek, bleek 
geen andere base-line factor van belang in dit kader, inclusief MBL-genotype. Van de tijdsafhankelijke 
variabelen, was kunstmatige beademing een risicofactor voor longontsteking en intraveneuze voeding 
een risicofactor voor sepsis. Cox-regressie met tijdsafhankelijke variabelen bleek een geschikte 
methode om risicofactoren die tijdens de opnameperiode variëren te kunnen bestuderen. 
De zwangerschapsduur beïnvloedt het geboortegewicht en ook de behoefte aan kunstmatige 
beademing en intraveneuze voeding. Daarom zullen inspanningen ter voorkoming van vroeggeboorte 
indirect leiden tot een vermindering van het aantal nosocomiale infecties. 
De selectiedruk van frequent gebruikte antibiotica in de NICU, in combinatie met de veelvuldige 
handcontacten tussen ziekenhuispersoneel en de pasgeborene, herbergt een hoog intrinsiek risico voor 
transmissie van, met name antibiotica-resistente, microorganismen. Het beëindigen van een epidemie 
veroorzaakt door een resistente K. pneumoniae stam, toont aan dat een aanpassing van het empirische 
antibiotisch regime van toegevoegde waarde kan zijn bovenop de klassieke infectiepreventie 
maatregelen. 
In de NICU worden nieuwe apparatuur/procedures frequent geïntroduceerd, zonder dat daar altijd het 
bijbehorend infectierisico bij betrokken wordt. De epidemie met een Bacillus cereus stam, die zich 
bevond in beademingsballonnen, is een duidelijk voorbeeld van de voortdurende gevaar van medische 
apparatuur voor de natuurlijke afweermechanismen van het menselijk lichaam. Bovendien leert deze 
epidemie dat iedere bacteriesoort als een potentieel gevaarlijk nosocomiaal pathogeen moet worden 
beschouwd. Wij concludeerden dat B. cereus ernstige infecties kan veroorzaken bij neonaten en dat de 
vondst van deze bacterie in kweken serieus genomen moet worden. 
De bijdrage van genotypisch typering bij de hiervoor genoemde endemische en epidemische bacteriën 
bleek onontbeerlijk.  
Tenslotte is het duidelijk dat prematuriteit ook van toepassing is op het functioneren van het 
immuunsysteem. We vonden geen relatie tussen het MBL-genotype en het risico op een nosocomiale 
infectie. Dit wordt waarschijnlijk veroorzaakt tussen de zwakke correlatie tussen het MBL genotype en 
fenotype en mogelijk ook door de zwakke binding van MBL aan coagulase negatieve stafylokokken, 
welke de meest voorkomende verwekkers zijn van nosocomiale infectie bij neonaten. Bovendien zal 
het grote effect van geboortegewicht als base-line factor al snel de kleinere effecten van andere 
risicofactoren overschaduwen. Om deze effecten aan te kunnen tonen zijn studies nodig met veel 
grotere patiëntgroepen. 
Verrassend was de bevinding dat zwangerschapsduur, en dus geboortegewicht, niet de belangrijkste 
voorspeller was van de neonatale VZV-IgG titer, dit in tegenstelling tot dan toe algemene opinie. 
Maternale bescherming, door hoge maternale VZV-IgG titer, is de beste bescherming voor iedere 
neonaat.  
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